{"title": "PDF", "author": "PDF", "url": "https://seq.es/wp-content/uploads/2019/07/full.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "REVISTA ESPA\u00d1OLA DEREVISTA ESPA\u00d1OLA DEQuimioterapiaQuimioterapia ISSN: 0214-3429 Volumen 32 N\u00famero 4 Agosto 2019 P\u00e1ginas: 288-409SPANISH JOURNAL OF CHEMOTHERAPY Imagen portada: Mar\u00eda Teresa CorcueraPublicaci\u00f3n Oficial de la Sociedad Espa\u00f1ola de QuimioterapiaQuimioterapiaREVISTA ESPA\u00d1OLA DE Revista Espa\u00f1ola de Quimioterapia tiene un car\u00e1cter multidisciplinar y est\u00e1 dirigida a todos aquellos profesionales involucrados en la epidemiolog\u00eda, diagn\u00f3stico, cl\u00ednica y tratamiento de las enfermedades infecciosas Fundada en 1988 por la Sociedad Espa\u00f1ola de Quimioterapia Indexada en Science Citation IndexExpanded (SCI),Index Medicus (MEDLINE), Excerpta Medica/EMBASE,\u00cdndice M\u00e9dico Espa\u00f1ol (IME), \u00cdndice Bibliogr\u00e1fico en Ciencias de la Salud (IBECS) Secretar\u00eda t\u00e9cnica Dpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 en de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madrid Atenci\u00f3n al cliente Tel\u00e9fono 91 394 15 12Correo electr\u00f3nicoinfo@seq.es Consulte nuestra p\u00e1gina web www.seq.es \u00a9 Copyright 2019Sociedad Espa\u00f1ola deQuimioterapia Reservados todos los derechos. Queda rigurosamente prohibida,sin la autorizaci\u00f3n escrita deleditor, la reproducci\u00f3n parcialo total de esta publicaci\u00f3npor cualquier medio oprocedimiento, comprendidos lareprograf\u00eda y el tratamientoinform\u00e1tico, y la distribuci\u00f3n deejemplares mediante alquiler opr\u00e9stamo p\u00fablicos, bajo lassanciones establecidas por la leySociedad Espa\u00f1ola de Quimioterapia Publicaci\u00f3n que cumple los requisitos de soporte v\u00e1lido ISSN 0214-3429 e-ISSN 1988-9518 Dep\u00f3sito Legal M-32320-2012 Maquetaci\u00f3n Kumisai Impresi\u00f3n Espa\u00f1a Esta publicaci\u00f3n se imprime en papel no \u00e1cido. This publication is printed in acid free paper. LOPD Informamos a los lectores que, seg\u00fan lo previsto en el Reglamento General de Protecci\u00f3n de Datos (RGPD) 2016/679 del Parlamento Europeo, sus datos personales forman parte de la base de datos de la Sociedad Espa\u00f1ola de Quimioterapia (si es usted socio) Si desea realizar cualquier rectificaci\u00f3n o cancelaci\u00f3n de los mismos, deber\u00e1 enviar una solicitud por e-mail a la Sociedad Espa\u00f1ola de Quimioterapia (info@seq.es)QuimioterapiaREVISTA ESPA\u00d1OLA DE Director J. Barber\u00e1n L\u00f3pez Comit\u00e9 Editorial F. \u00c1lvarez Lerma (Barcelona) F. Baquero Mochales (Madrid) E. Bouza Santiago (Madrid) J. A. Garc\u00eda Rodr\u00edguez (Salamanca) M. Gobernado Serrano (Valencia) Consejo Editorial L. Aguilar (Madrid) J. I. Al\u00f3s (Madrid) J. R. Azanza (Pamplona) J. Arag\u00f3n (Las Palmas de Gran Canaria) A. Artero (Valencia)V. Asensi (Oviedo) G. Barbeito (Santiago de Compostela) J. M. Barbero (Madrid) J. Campos (Madrid)F.J. Candel (Madrid) E. Cant\u00f3n (Valencia) R. Cant\u00f3n (Madrid) J. A. Capdevila Morell (Barcelona) M. Casal (C\u00f3rdoba) J. Castillo (Zaragoza) F. Cobo (Granada) J. Cobo Reinoso (Madrid) N. Cobos (Madrid) J. L. del Pozo (Navarra)R. De la C\u00e1mara (Madrid) C. De la Calle (Barcelona) M. Dominguez-Gil (Valladolid) J. Eiros (Valladolid)P. Escribano (Madrid) A. Estella (C\u00e1diz) M. C. Fari\u00f1as \u00c1lvarez (Santander) C. Fari\u00f1as (Santander)J. Fort\u00fan (Madrid)J. J. Gamazo (Vizcaya) E. Garc\u00eda S\u00e1nchez (Salamanca) I. Garc\u00eda Garc\u00eda (Salamanca) J. E. Garc\u00eda S\u00e1nchez (Salamanca)E. Garc\u00eda V\u00e1zquez (Murcia) J. G\u00f3mez G\u00f3mez (Murcia) M. L. G\u00f3mez-Lus (Madrid) J. Gonz\u00e1lez del Castillo (Madrid)F. Gonz\u00e1lez Romo (Madrid) J. J. Granizo (Madrid) S. Grau (Barcelona) J.M. Guardiola (Barcelona) J. Guinea (Madrid) X. Guirao (Barcelona) J. Guti\u00e9rrez (Granada) J. B. Guti\u00e9rrez (C\u00f3rdoba) B. Isidoro (Madrid) P. Llinares (La Coru\u00f1a) J. E. Losa Garcia (Madrid)J. R. Maestre Vera (Madrid) L. Mart\u00ednez Mart\u00ednez (C\u00f3rdoba) E. Maseda (Madrid) R. Men\u00e9ndez (Valencia)P. Merino (Madrid)) P. Mu\u00f1oz (Madrid) J. L. Mu\u00f1oz Bellido (Salamanca) V. Navarro (Alicante)M. Ortega (Barcelona) J. Oteo (Madrid) J. A. Oteo (Logro\u00f1o) E. Palencia Herrej\u00f3n (Madrid) A. Pascual Hern\u00e1ndez (Sevilla) M. Ramos (Alicante)J. Reina (Palma de Mallorca) M. A. Ripoll (\u00c1vila) I. (Madrid) A. Su\u00e1rez (Madrid) A. Tenorio (Huelva)A. Torres (Murcia)C. Vallejo (Oviedo)J. Vila (Barcelona)J. Yuste (Madrid)J. Mensa Pueyo (Barcelona) J. J. Picazo de la Garza (Madrid) J. Prieto Prieto (Madrid) B. Regueiro Garc\u00eda (Santiago de Compostela) A. Torres Mart\u00ed (Barcelona)Secretario de Redacci\u00f3n Luis Alou CerveraSumario S\u00edndrome de Guillain-Barr\u00e9 y vacuna antigripal: evidencia actual 288 Rosario Sanz Fadrique, Luis Mart\u00edn Arias, Juan Arcadio Molina-Guarneros, Natalia Jimeno Bulnes, Pilar Garc\u00eda Ortega Efectividad de ledipasvir/sofosbuvir durante 12 semanas de tratamiento y factores 296 predictivos de fracaso del tratamiento en pacientes con hepatitis C Juan Carlos del Rio-Valencia, Roc\u00edo Asensi-Diez, Roc\u00edo Tamayo-Bermejo, Isabel Mu\u00f1oz-Castillo Bacterias resistentes en las manos de trabajadores sanitarios y en el \u00e1rea de 303 paciente: un estudio ambiental en un hospital del sur de Italia Vincenza La Fauci, Gaetano Bruno Costa, Cristina Genovese, Maria Angela Rita Palamara, Valeria Alessi, Raffaele Squeri Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital 311 terciario Laura Sante, Mar\u00eda Lecuona, Armando Aguirre Jaime, \u00c1ngeles Arias Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un 317 hospital de tercer nivel Roc\u00edo Asensi-Diez, Cristina Fern\u00e1ndez-Cuerva, Juan Jos\u00e9 Alcaraz S\u00e1nchez, Isabel Mu\u00f1oz-Castillo Prevalencia de micoplasmas genitales y respuesta al tratamiento de descolonizaci\u00f3n 327 en pacientes de reproducci\u00f3n humana asistida Ernesto Veiga, Mercedes Trevi\u00f1o, Ana Bel\u00e9n Romay, Daniel Navarro, Roc\u00edo Trastoy, Manuel Mac\u00eda Vacunas para la prevenci\u00f3n de infecciones en adultos: art\u00edculo de opini\u00f3n sobre la 333 situaci\u00f3n en Espa\u00f1a Emilio Bouza, Julio Ancochea-Berm\u00fadez, Magda Campins, Jos\u00e9 Mar\u00eda Eir\u00f3s-Bouza, Jes\u00fas Fargas, Am\u00f3s Jos\u00e9 Garc\u00eda Rojas, Diego Gracia, Alipio Guti\u00e9rrez S\u00e1nchez, Aurora Limia, Jos\u00e9 Antonio L\u00f3pez, Mar\u00eda del Carmen Magro, Gloria Mirada, Patricia Mu\u00f1oz, Eduardo Olier, Ra\u00fal Ortiz de Lejarazu, Luis Urbiztondo, Esteban Palomo Comparaci\u00f3n de dos m\u00e9todos que eluden la lisis celular y la extracci\u00f3n de prote\u00ednas 365 para la identificaci\u00f3n de bacterias crecidas en hemocultivos mediante espectrometr\u00eda de masas MALDI-TOF Ignacio Torres, Estela Gim\u00e9nez, Dixie Huntley, Mireia Mart\u00ednez, Javier Colomina, David Navarro Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en 370 Staphylococcus aureus Roc\u00edo S\u00e1inz-Rodr\u00edguez, Inmaculada Berm\u00fadez Ru\u00edz, Bego\u00f1a Palop-Borr\u00e1s \u00bfEs posible extrapolar las tasas de resistencia de Escherichia coli de bacteriurias 375 asintom\u00e1ticas en gestantes a las de E. coli en ITU no complicada adquirida en la comunidad? Alejandra Asenjo, Mart\u00edn C. Grados, Jes\u00fas Oteo-Iglesias, Juan-Ignacio Al\u00f3sRevisi\u00f3n Sistem\u00e1tica Originales Original BreveQuimioterapiaREVISTA ESPA\u00d1OLA DE Volumen 32 N\u00famero 4 Agosto 2019Sumario Reactivaci\u00f3n del s\u00edndrome peri\u00f3dico asociado a criopirinas tras la vacunaci\u00f3n 379 en una paciente candidata a inmunosupresi\u00f3n Mar\u00eda Fern\u00e1ndez-Prada, Jessica Rugeles-Ni\u00f1o, Luc\u00eda Su\u00e1rez-P\u00e9rez, Miguel L\u00f3pez-D\u00edaz, Mart\u00ednez-Ortega, Ismael Huerta- Gonz\u00e1lez Meningitis por Nocardia farcinica en un paciente con enfermedad de Beh\u00e7et: 381 caso y revisi\u00f3n de la literatura Kiana Shirani, Fatemeh Mohajeri Desbridamiento y tratamiento antibi\u00f3tico en infecci\u00f3n 384 prot\u00e9sica de rodillla por Pasteurella multocida Maria Pilar Ortega Lafont, Luis Buz\u00f3n Mart\u00edn, Ledicia \u00c1lvarez Paredes, Mar\u00eda Mora Fern\u00e1ndez, Antonio Rodr\u00edguez P\u00e9rez, Miguel \u00c1ngel Mor\u00e1n Rodr\u00edguez Uso de dolutegravir en infecci\u00f3n aguda por VIH-1: primer caso reportado 387 Franco Garibaldi, Marcia Pozzati, Claudia Rodriguez, Diego Cecchini Shock s\u00e9ptico secundario a Elizabethkingia meningoseptica : descripci\u00f3n de un caso 390 David Brandariz N\u00fa\u00f1ez, Paula Rodr\u00edguez Pedreira, Virginia Hern\u00e1ndez Corredoira, Joaquin Puig Forcada, Francisco J Gurri Hernand, Arturo S Boix Boix Bacteriemia por Actynomices oris 393 Javier Miguel Mart\u00edn Guerra, Miguel Mart\u00edn Asenjo, Claudia Iglesias P\u00e9rez, Carlos Jes\u00fas Due\u00f1as Guti\u00e9rrez Endocarditis infecciosa por Candida glabrata : evidencia del desarrollo in vivo de 395 resistencia a equinocandinas Caroline Agnelli, Jesus Guinea, Maricela Valerio, Pilar Escribano, Emilio Bouza, Patricia Mu\u00f1oz Absceso periamigdalino producido por Actinomyces marseillensis 398 Sara G\u00f3mez de Frutos, Marta Soledad Rodr\u00edguez Anzules, Arturo Manuel Fraile Torres, Laura Carde\u00f1oso Domingo, Diego Domingo Garc\u00eda Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la 400 Comunidad de Madrid Eduardo Palencia Herrej\u00f3n, Juan Gonz\u00e1lez del Castillo, Fernando Ramasco Rueda, Francisco Javier Candel Gonz\u00e1lez, Beatriz S\u00e1nchez Artola, Andr\u00e9s von Wernitz Teleki, Federico Gordo Vidal, Patricia Roces Iglesias, Guillermina Bejarano Redondo, Diego An\u00edbal Rodr\u00edguez Serrano, Francisco Javier Cobo Reinoso, Ervigio Corral Torres, Milagros Mart\u00ed de Gracia, Ana Ruiz \u00c1lvarez y el Grupo Multidisciplinar C\u00f3digo Sepsis MadridQuimioterapiaREVISTA ESPA\u00d1OLA DE Volumen 32 N\u00famero 4 Agosto 2019 Cartas al Director Documento de ConsensoContents QuimioterapiaREVISTA ESPA\u00d1OLA DE Volume 32 Number 4 August 2019 Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence 288 Rosario Sanz Fadrique, Luis Mart\u00edn Arias, Juan Arcadio Molina-Guarneros, Natalia Jimeno Bulnes, Pilar Garc\u00eda Ortega Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in 296 patients with hepatitis C Juan Carlos del Rio-Valencia, Roc\u00edo Asensi-Diez, Roc\u00edo Tamayo-Bermejo, Isabel Mu\u00f1oz-Castillo Drug-resistant in patient area: 303 environmental survey in Southern Italy's hospital Vincenza La Fauci, Gaetano Bruno Costa, Cristina Genovese, Angela a tertiary hospital 311 Laura Sante, Mar\u00eda Lecuona, Armando Aguirre Jaime, \u00c1ngeles Arias Hospital admission and mortality causes of HIV patients in a third level hospital 317 Roc\u00edo Asensi-Diez, Cristina Fern\u00e1ndez-Cuerva, Juan Jos\u00e9 Alcaraz S\u00e1nchez, Isabel Mu\u00f1oz-Castillo Prevalence genital Ernesto Mercedes Navarro, Roc\u00edo Trastoy, Manuel Mac\u00eda The situation of for the prevention of infections in adults: An opinion 333 paper on the situation in Spain Emilio Bouza, Julio Ancochea-Berm\u00fadez, Magda Campins, Jos\u00e9 Mar\u00eda Eir\u00f3s-Bouza, Jes\u00fas Fargas, Am\u00f3s Jos\u00e9 Garc\u00eda Rojas, Diego Gracia, Alipio Guti\u00e9rrez S\u00e1nchez, Aurora Limia, Jos\u00e9 Antonio L\u00f3pez, Mar\u00eda del Carmen Magro, Gloria Mirada, Patricia Mu\u00f1oz, Eduardo Olier, Ra\u00fal Ortiz de Lejarazu, Luis Mireia Mart\u00ednez, Javier Colomina, David Navarro Evaluation rapid assay for detection PBP2a Berm\u00fadez extrapolate the Escherichia coli from 375 asymptomatic bacteriuria in pregnant women to those of E. coli in uncomplicated community-acquired UTI? Alejandra Asenjo, Mart\u00edn vaccination 379 in patient candidate for immunosuppression Mar\u00eda Fern\u00e1ndez-Prada, Jessica Luc\u00eda a patient with Pilar Ortega Lafont, Luis Buz\u00f3n Mart\u00edn, Ledicia \u00c1lvarez Paredes, Mar\u00eda Mora Fern\u00e1ndez, Antonio Rodr\u00edguez P\u00e9rez, Miguel \u00c1ngel Mor\u00e1n Rodr\u00edguez Dolutegravir in acute HIV-1 infection: first reported case 387 Franco Marcia Rodriguez, Diego Cecchini Septic shock secondary to Elizabethkingia meningoseptica : A case report. 390 David Brandariz N\u00fa\u00f1ez, Paula Rodr\u00edguez Pedreira, Virginia Hern\u00e1ndez Corredoira, Joaquin Puig Forcada, Francisco J Gurri Hernand, Arturo S Boix Boix Bacteremia by Actynomices oris 393 Javier Miguel Mart\u00edn Guerra, Miguel Mart\u00edn Asenjo, Claudia Iglesias P\u00e9rez, Carlos Jes\u00fas Due\u00f1as Guti\u00e9rrez Infectious endocarditis caused by Candida glabrata : evidence of in vivo development 395 of echinocandin resistance Caroline Agnelli, Jesus Guinea, Maricela Valerio, Pilar Escribano, Emilio Bouza, Patricia Mu\u00f1oz Peritonsillar abscess due to Actinomyces marseillensis 398 Sara G\u00f3mez de Frutos, Marta Soledad Rodr\u00edguez Anzules, Arturo Manuel Fraile Torres, Laura Carde\u00f1oso Domingo, Diego Domingo Garc\u00eda Consensus document for sepsis code implementation and development in 400 the Community of Madrid Eduardo Palencia Herrej\u00f3n, Juan Gonz\u00e1lez del Castillo, Fernando Ramasco Rueda, Francisco Javier Candel Gonz\u00e1lez, Beatriz S\u00e1nchez Artola, Andr\u00e9s von Wernitz Teleki, Federico Gordo Vidal, Patricia Roces Iglesias, Guillermina Bejarano Redondo, Diego An\u00edbal Rodr\u00edguez Serrano, Francisco Javier Cobo Reinoso, Ervigio Corral Torres, Milagros Mart\u00ed de Gracia, Ana Ruiz \u00c1lvarez y el Grupo Multidisciplinar C\u00f3digo Sepsis MadridVolume 32 Number 4 August 2019 Quimioter 2019;32(4): 288-295288 \u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).S\u00edndrome de Guillain-Barr\u00e9 y vacuna antigripal: evidencia actual RESUMEN Introducci\u00f3n. El s\u00edndrome de Guillain-Barr\u00e9 (GBS) despu\u00e9s de la administraci\u00f3n de la vacuna frente a la gripe es un tema actual que sigue causando preocupaci\u00f3n tanto en el personal sanitario como en la poblaci\u00f3n y que permanece sin esclarecer. El objetivo del presente trabajo es investigar la publicaci\u00f3n de nuevos datos desde la realizaci\u00f3n de nuestro metaan\u00e1lisis so - bre el GBS y las vacunas frente a la gripe (publicado en 2015). M\u00e9todos. Se ha realizado una revisi\u00f3n sistem\u00e1tica en las bases de datos PubMed, Embase y Web of Science (WOS) de estudios observacionales que evaluar\u00e1n el riesgo de GBS des - pu\u00e9s de la administraci\u00f3n de vacunas influenza, desde mayo de 2014 hasta el 20 de julio de 2017. Resultados . El resultado de las b\u00fasquedas fue de 107 art\u00ed - culos. Finalmente, solo 3 estudios cumpl\u00edan con los criterios de inclusi\u00f3n establecidos y refer\u00edan una estimaci\u00f3n del riesgo de GBS despu\u00e9s de alguna de las vacunas antigripales. Dos estu - dios investigaron el riesgo de GBS con la vacuna pand\u00e9mica A/ H1N1 y un estudio investig\u00f3 las vacunas estacionales. Conclusiones. Esta revisi\u00f3n sistem\u00e1tica parece confirmar los hallazgos obtenidos en nuestro metaan\u00e1lisis. El SGB se po - dr\u00eda considerar como un posible efecto adverso poco frecuente de las vacuna antigripales, lo cual no deber\u00eda afectar negati - vamente en su aceptaci\u00f3n. Desafortunadamente, en nuestra revisi\u00f3n sistem\u00e1tica, hemos encontrado muy pocos estudios que cumplieran los criterios de inclusi\u00f3n, este hecho resulta llamativo ya que el consenso actual se\u00f1ala la necesidad de una monitorizaci\u00f3n continua sobre la seguridad de las vacunas an - tigripales. Palabras clave: yet to clarified, which raises concern both amongst health care personnel and the general population. Every study and pharmacovigilance system point to need of further research and the importance of continuous monitoring of safety regarding influenza vaccines. The aim of the present study is to investigate the publication of new data since the realisation of our meta-analysis of GBS and influenza vaccines (published in 2015). Methods. A systematic revision of PubMed, Embase, and Web of Knowledge (WOS) been carried out. These report observational GBS risk after the administration of influenza from May 2014 up to July 20th, 2017. Results. The research referred to an some influenza vaccine. Two studies investigated GBS risk by the pandemic into season The present as to the need of continuously monitoring the safety Valladolid 2Department of Faculty of Medicine. National Autonomous University of Mexico. 3Faculty of Medicine, Valladolid University Spain.Rosario Sanz Fadrique1 Luis Mart\u00edn Arias1 Juan Arcadio Molina- Guarneros2 Natalia Jimeno Bulnes3 Pilar Garc\u00eda Ortega3 Correspondence: Juan A. Molina Guarneros. School of Medicine C/Ram\u00f3n y Cajal, 7 - 45005 Valladolid (Spain) Phone: / 983 syndrome and influenza vaccines: current evidence R. Sanz, et al. Rev Esp Quimioter 2019;32(4): 288-295289RESULTS The those containing our earlier meta-anal - (n=10) [16]. Then, we read the whole texts of the potentially based on non-serious supposedly related to any of the influenza vaccines that did not report any estimates of GBS risk following influenza vaccination [17-22], b) pharmacovigi - lance studies on GBS that included any types of paediatric whose design or analysis of data on vaccine safety was considered not to be suitable [27, 28, 29], Only 3 studies met all the eligibility criteria (table 1), as follows: Kim et al .; 2015 [30], in which an increased risk of GBS was observed in South Korea following adjuvanted non-adjuvanted pandemic ratio 95% CI: 1.26-1.68); Ghaderi et al .; 2015 [31], in which the authors found an increased risk of GBS in Norway within 42 days after the administration of the pandemic vaccine A/H1N1 (Pandem - rix\u00ae), with the risk expressed as a hazard ratio (HR= 95% CI: 0.51-2.43); and Sandhu et al.; 2017 the outcomes for four influenza vaccination campaigns (from 2010/11 to 2013/14). Medi - care population (USA); with the risk being much lower than the 2.76), an not found in the remaining three vaccination campaigns (i. e. from 2011/12 to 2013/14). DISCUSSION Our systematic review focused on the new data about influenza vaccination and its potential association with GBS published after the publication of our prior meta-analysis [16]. The review of the published articles enabled us identify only studies estimating the magnitude of the GBS risk linked to or following the administration of the influenza vaccines when taking into account that the relevant nervous sys - tem. It causes weakness, paralysis, and, in some cases, leads to death GBS is regarded to be a rare autoimmune disease, in which the body is attacked by its own immune system [3-5]. GBS incidence ranges from 0.8 to 1.9 per 100,000 persons/ year, being more frequent among males, and the incidence increase with age [1, 2, 6, 7]. So far, the precise causes that trigger the disease are not well known. It has been reported that GBS is preceded by an infection of the gastrointestinal or respiratory tract in 2/3 of cases. It has been also linked to some viral infections, and even to influenza vaccination [5, 8-11]. The association of GBS with influenza vaccination was first reported in 1976, when the seasonal vaccination cam - paign was stopped in the United States due to an of cases (relative of GBS to influenza vaccination were published between 1976 and 2009. Since the pandemic outbreak of influenza A in 2009, the vaccine A/ H1N1/2009 were rapidly developed, manufactured surveillance systems were reinforced, adapted or set up with the aim of identifying as early as possible any incidence excess of GBS, notably in the United States, wherein an increased risk of GBS associated to influenza vaccine found [13, 14]. While isolated studies of cases by surveillance sys - tems have been conducted; so far, little research has been de - voted to synthesising the results from epidemiological 2015, carried the aim of studying relationship between GBS and influ - enza vaccination. Now, in this article, we present the results of a systematic review of the literature, whose objective was to analyze the new data that has been appearing since the publi - cation of We (WoS) the period 1-May-2014 / 20-Ju - ly-2017. We used the same search terms and study selection criteria as in our prior meta-analysis [16]. The search was con - ducted by terms Influenza Criteria the studies were following: (a) observational studies evaluating the risk of GBS associated with any of the influen - za vaccines, and (b) studies reporting risk measures as relative or incidence rate ratio (IRR); though, in the present review, we included a new risk measure as well, namely the hazard ratio (HR). In all cases, we the respective 95% confidence intervals (95% CI). Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al. Rev Esp Quimioter 2019;32(4): 288-295290ly published meta-analysis (table 2), it should out that, in one of the studies selected for our review, Kim et al. [30] concluded that the pandemic vaccine (pH1N1) was as - sociated with an increased risk of GBS expressed as a relative risk of 1.46; (95% CI, 1.26-1.68). This finding is keeping 2.09 (95% CI: 1.84 (95% CI: 1.36- 2.50), respectively. The finding by Kim et al. is also in line with the results from other the vaccine H1N1 2009 expressed as an incidence rate ratio of 2.35 (95% CI: 1.42-4.01), which con - curs with the results from other individual studies [33, 41]. The second study identified by our systematic review was that by Ghaderi et al. [31], who reported that the pandemic vaccine (pH1N1) was not associated with an increased risk of GBS. This finding is in keeping with the results from some pre -29, 32] .Furthermore, it is the importance difficult to quantify any caus - al associations; they present advantage the causal studies systematic et al. Rev Esp Quimioter 2019;32(4): 288-2952918-11, 46-47]. One of review supported the risk expressed hazard ratio (HR) of 4.89 (95% CI: 1.17-20.36), this risk magnitude review reported that in 82.5% of GBS cases there had testinal the from a study a strong of since the an Thus, Tam et 18.6, (95% CI: 7.5-46.4), whilst Stowe et al. spoke relative risk (RR) of 7.35, (95% CI: 4.36-12.38) within the first 60 and 90 days of influenza-like illness (ILI), we reviewed is surgery. According to the re - sults of a study conducted in Finland, the relative risk of devel - oping GBS within the first weeks (95% 49]. cases related to the ZiKa virus infection [50]. With regard to the type of study, in our systematic review we found that some of the published studies were based on vious studies [34, 42]. Finally, study is, that by Sandhu et al. [7] , focused on the outcomes of four influenza in the season 2010/11. How - ever, they failed to observe any risk excess in the remaining three seasons. In this latter study, the authors found an in - creased risk GBS on both tion models and previously risk estimates [26] sup - ported the hypothesis posed in an earlier study that influenza immunisation was protective against GBS, and, therefore, re - . At any rate, it should be borne in mind that the differences in the risk magnitudes reported in each study are small and they only approximated to the value with statistical significance by either excess or defect. On the other hand, the coverage of influenza vaccination programmes is broader every year, and this is not correlated with the number of hospitalisations for GBS [44]. addition, it is worth reminding that the financial burden associated with the complications derived from the infections caused by the in - tion. The current evidence indicates that previous infections are likely to play an important in the development of GBS, notably the infections involving the upper respiratory tract or the gastrointestinal tract, those caused by the influ - enza virus al. Norwey 410 Cohort A(H1N1) 2009 HR=1.11 (95% CI 0.51-2.43) Kim et al. 245 Cohort A(H1N1) 2009 (95% al. 2013 USA Meta-analysis A (H1N1) 2009 IRR=2.35 (95% CI 1.2-4.01) Dodd et Meta-analysis A (H1N1) 2009 RI= 2.09 (95%CI 1.28-3.42) Finland, The Netherlands, Singapore, Spain, Kingdom and Rev Esp Quimioter 2019;32(4): 288-295292dren. Further investigation during pregnancy. This issue was addressed by only three of the studies we found in our initial search [22, 52, 53]. Thus, in a large cohort pregnant to whom the vaccine A/H1N1 was given, the authors did not find any cases of GBS within the first 42 days after vaccination [52]. Nevertheless, it was notified a case of GBS that occurred 24 days after the administration of a trivalent influenza vac - cine (TIV) to a pregnant woman during the 2013/14 campaign [53]. The pharmacovigilance system deployed in Latin America and the Caribbean to monitor the potential adverse which circulate both Few in the UK based on the UK pharmacovigilance system (British Paediatric Surveil - lance Unit System) [47] showed that GBS and \"Miller Fisher syndrome\" associated with pandemic influenza vaccine were more prevalent among boys compared to girls. In ad - dition, this study revealed that most of the affected children had suffered a previous infection, and that the cases associat - ed with the pandemic vaccine were more frequent than those associated with the seasonal vaccine, though this difference did not reach statistical significance. This finding is in keeping with the results of another study [7], and coincides with those of our previous meta-analysis [16]. a safety study in in Taiwan, the authors failed to find serious adverse events within the first 7 days after the administration of a killed TIV during the 2010/11 campaign [54]. In a USA pharmacovigilance study with the live quad - rivalent influenza vaccine (LAIV4), it was found that the most frequently notified non-fatal serious adverse reactions were those systems. Neuro - logical children genetic heredity or to the type of vaccine, since live vaccines have not been sufficiently investigated in children aged under 2 years, and the established safety of a given influenza vaccine cannot be extrapolated to the remain allow us to identify the differences in both individual and group pathophysiologic mechanisms. In turn, these differences might explain why certain or groups present autoimmune diseas - es the (VAERS). However, it should be kept in mind that, while these notifications are very useful for the quick detection of safety concerns, they are not of val - the field observational studies, since, in this type of investigation, each case acts as its own control. In addition, these studies are adjusted for all confounding factors that may vary with time. In our earlier meta-analysis, 24 of the 39 weighted studies review, the authors referred to seasonality as an important factor. In one of these studies, a larger number of cases was found during the to intervals [31]. studies selected for of GBS following influenza vaccination, showing very small risk excess magnitude when taking into account the financial and health benefits obtained from im - munisation. Indeed, the risk coincidence with the periods with the largest circulation of the influenza virus, the occurrence of respiratory and gastrointestinal infections, or the administration of the vaccine for either seasonal (Oc - tober-November) or pandemic influenza. All the factors may make it difficult interpret the GBS. In relation to the differences in the estimates of the risk as reported in the different studies, they can be combined or rec - case-population approach (CPA) consistent odds ratios in the case-control studies, and discrepancies were ob - served only with the vaccine A (H1N1) in Sweden and UK [27, 28]. In a review of the statistical methods used in vaccine sur - veillance studies, the authors indicated that up to 37 different methods can be used depending on the kind of analysis [29]. The studies selected for our systematic review was more prevalent among males and elderly peo - ple, which is in agreement with the results from earlier inves - tigation [1-2, authors stated that GBS was more frequent in males, in - cidence increased with age, and incidence rates particularly sensitive popula - tions is vaccine safety for pregnant women and chil -Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al. Rev Esp Quimioter 2019;32(4): 288-295293Mycoplasma CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barre syndrome and preceding infection with campy - lobacter, influenza Epstein-Barr virus research database. PLoS One. 2007;2(4):e344. DOI: 10.1371/journal. pone.0000344 10. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Re J Epidemiol. - ing vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 2009 monovalent vaccine - United 2009-2010. W, DR, al. between 15. Dodd Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, et al. International collaboration to assess the risk - Martin Arias LH, Sanz R, Sainz M, Treceno C, Carvajal A. Guil - lain-Barre syndrome and A meta-analysis. Vac - cine. 2015;33(31):3773-8. DOI: 10.1016/j.vaccine.2015.05.013 17. Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, et al. Post-licensure surveillance of trivalent live attenuated influenza vaccine Winiecki S, Lewis P, Shimabukuro TT, Cano M. Surveillance of adverse events after the first trivalent inactivated produced 10.1016/j. vaccine.2015.10.084 19. Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT. Post-licensure surveillance of quadrivalent live disease in 73 genes may be implicated [25]. Nonetheless, and of GBS [59]. The present systematic review conducted the meeting inclusion criteria that we found in sented sufficient quality. This fact sharply contrasts with as to the need of continuously monitoring the safety of influenza it is not easy find such studies in the medical literature. FUNDING None to declare CONFLICT OF INTEREST The authors declare of interest. REFERENCES Amato AA, Sheikh SI, et al. Guillain-Barre syndrome incidence in J Med. 2012;366(24):2294-304. DOI: R, Beghi E, Chio A, Logro - scino G, et al. Multicentric Incidence et - 8. Tam SJ, LC. Influenza, Campylobacter and Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. et al. Rev Esp Quimioter 2019;32(4): 288-29529433. Yih WK, Lee GM, Lieu TA, Ball Kulldorff M, Rett M, et al. Sur - veillance for adverse events following receipt of pandemic 2009 Immunization Safe J, M, al. influenza 36. Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, et al. Risk of confirmed Guillain-Barre syndrome following receipt seasonal influenza vaccines in 2009-2010. J Viray M, Sejvar Baughman AL, Connor al. Boulianne N, Brunet D, Bouch - RM, et al. of Guillain-Barre syndrome following H1N1 A, Andrews influenza A HP, Keller-Stanislawski B, al. of syndrome fol - lowing pandemic Yang SE, PLoS 2013;8(3):e58827. DOI: 10.1371/journal.pone.0058827 42. Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barre syndrome influenza - lic Health. 2014;104(4):696-701. DOI: 10.2105/AJPH.2013.301651 44. Iqbal S, Li 2015;33(17):2045-9. DOI: 10.1016/j.vaccine.2015.01.080 20. Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licen - sure surveillance of quadrivalent inactivated influenza (IIV4) vac cine United Vaccine Adverse Event Reporting System A (H1N1) vaccination campaigns Latin the Caribbean. Vaccine. 2015;33(1):187-92. DOI: 10.1016/j.vac - cine.2014.10.070 23. Top KA, Desai S, Moore D, Law BJ, Vaudry W, Halperin SA, et al. Guillain-BarrE Conkright B, S, et al. In silico analysis al. Simulation study of the effect of influenza and influenza vaccination B\u00e9gaud B, Pariente A. Application of the case-population approach to safety surveillance. Drug Saf. 2015;38(10):1014. 28. Th\u00e9ophile H, N, B\u00e9gaud B. Is the case-population approach useful for A, Andrews NJ, SL. Near real-time vaccine safety sur - veillance using electronic health records-a systematic review of methods. 2016;25(3):225-37. DOI: 10.1002/pds.3966 30. Suh M, Kang DR, Choi YJ, Bae GR, et al. Pandemic influenza A vaccination syndrome and influenza et al. Rev Esp Quimioter 2019;32(4): 288-29529510.1016/j.vaccine.2015.02.064 45. Carias C, Reed C, Kim IK, Foppa IM, Biggerstaff M, Meltzer MI, et al. Net Costs Due to M, et al. Guillain-Barre Syndrome, Influenza Vaccination, Anteced - ent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis AM, Stowe J, Andrews N, Miller E. Pandemic A/H1N1 2009 influenza vaccination, preceding in - findings in Gensicke H, Datta AN, P, Schindler C, Fischer D. Increased in - cidence 10.1111/j.1468-1331.2012.03730.x Yang B, Lian Y, Liu Y, Wu BY, Duan RS. A retrospective analysis of syndrome Monovalent H1N1 vaccine safety in pregnant Tomimatsu Sugihara M, T, Shimoya K. Guillain-Barre syndrome after trivalent TY, Wei HM, et al. Im - munogenicity and safety of a trivalent inactivated 2010-2011 E, Dudley MZ, Proveaux T, et al. The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. Vaccine. 2015;33 Suppl 5:F1-F67. DOI: 10.1016/j.vaccine.2015.10.080 56. Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, et al. Post-Li - censure Surveillance of Trivalent Live-Attenuated Influenza Vac Aged 2-18 Vaccine Adverse Event C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole PP, Sun LL, Ding BJ, Qin N, Zhou B, Xia F, et al. Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms 2019. by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Efectividad de ledipasvir/sofosbuvir durante 12 semanas de tratamiento y factores predictivos de fracaso del tratamiento en pacientes con hepatitis C RESUMEN Introducci\u00f3n. La eficacia de ledipasvir/sofosbuvir (LDV/ SOF) se ha demostrado en ensayos cl\u00ednicos, sin embargo, son necesarios m\u00e1s estudios sobre su eficacia en la pr\u00e1ctica cl\u00ednica. Adem\u00e1s es importante estudiar los posibles factores predictivos de fracaso de tratamiento con LDV/SOF. Los factores predicti - vos de respuesta viral sostenida (RVS) a antivirales de acci\u00f3n directa pueden informar sobre decisiones de tratamiento. Los objetivos de este estudio fueron evaluar la efectividad de LDV/ SOF, RVS12 como variable principal y RVS24 como secundaria, e identificar los factores predictivos de fracaso del tratamiento. Material y m\u00e9todos. Estudio retrospectivo y observacio - nal realizado desde abril de 2015 a enero de 2016. Criterios de inclusi\u00f3n: pacientes con infecci\u00f3n por VHC tratados con LDV/ SOF durante 12 semanas. Se excluyeron los pacientes tratados durante 24 semanas y los tratados con peg-interfer\u00f3n. Apli - camos el m\u00e9todo estad\u00edstico denominado regresi\u00f3n log\u00edstica binaria para predecir qu\u00e9 variable estaba relacionada con el fracaso del tratamiento. Resultados. Se analizaron 122 pacientes logrando el 91,80% (112/122) RVS12. Los pacientes infectados con genoti - po (GT) 1a o GT1b o GT4 lograron RVS12. Solo un paciente, no cirr\u00f3tico y previamente tratado, infectado con GT1 no alcanz\u00f3 RVS12. Las tasas m\u00e1s bajas de RVS12 se obtuvieron para GT3, 43.75%, (7/16). Todos los pacientes que obtuvieron RVS12 lo - graron RVS24. Ninguna de las variables analizadas influy\u00f3 sig - nificativamente en la RVS12, excepto GT (p=0.001). Casi todas las reca\u00eddas ocurrieron en GT3. Conclusiones. La combinaci\u00f3n LDV/SOF ha sido muy efec - tiva para tratar a los pacientes infectados con GT1 y GT4, sin SUMMARY Introduction. The controlled trials, there is unmet for real-world effectiveness data. It is important data evaluate effectiveness of LDV/SOF, SVR12 as as second endpoint, identify predictors of failure. Material and methods. Retrospective and observational study carried study period. The patients that were treated during 24 weeks were was used to predict what variable was associated with treatment failure. Results. A total of 122 patients were analyzed (GT) 1a patients infected with of the variables analyzed. Keywords: Hepatitis C, ledipasvir/sofosbuvir, effectiveness, treatment fai - lure, predictors.Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C Hospital Regional Universitario de M\u00e1lagaJuan Carlos del Rio- Valencia Roc\u00edo Asensi-Diez Roc\u00edo Tamayo-Bermejo Isabel Mu\u00f1oz-Castillo Correspondence: Juan Carlos del Rio-Valencia. Hospital Regional Universitario de M\u00e1laga. Avenida de Carlos CP.29010. week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al. Rev Esp Quimioter 2019;32(4): 296-302297ications that reduce the concentrations of LDV or hu - study evaluate the effectiveness of LDV/SOF treatment in HCV genotype 1, 3 and 4 as measured by the rate of SVR12 as main endpoint and SVR24 as second endpoint and to identify predictors of treatment failure in the patients. MATERIAL AND METHODS Retrospective and observational study carried out in a patients that were treated during 24 weeks were excluded as well as those treated with peg-interferon. The information was obtained from the electronic clinical/ medical records and dispensing records from outpatient soft (viral RNA content before starting therapy) (VL), SVR at week 12 (SVR12), defined as HCV RNA ti - tres lower than 15 IU/mL 12 weeks after the final of treatment, SVR at week 24 (SVR24), defined as HCV RNA titres lower than 15 IU/mL 24 weeks after the final of treatment. HCV-RNA levels measured by quantifi (LLOQ) adherence. The main endpoint measured event that one of the patients was admitted to our hospital, the account by unit dose to hospitalized patients. Statistical analysis. The variables collected were ex -embargo, ha constituido una opci\u00f3n terap\u00e9utica sub\u00f3ptima para los infectados con GT3, independientemente del resto de las variables analizadas. Palabras claves: Hepatitis C, ledipasvir/sofosbuvir, efectividad, no respues - ta tratamiento, factores predictivos INTRODUCTION Chronic hepatitis C (CHC) is a worldwide liver-re - lated morbidity and mortality. It affects over 185 approximately 2-3% of the world's population. Although this prevalence may be relatively low overall, it varies by age group and is typically much higher in cohorts between the ages of 45 and 75. For example, in Central and East Asia, the prevalence peaks at 8.8-8.9% for those aged 55-64 [1]. Over the last several years, the management of CHC has been revolutionized by the development of cell-mediated tar - geted therapies antiviral agents (DAAs)] against hepatitis C virus (HCV). Indeed, we are at the beginning of a new era of HCV management, which is beneficial to patients and clinicians alike. Treatment regimen that have left behind fraught with side effects, quality of life (QOL) impairment and high treatment The new regimens simple, safe, side different genotypes of hepatitis C virus HCV (geno - types 1, 2, 3, 4, 5, 6) have been identified [3]. Genotype 1, spe - cifically 1b, is subtype worldwide affecting HCV-infected individuals [3]. This is followed by geno - type 3 (26%), most commonly found in Pakistan and India, and genotype 4 (14%) which is most common in North Africa and the Middle East. In the US, genotype 1a is the most common, accounting for 58% and genotype 3 accounts for 5% [3]. In Spain, different studies [4-6] have re - vealed is some not have pangenotypic efficacy. In addition, each genotype is associated demonstrated there is an need for real-world data and studies that population. to gather data regarding po - tential predictors of treatment failure with LDV/SOF. Studies have assessed the association between the factors, as sex, history of treatment failure, presence of cirrhosis, basal viral load, concomitant use of med -Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al. Rev Esp \u00b1 g/dL. The median AST, ALT and total bilirubin - and demographic factors associated with treatment failure. All analyses were performed by using SPSS v.17. 0.05 were considered statistically significant. RESULTS In the study period, in our 124 HCV patients were treated with LDV/SOF. Two patients in - sufficient clinical or analytical information. The genotypic dis - patients is summarized in table 1. Baseline characteristics. Of the 122 patients included in the study, 78 (63.93%) were male, with mean age of 56.23 \u00b1 9.14 years. Cirrhosis was present in 33.60% (n=41) of the Also, (9.68%) GT 1a 29 (23.38%) GT 1b 46 (37.10%) GT 3 16 (12.90%) GT 4 21 (16.94%) Total 124 (100.00%)Table 1 Genotypic distribution of different F4 F3 F2 F13 5 2 -10 8 8 314 15 16 17 6 2 17 7 4 341 41 32 80.682 Liver transplant 2 3 9 1 0 15 0.625 Previously treated 3 11 20 4 10 48 0.528 HIV co-infected 2 12 3 1 14 32 0.243 Basal VL > 800,000 U/ml 8 24 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al. Rev Esp Quimioter 2019;32(4): 296-302299Finally, we analyzed the treatment adherence and it was of 100% in all patients. Therefore, this variable was not included analysis. Sustained virologic response (SVR). 112 patients (91.80%) achieved SVR12. If we analyze to de of patients Response with ledipasvir/sofosbuvir. termine if there were factors associated with treatment failure, and it was found that none of the baseline variables analyz - ed in table 2 had a significant influence on SVR12 (p> 0.05), analyze the of patients, we observe that predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al. Rev Esp Quimioter 2019;32(4): 296-302300ed and seven of the totals were cirrhotic. In ELECTRON-2 study, we do not know if any patients were cirrhotic or not. These results are aligned with the treatment regimens as val - uable options for genotype 3 recommended by European Associa of the Liver (EASL) (guideline 2016), moment in which the determines in real studies. In our GT4 is to SVR12 rate to other real world studies such as Ramos et al. 2017 [5] the achieved study the treatment SOF/LDV match the results ob - ION-4 [16] with SVR12=96% (n=322/335). On the other have found that subject who achieved SVR12 subsequently got subjects who achieved a These studies identify independent clinical and demograph - ic factors associated with treatment failure, we can affirm that LDV/SOF but These outcomes match the results achieved by Kouris G et al. [7], in which ana - lyzed the effectiveness of LDV/SOF and predictors patients HCV GT-1 infection. None of the in - cluded variables were found to be associated with statistical - ly significant differences in odds treatment failure. The same got in our cohort, however, we also assessed if the genotype variable could be an important factor of treatment failure observing that GT-3 is a decisive predictor of SVR12 failure. According to the study of [19] load for predict - ing in activity against all 6 HCV genotypes in both in - ro replicon assays replicons of gen - in vitro, with an average EC50 of 168 nM against wild-type virus. b) Genotype 3 If we analyze the different subgroups of patients have investigated real-world effec - tiveness of the regimen LDV/SOF administered for 12 weeks in patients infected with hepatitis C virus (HCV) genotype 1, 3 and 4 who met inclusion criteria in materials and methods. Also, genotypic distri - bution was similar to that published in other studies in Spain [5, 6], regarding to GT1, concretely, our patients 70.16% vs. 69.6%-78.4%.) As to genotype 3 was and genotype 4 was 16.94% vs. 9.1-12.54%, genotypic distribution a little bit different and it may be explained by the fact that a lot of GT3-4 infected patients were treated other similar to SVR12 rate (95%) derived from the study Ramos et al. We analyzed different subgroups of patients it important to underline that the - ple size in the ION-1 and ION-2 studies was bigger than our study and basal conditions of the patients could differ. b) Genotype 3 Patients with HCV genotype 3 in patients with liver cirrhosis. In our study, global ELECTORN-2 study, only naive patients were treated with this treatment regimen, conversely, in our study, four patients were pre-treat -Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al. Rev Esp Quimioter 2019;32(4): 296-302301In addition to EC50, another important factor keep in mind is the Resistance-Associated Substitution (RAS). Howev - er, the genotypic presence of a RAS does not necessarily translate to a phenotypic treatment failure. Like advanced cirrhosis or prior treatment experience, the presence of RAS represent an important factor in overall treatment outcomes, and when combined with other negative predictors may result in treatment failure. The clin - ical relevance of resistance testing has been limited to RASs in the NS5A gene. Two RASs in particular, Y93H A30K, as currently approved regimens, and are present at baseline in up 8.3 and 6.3% of all HCV-3-infected patients, respectively [14]. To put this with the signature Y93H resistance-associated substitution in a genotype 1a virus re - sults in an EC50 of approximately 6 nM resistant portant but also suggest that that can assess all stages of life cycle are limit deeper - vestigation into the activity LDV This study has the usual limitations related to its observa - tional and retrospective design, electronic data collection and the small number of patients included in each arm of treat In resistance we were unable to assess the impact of this factor. On the oth - er hand, we have not analyzed concomitant drugs, except HIV drugs, therefore, we do not know the influence of this factor on the effectiveness and it could be analyzed in future studies. In addition, it is important to note that this study was carried out between 2015-2016 and the EASL HCV recommend its use for these patients [15]. With respect to genotype 3, both - lished by the Ministry of Health, Consumption and Social Wel - fare in Spain in 2015 [22]. In conclusion in fected with of the rest the FUNDING None to declare.CONFLICT OF INTEREST The Glob al epidemiology hepatitis Y, Younossi ZM. The chang - ing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015;8(5):298-312. DOI: 10.1177/1756283X15587481 3. Messina Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of genotypes. agents in patients with hepatitis C genotype 1-4 tertiary hospital. Rev Esp Quimioter. 2018;31(3):226-36. PMID: 29771105 5. Ramos H, Linares P, Badia E, Martin I, Gomez J, Almohalla C, et al. Interferon-free treatments in patients with hepatitis C genotype - man M. Distribution of the genotype of the Hepatitis C Virus in Cordoba-Spain. Rev Esp Quimioter. 2018;31(2):164-165. Price M, Clements K, et al. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 In - fection: A Retrospective Cohort TP, Biomarkers for Predicting Chojkier Gitlin N, Puoti M, for Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Na - hass R, Ghalib R, Gitlin N, Herring R, PJ, Bisceglie AM, Arora Subramanian Moa1316366Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al. Rev Esp Quimioter 2019;32(4): 296-30230212. Bochud T, Overbeck Dufour J-F, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progres - sion in chronic hepatitis Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepatocel - lular carcinoma incidence in patients with 2011;18(10):e516-22. DOI: 10.1111/j.1365- 2893.2011.01441 D, Svarovskaia E, Pang PS, Brainard D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavi - rin, for 12 weeks in patients with the Liver . EASL Recom - mendations on J Hepatol. 2018; 69(2):461-511. DOI:10.1016/j.jhep.2018.03.026 16. Naggie S, Cooper C, Saag Workowski K, Ruane P, Towner WJ, et al. DOI: 10.1056/NEJ - Moa1501315 Chen W, Fleischer RD, TS, Jadhav PR, regu - latory approval 2013;144(7):1450-1455.e2. DOI: 10.1053/j.gas - Herring RWJ, al. Concordance 4, 12, and 24 weeks hepatitis C FL, Hwang P, Barr E, et al. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis. J al. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis the Liver . EASL Rec - ommendations on Treatment of 2016. J Hepatol. 2017;66(1):153-94. DOI: 10.1016/j.jhep. 2016 .09.001 22. Ministerio de Sanidad, Consumo y Bienestar Social . Estrategia ter - ap\u00e9utica para la hepatitis cr\u00f3nica causada por el virus de hepatitis C en el Sistema Nacional de Salud. Recomendaciones generales y pautas actuales de tratamiento [web page]. Madrid by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Bacterias resistentes en las manos de trabajadores sanitarios y en el \u00e1rea del paciente: un estudio ambiental en un hospital del sur de Italia ABSTRACT Introducci\u00f3n. La OMS reconoce la resistencia a los anti - microbianos como una creciente amenaza para la salud mun - dial con una amplia variabilidad en toda Europa: en Italia estas tasas son m\u00e1s altas que en otros pa\u00edses. El objetivo de nuestro estudio fue detectar la resistencia a los antimicrobianos en las manos de trabajadores sanitarios y en las superficies alrededor del paciente as\u00ed como evaluar la variabilidad entre los niveles de contaminaci\u00f3n bacteriana en estas superficies y los resulta - dos obtenidos hace seis a\u00f1os. Material y m\u00e9todos. El estudio se realiz\u00f3 entre junio de 2017 y mayo de 2018 utilizando dispositivos de contacto para superficies y muestreo activo de aire. Se emple\u00f3 m\u00e9todos bio - qu\u00edmicos automatizados para identificar microorganismos y la sensibilidad antimicrobiana fue realizada de acuerdo con las normas del EUCAST. Resultados . Se analizaron 3.760 muestras, de las cuales el 16,17% fueron positivas y el 34% de ellas fueron resistentes a antibi\u00f3ticos. Al analizar los estafilococos, el 39% fueron multirresistentes y el 5% extremadamente resistentes. Un 30% de las cepas de Enterococcus faecalis fueron resistentes a gentamicina y vancomicina. Se Klebsiella pneumoniae resistentes a ceftrixona, cefoxitina, mecillinam e imipenem. Un 7% de las cepas de Acinetobacter baumannii y un 8% de las cepas de Pseudomonas aeruginosa fueron resistentes a gentamicina, imipenem y ceftazidima. Conclusiones. Estos hallazgos est\u00e1n en l\u00ednea con los estu - dios publicados en otros pa\u00edses, lo que confirma que la resisten - cia a los antibi\u00f3ticos tambi\u00e9n est\u00e1 creciendo constantemente en Italia con tasas variadas para los diferentes pat\u00f3genos Palabras clave: resistencia a antimicrobianos, bacterias, pacientes, superfi - cies de hospitales, trabajadores sanitarios.ABSTRACT Background. The WHO recognized antimicrobial resist - ance as a growing global a wide variabili - than in other countries. The aim of our study was to detect antimicrobial resistance on the hands of the patient, to assess the variability between levels of bacterial contamination on these surfaces and to compare the results with those achieved six years ago. Material and methods. The study was conducted from June 2017 to May 2018 using contact slides for surfaces and active sampling for air. these were antimicrobial-resistant. On analyzing the isolated Staphylococci, 39% were multidrug- findings are line international literature, confirming that antimicrobial resistance is also steadily hands healthcare workers and area: survey in Southern Italy's hospital 1Department of Biomedical and Dental Sciences Messina, Medical School in Hygiene and Preventive Medicine, University of Messina, Messina, ItalyVincenza La Fauci1 Gaetano Bruno Costa1 Cristina of Messina, Policlinico and in the patient area: an environmental survey in Southern Italy's hospital V. La Fauci, et al. Rev Esp Quimioter 2019;32(4): 303-310304of bacterial contamination on different surfaces examined (Universitary Hospital of Messina, Gaetano Martino) and to compare the results with those achieved six years ago from a previous study. MATERIAL AND METHODS Samples were collected from the of HCWs and surfaces considered at risk, namely ones near the patient and ones touched by HCWs (bed and headboard, sink, floor, med trays). A longitudinal study was conducted from June 2017 to May 2018. (Liofilchem) hands of healthcare workers with a contact time of 10 seconds for the following types of culture medium used: PCA for bacterial Agar Agar Rose Bengal-CAF Yeast and Mold Agar, VRBG Agar for Entero - bacteriaceae and Bile-Esculin Agar for Enterococcus spp. All samples were taken directly to the laboratory and in - cubated at 37 \u00b0C for 48-72 hours. Samples were classified as positive in accordance with the manufacturer's instructions for the contact slides (> 14 colo (expressed as CFU/m3) were collected from the center of the room using a semi-automatic sampler (SAS Super100, Sampler Air System, PBI), which aspirated a volume of 180 l/min. The SAS held one 55 mm diameter plate containing the different selective agar culture media (Mannitol Salt Agar, MacConkey Agar, - and at 37\u00b0C 18 hours. Antimicrobial sus - ceptibility to the different bacteria: for INTRODUCTION infections the leading cause of morbidity and worldwide. According to the European Centre for Disease Prevention to main infections [3]. Antimicrobial resistance is one of the HCAIs [4]. The Centers for Disease Prevention million antimicrobial-resistant infections, healthcare en - vironments for long periods of the by antimicrobial-resistant microorganisms are becom - ing more more common, with a mortality rate of 20-30% [10]. Some or - ganism (MDROs) play a fundamental role, even in our hospital reality [14-16]. Many studies have reported the and of isolated germs is essential [24]. our study was to detect antimicrobial resistant bacteria on the hands of HCWs the patient; patient area: an environmental survey in Southern Italy's hospital V. La Fauci, et al. Rev Esp Quimioter 2019;32(4): 303-310305the analysed samples were found to be resistant to at least one agent in three these were co - agulase-negative staphylococci (CoNS) belonging to the fol - lowing species: S. auricularis (3%), S. capitis (8%), S. caprae (1%), S. cohnii (4%), S. epidermidis (6%), S. haemolyticus (9%), S. hominis (19%), S. lugdunensis (1%), S. pasteuri (1%), S. saprophyticus (4%), S. simulans (6%), S. warnerii (5%), S. xy- losus (14%) . The remaining 19% were coagulase-positive, of were S. aureus . Analysis of isolated Staphylococci showed 54% at least antimicrobial, 39% MDR and 5% (75% S. aureus and 25% S. capitis ) isolated on bed - room patient (25%) and on floor (75%) (table 2). Other re - sistance to ampicillin, gentamycin and vancomycin and Gram-negative bacteria Enterobacteriaceae were Enterobacteriaceae MDR, and isolated ceftriaxone, 44% to cefoxitin and ampicillin, 52% to mecillinam and 33% to we a percentage of MDR for Staphylococcus 15% in our hospital estimating a 99% Confidence Interval (CI) and abso - lute precision of 5%. For others organisms we did not know the percentage of MDR in our hospital facilities and so we as - sumed the percentage of So, the to the patient and on surfaces of the 'patient zone' defined WHO). tables were built method, while degrees of freedom were used to partition r x k tables. Also we evaluated statistical differenc - es between the results recorded between 2012 and 2016 only for Staphylococcus spp. P-values of <0.05 were considered to indicate significance. used - RESULTS to one antimicrobial) found 33.55% (204/608) analysed environmental light switch, door handle); 38% floor; 10% air; 9% medical devices and 3% hands. the the first four genera for antimicrobial susceptibility because others only cause in - fections in 2% (196/608) patient area: an environmental survey in Southern Italy's hospital V. Fauci, et al. Rev Esp Quimioter 2019;32(4): 303-310306'patient antimicrobial resistance for S. aureus and for CoNS a decrease in an - timicrobial resistance was detected demonstrating MDROs in the patient care environment. [29]. These stud of other MDROs on environmen - tal surfaces. Our research health care pro - viders can be involved in the transmission of nosocomial in - fections and have been often described as the source for such outbreaks [31-34]. In our study, we noticed a high percentage of MDR for S. aureus and CoNS similar to previous studies [35]. In one MRSA MRSA positive [29]. 35.7% of those from hospital surfaces [30]. When we compared both studies, Klebsiella was and resistance rates were as follows: 33% for ceftriaxone, 44% for cefoxitin, 56% for mecillinam and 25% for imipenem. Proteus mirabilis was isolated in 0.7% of the samples and found to be resistant to all tested antimicrobials, with the 21% of the isolated microorganisms were resistant to gentamicin and 31% to imipenem ceftazidime. A. baumannii was iso - lated in 9.2% of cases and 36% of the isolated microorganisms were resistant to imipenem, 20% to gentamicin and 22% to ceftazidime. Other Gram-negative bacteria. The Rhizobium radio - bacter species was isolated in 5.26% of to the patient surfaces of the Resistant to Isolated microorganism AMP CTX FOX OX MEL VaN IMP PEN GEN CAZ Gram-positive Staphylococcus spp. 37% 35% 24% 39% 0% 50% 63% 40% 0% 0% 20% Other 48% 36% 27% Enterococcus faecalis 30% 30% 30% Gram-negative Enterobacteriaceae 41% 44% 52% 33% Klebsiella spp. 33% 44% 56% 25% Proteus spp. 0% 100% 100% 0% Pseudomonas spp. 31% 21% 31% Acinetobacter spp. 36% 20% patient area: an environmental survey in Southern Italy's hospital V. Fauci, et al. Rev Esp Quimioter 2019;32(4): 303-310307tamination rate microbial on in the patient's room and the evaluation of clinical an - is - sociated with multiple to different classes of an - timicrobials (pan-resistant studies described that surfaces play only a minor role in the trans - mission of CRE as it was seldom isolated from environmental surfaces. By contrast, our principal CREs involved in HCAIs (the ECDC data for Eu - rope show an increase in the spread of CRE, which is endemic in Greek, Italy, Turkey and Malta), is that patient zone and their furnishing of patient colo - nized with CRE is often contaminated by these organisms, with a reduction in as you [41]. baumannii and P. aeruginosa , with MRSA, are the most common causes of HCAIs and their pres - ence is correlated with environmental surface contamination [42]. While P. aeruginosa patients. In study, resistance to imipenem was 36% for strains isolated from the microor - and it therefore spread easily through a one As mentioned above, antimicrobial resistance Acinetobacter spp. is common in Eu - rope and in most cases is combined with resistance to fluoro - quinolones and aminoglycosides. In our study, 36.4% of strains were found to be resistant to imipenem. It can also cause dan - gerous outbreaks and the application of environ and strict compliance have required the complete closure of units [44]. We no resistance of microorganisms isolated from surfaces for aureus and for CoNS while we observed a decrease in the antimicrobial resistance rates of VRE surfaces (13- 16%) [38]. This contamination of rooms is due to not only to microorganisms spread by previous occupiers, but could also be due to transmission by HCWs, guests, objects as well as air flow and this explains the different contamination levels we detected [29, 39]. It 50% 50% 25% 75% 0.375 CoNS 0.306 FOX 0% 50% NA VAN 0% NA MEL 8% 0% NA S. epidermidis OX 3% 0% NA FOX 1% 0% NA VAN 4% 0% NA MEL 13% 0% NA CoNS OX 0% 28% NA FOX 0% 36% NA VAN 19% 9% 0.203 MEL 29% 28% 0.878Table 4 Evaluation of the antimicrobial bacteria after years healthcare workers and in the patient area: an environmental survey in Southern Italy's hospital V. Fauci, et al. Rev Esp Quimioter are increasingly lim - ited. Consequently, if we do not take widely used meas - ure to keep them under control and also the most cost-effec - tive; the savings from prevention specialists, correct use of an - timicrobials and vaccine are all measures implemented world - wide to control HCAIs [47, 51-60]. REFERENCES 1. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducom - ble T et al. Burden of 2016; Dumyati G, Kainer MA et Zimlichman E, D, Tamir O, Franz C, Song P, Yamin CK et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health system. Intern Med 2013; 173(22): 2039-46. doi: 10.1001/jamainternmed.2013.9763. Larson E. Trends in mortali - ty, length hospital associated antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2015. European Food Safety Authority European Centre for C Jr, Ghantoji SS, Rodriguez M, Gubb J, et al. The role of the healthcare environment in the spread of multidrug-resistant organisms: update on current best practic - holm: ECDC, 2013. prevalence survey of healthcare-associat - antimicrobial 9. AD. How hands of HCWs, con - firming literature data that the bacteria on hospital surfaces are transferred by the hands of healthcare staff. The of handwashing is thus vital to the spread of these - sistant microorganisms [45]. In literature many studies described that the healthcare area may be contaminated by bacteria from different patient zones in two ways: shedding from patients and HCWs' patients rate For example, after one of every three interactions with a patient carrying A. baumannii nation by MDROs were positive environmental cultures, stay in room for more than 5 minutes, performing physical examina - tion and contact with the ventilator [46]. Limitations of our study are that we did not perform a molecular analysis and we did not evaluate the actions carried out by HCWs first of sampling. In our study, after finding the positivity of the examined surfaces we made a signal to the health management and to the interested operative unit giving prescriptions on the en - vironmental sanitation and on the behaviour of the HCWs. In particular, we have prescribed a more thorough cleaning VIRKON\u00ae (powdered um to be diluted according to the indica - tions ammonium propion - ate, perfume). For the behaviour of the operators it was prescribed the respect of the correct technique of washing and of the methods and products, according to the activities that must be carried out, by performing the 5 fundamental moments for hand hygiene present on the guide - lines issued by the Ministry of Health with the use of hydro-al - coholic gel for the clutch and chlorhexidine for both of HCWs hands that and did found confirming improve the of of clean staff, although this effect can still be reduced in [48]. We hope, therefore, to reassess the obtained and evaluate reduction of MDROs in our Drug-resistant patient area: an environmental survey in Southern Italy's hospital V. La Fauci, et al. Rev Esp Quimioter 2019;32(4): 303-310309role of the hospital environment in the healthcare-associated in - fections: a general review of the literature. Eur Rev Med Pharmacol Sci. 2019;23(3):1266-1278. doi: 10.26355/eurrev_201902_17020. 24. World Health Organization (WHO). resistance animal -- sampling techniques 26. ISO . of the food chain -- Horizontal methods surface sampling 27. international (https://www.r-project.org/) 29. French GL, Otter JA, Shannon KP, Adams NM, Watling D, Parks MJ. Tackling contamination of the hospital environment by me - Staphylococcus aureus OC, Fauci V. Surveillance and evidence of con - tamination in hospital environment from meticillin and vancomy Gram-positive Infect 2004; Sickbert-Bennett EE. Carbapenem-resistant Enterobacteriaceae Conti A, Riso, R. Squeri.Humidifiers for oxygen therapy: what risk P, Mana TS. Are hospital floors an underappreciated reservoir for transmission of health environ - ment as 1221-36. 38. Trick WE, Temple RS, Chen D, Wright MO, Solomon SL, Peterson LR. Patient colonization and environmental contamination by and SPIN-UTI network of the GISIO Working Group of the Italian Society of Hygiene, Preventive Med - icine L, Berloco F, Antonioli P and the SAN-ICA Study Group. Squeri La Fauci V, Costa GB, Arena A, et al. Trend of MDR-microorganisms isolated from the biological samples of patients with HAI the patient. Microbiol 2018;41(1): 42-6. Dorrian S, Dolan A, Sherlock O, Fitzgerald-Hughes D, Thomas T. When are hands sepsis B, Lo Pinto G, Schinca E and Hospital Infection Control Operating Group Clostridium difficile L, Auxilia Baldovin T, Barchit - ta M et al.Hospital and in the patient area: an environmental survey in Southern Italy's hospital V. Fauci, et al. Rev Esp Schmid CH, Barefoot L, Hansjosten K, Vue PM et al. Prior environmental contamination increases the risk L, Gatermann S, Muhr G. Colonization of patients and contamination of the patients' - ronment 209-15. Morgan DJ, Rogawski E, Thom KA, Johnson JK, Perencevich EN, Shardell M et al. Transfer of multidrug-resistant bacteria to healthcare workers' gloves and gowns after patient contact in environmental contamination. Critical Care Medicine. 2012;40(4):1045-1051. doi: 10.1097/CCM.0b013e31823bc7c8. 42. Lerner A, Adler A, Abu-Hanna J, I, Navon-Venezia S, Carmeli Y. of drug-resistant Pseudomonas aeruginosa 2007; 13(6): 418-22. 44. Kohlenberg der Linden P, Sohr D, V\u00f6geler S, Kola A et al. Pseudomonas M, Jones-Paul L, Barry C, Gomez M et al. An outbreak due to multiresistant Acinetobacter baumannii in a burn 261-7. World (WHO). Guidelines on Hand Hy - giene in Health Care: First Global Patient Safety Challenge Clear Care is Safer Care. Cap. 7: Transmission of health care. Epidemic and pandemic alert and response. World Health Organization (2007). on: EPR_AM2_E7.pdf Winning Gastmeier P, Brunk - horst FM et al. Quantifying the Hawthorne effect in hand hygiene compliance through C, Lo Giudice D, Calimeri et V, chickenpox Ig. 2017;29(6):595- 606. doi: 10.7416/ai.2017.2188. Genovese C, Palamara MA, Ceccio C et al. Management of two influenza vaccination campaign in health care workers of a university hospital in the south Italy. Ann Ig. 2017;29(3):223-231. doi: 10.7416/ai.2017.2150. G, Egitto G. et al. Evaluation of vaccine coverages in the health care workers of a university hospital in southern Italy. et al. Vaccination coverage in healthcare workers: a multi - D, Capua A, La Fauci V, Squeri R, Grillo OC, Calimeri S. Congenital rubella syndrome and immunity status of immigrant women living in southern Italy: a cross-sectional, seroepidemio - diseases: systematic review and meta-anal - L, Cannav\u00f2 G, Ventura Spagnolo E. Study on hepatitis B and C serologic status among municipal solid waste workers in Messina \u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).su aparici\u00f3n y mejorar la seguridad de los pacientes hospitali - zados. Palabras clave: infecci\u00f3n tracto urinario, factores de secundaria, epidemiolog\u00eda Risk factors to secondary of episodes associated mortality can increase up to 33%. However, very little is known about the epidemiology of these infections. The determination of modifiable risk factors to develop this ty - pe of bacteremia could help to control the infection and redu - ce health costs. Material and methods. Cases-control study of NBS-UTI diagnosed at the University Hospital of Canary Islands bet - ween 2010-2014. The clinical-epidemiological variables and the collected. Logistic regression was used to study the variables associated with the development of NBS-UTI. Results. A total of 178 episodes were studied, 85 cases and 93 controls. The average stay was significantly greater in the cases; from admission to bacteremia (p <0.091), the central venous catheter (p <0.043) and in the episode (p behaved as factors the acquisition as that had not previously been studied; as well as the surgery in the episode, which had not been studied either, increase in is RESUMEN Introducci\u00f3n. Las bacteriemias nosocomiales secunda - rias a infecciones del tracto urinario (BNS-ITU) ocurren en un 1-4% de los episodios y la mortalidad asociada puede aumen - tar hasta el 33%. Sin embargo, se conoce muy poco sobre la epidemiolog\u00eda de estas infecciones. La determinaci\u00f3n de los factores de riesgo modificables para desarrollar este tipo de bacteriemias podr\u00eda ayudar al control de la infecci\u00f3n y reducir el gasto sanitario. Material y m\u00e9todos. Estudio de casos y controles de las BNS-ITU diagnosticadas en el Hospital Universitario de Cana - rias entre 2010-2014. Se recogieron las variables cl\u00ednico-epi - demiol\u00f3gicas y los factores de riesgo potenciales intr\u00ednsecos y extr\u00ednsecos. Se utiliz\u00f3 la regresi\u00f3n log\u00edstica para estudiar las variables asociadas al desarrollo de BNS-ITU. Resultados. Se estudiaron 178 episodios, 85 casos y 93 controles. La estancia media fue significativamente mayor en los casos; desde el ingreso hasta la bacteriemia (p< 0,003), co - mo desde \u00e9sta hasta el alta (p< 0,005). La insuficiencia hep\u00e1ti - ca (p< 0,091), el uso de ventilaci\u00f3n mec\u00e1nica (p<0,001), de el cat\u00e9ter venoso central (p<0,043) y la cirug\u00eda en el episodio (p< 0,001) se comportaron como factores de riesgo para la adqui - sici\u00f3n de BNS-ITU. Conclusiones. Los dispositivos invasivos, como el cat\u00e9ter venoso central y la ventilaci\u00f3n mec\u00e1nica, que no hab\u00eda sido estudiada previamente; as\u00ed como la cirug\u00eda en el episodio, que tampoco hab\u00eda sido estudiada, suponen factores de riesgo. Adem\u00e1s, la BNS-ITU causa un aumento significativo de la es - tancia hospitalaria. Por ello, es necesario conocer los factores de riesgo para la aparici\u00f3n de estas infecciones, y as\u00ed, prevenir Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario 1Servicio de Microbiolog\u00eda y Control de la Infecci\u00f3n, Hospital Universitario de Canarias, Tenerife, Espa\u00f1a 2Servicio de apoyo a la investigaci\u00f3n. Colegio Oficial de Enfermer\u00eda de Santa Cruz de Tenerife, Espa\u00f1a. 3Departamento de Medicina Preventiva y Salud P\u00fablica de la Universidad de La Laguna, Tenerife, Espa\u00f1aLaura Sante1 Mar\u00eda Lecuona1 Armando Aguirre Jaime2 \u00c1ngeles Arias3 Correspondencia: Laura Sante Servicio de Microbiolog\u00eda y Control de la Infecci\u00f3n, Hospital Universitario de Canarias Ctra. Ofra S/N La Cuesta 38320 La Laguna, en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al. Rev Esp Quimioter 2019;32(4): 311-316312Los controles se obtuvieron de la base de datos de los uri - nocultivos procesados en el Servicio de Microbiolog\u00eda y Con - trol de la Infecci\u00f3n, procedentes de pacientes ingresados en el hospital. Se comprob\u00f3 que correspond\u00edan a un episodio de ITU durante ese periodo, pero que no hab\u00edan desarrollado una BNS, siguiendo la definici\u00f3n de los CDC [8] para su diagn\u00f3stico: \u00b7 El paciente con o sin sondaje urinario presentaba al menos uno de los siguientes signos o s\u00edntomas: \u00b7 fiebre (>38\u00ba C) \u00b7 dolor en el \u00e1ngulo costovertebral \u00b7 frecuencia urinaria* \u00b7 disuria* \u00b7 y adem\u00e1s, el paciente tuviese un cultivo de orina con no m\u00e1s de dos especies de organismos identificados, al menos uno de los cuales fuese una bacteria con una recuento 105 UFC/ mL. *Estos dos s\u00edntomas no pueden considerarse cuando el pacientes es portador de sondaje urinario. Los controles se aparearon a los casos por fecha de ingreso, sexo, edad, servicio de ingreso y microorganismo causal de la infecci\u00f3n. Se revisaron las historias cl\u00ednicas de cada uno de los episo - dios de los casos y de los controles. Se recogieron las variables cl\u00ednico-epidemiol\u00f3gicas (sexo, edad, servicio, microorganismo, d\u00edas de hospitalizaci\u00f3n previos a la bacteriemia, d\u00edas de hospi - talizaci\u00f3n desde la bacteriemia hasta el alta, ingreso previo en los \u00faltimo 6 meses); as\u00ed como los factores de riesgo potencia - les intr\u00ednsecos (Neoplasia, Insuficiencia hep\u00e1tica, Insuficiencia renal, \u00dalcera por Presi\u00f3n, Hipertensi\u00f3n Arterial, Diabetes Me - llitus, Inmunosupresi\u00f3n, \u00cdndice de comorbilidad de Charlson) y los factores de riesgo potenciales extr\u00ednsecos (tratamiento antibi\u00f3tico previo a la infecci\u00f3n, Sondaje vesical, Ventilaci\u00f3n mec\u00e1nica, Cat\u00e9ter venoso central y Cirug\u00eda durante el ingreso). En cuanto a la prescripci\u00f3n de antibi\u00f3ticos previa a la fecha de infecci\u00f3n se consult\u00f3 en las historias cl\u00ednicas de los pacientes si \u00e9stos hab\u00edan recibido terapia antimicrobiana la se - mana anterior a la fecha de infecci\u00f3n y si el microorganismo aislado era sensible a la misma. An\u00e1lisis estad\u00edstico. Para dotar al estudio de una poten - cia del 80% en pruebas bilaterales de contraste de hip\u00f3tesis a un nivel de significaci\u00f3n p 0.05, se consider\u00f3 que la preva - lencia del factor con sospecha de asociaci\u00f3n a la bacteriemia secundaria era de un 30% entre los controles y en un 20% mayor, como diferencia sustancial, entre los casos, se estim\u00f3 necesario disponer de 93 sujetos por grupo. Ese tama\u00f1o de muestra permitir\u00eda el empleo de modelos de regresi\u00f3n log\u00eds - tica binaria con un m\u00e1ximo de 8 factores con posibilidad de asociaci\u00f3n a la bacteriemia secundaria como efecto, seg\u00fan los requisitos de adecuaci\u00f3n de Hosmer-Lemeshov para el empleo de un modelo de regresi\u00f3n log\u00edstica. La muestra se describi\u00f3 resumiendo las variables nomi - nales con la frecuencia relativa de sus categor\u00edas componen -necessary to know the risk factors for the appearance of these infections, and thus - teremia, epidemiology. INTRODUCCI\u00d3N Las infecciones del tracto urinario (ITU) son una de las causas m\u00e1s frecuentes de infecci\u00f3n nosocomial en Europa [1] y en EEUU [2]. Aproximadamente un 80% de los casos, se relacionan con la presencia de cat\u00e9ter urinario [3]. Las bacte - riemias nosocomiales secundarias a infecciones del tracto uri - nario (BNS-ITU) ocurren en un 1-4% [4] de los episodios y la mortalidad asociada a estos procesos puede aumentar hasta el 33% [2,5]. No obstante, en EEUU se estima que un 17% de las de las bacteriemias nosocomiales son secundarias a ITU [6] y en Espa\u00f1a, seg\u00fan los datos obtenidos del Estudio de Prevalencia de las Infecciones Nosocomiales en Espa\u00f1a (EPINE) suponen un 37,3% del total de BNS y un 11,8% del total de BN, ocupando el primer puesto de las bacteriemias nosocomiales secundarias (BNS) [7]. Adem\u00e1s, las consecuencias econ\u00f3micas de este tipo de infecciones son tambi\u00e9n importantes y cuantiosas. En un estudio realizado por Saint et al. [4] describieron que cada epi - sodio relacionado con BNS-ITU supon\u00eda un incremento en el coste sanitario de 3.000 d\u00f3lares. A pesar de estas cifras, se conoce muy poco sobre la epi - demiolog\u00eda de las bacteriemias nosocomiales relacionadas con las ITU. La determinaci\u00f3n de los factores de riesgo modificables para desarrollar este tipo de bacteriemias podr\u00eda ayudar a de - finir pr\u00e1cticas apropiadas para el control de la infecci\u00f3n y a mejorar la seguridad de los pacientes hospitalizados, al mismo tiempo que se reducir\u00eda el gasto sanitario. El objetivo del presente estudio es identificar factores de riesgo potenciales de padecer una bacteriemia secundaria a in - fecci\u00f3n urinaria en los pacientes hospitalizados. MATERIAL Y M\u00c9TODOS Se realiz\u00f3 un estudio de casos y controles de las BNS-ITU diagnosticadas en el Hospital Universitario de Canarias entre el 1 de enero de 2010 y el 31 de diciembre de 2014. Se trata de un hospital de tercer nivel de 660 camas, que dispone de una Unidad de Cuidados Intensivos m\u00e9dico-quir\u00fargica y se reali - zan trasplantes renales. Los casos se obtuvieron de las bases de datos las bacteriemias nosocomiales (BN) que fueron cla - sificadas por la Secci\u00f3n de Control de la Infecci\u00f3n siguiendo los criterios de los CDC [8] en: Bacteriemias Primarias, Bacte - riemias Relacionadas con Cat\u00e9ter y Bacteriemias secundarias a otros procesos infecciosos. Se consider\u00f3 que la bacteriemia era secundaria a una ITU cuando se diagnosticaba una infecci\u00f3n con un hemocultivo positivo para al menos un mismo microor - ganismo aislado y causante de la infecci\u00f3n de la ITU, y que hubiese sido recogido durante el periodo en que se atribu\u00eda la bacteriemia secundaria. Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al. Rev Esp Quimioter 2019;32(4): 311-316313Whitney si son ordinales o de escala no- normal. Los factores que alcanzaron en estas comparaciones una diferencia a un nivel p0,20 fueron introducidas como variables explicativas de la bacteriemia se - cundaria a ITU en modelos de regresi\u00f3n lo - g\u00edstica binaria multivariable empleando la estrategia de modelo lleno por pasos hacia atr\u00e1s y criterio de Wald. Para la retenci\u00f3n del factor se estableci\u00f3 un valor p 0,05. Todos los c\u00e1lculos se realizaron con ayuda del paquete de procesamiento esta - d\u00edstico informatizado SPSS 24.0 de IBM- SPSS Inc, Armonk, NY\u00a9. RESULTADOS Se estudiaron un total de 178 episo - dios de infecciones del tracto urinario, de los cuales 85 correspond\u00edan a casos, que desarrollaron bacteriemia nosocomial pos - terior y 93 a controles, que no la desarro - llaron. En la tabla 1 se observan los poten - ciales factores de riesgo estudiados, para los casos y para los controles. En los ca - sos de BNS-ITU recogidos, observamos un predominio de hombres (54,1%) con una edad media de 67 a\u00f1os. La mayor\u00eda de es - tas BNS se diagnosticaron en los servicios m\u00e9dicos (40%), seguidos de los servicios quir\u00fargicos (25,8%). El uso de dispositivos invasivos, como la sonda vesical (77,6%), la ventilaci\u00f3n mec\u00e1nica (VM) (40%) o el cat\u00e9ter venoso central (CVC) (63,5%) fue - ron utilizados en con frecuencia en estos pacientes. Adem\u00e1s, un 51,7% de estos pa - cientes hab\u00edan sido sometidos a cirug\u00eda en el ingreso. Un 18,8% fueron exitus duran - te el episodio. Entre los casos, los microorganismos m\u00e1s frecuentemente aislados fueron los bacilos gramnegativos (74,4%), principal - mente Enterobacterias (54,9%), grampositivos (18,2%), ma - yoritariamente Enterococcus spp. (14,2%) y en tercer lugar las levaduras del g\u00e9nero Candida (6,5%) (tabla 1 y 2). La estancia media fue significativamente mayor en los casos que en los controles; tanto desde la fecha de ingreso hasta el desarrollo de la bacteriemia (p< 0,003), como desde \u00e9sta hasta el alta (p< 0,005). Adem\u00e1s, este grupo present\u00f3 con mayor frecuencia insuficiencia hep\u00e1tica (p< 0,091). Asimismo, el uso de dispositivos invasivos, como la VM o el CVC fue sig - nificativamente mayor entre los casos (p<0,001 y p<0,043). El tes, las ordinales y de escala no-normal con mediana(P5P95) o mediana(rango) y las de escala normal con media (DT). La nor - malidad se prob\u00f3 con histogramas y test de Kolmogorov-Smir - nov. Los resultados se ofrecen en intervalos de confianza al 95%. La comparaci\u00f3n de los potenciales factores de riesgo en - tre casos y controles se efectu\u00f3 con la prueba chi2 de Pearson cuando los factores eran variables nominales y U de Mann-POTENCIALES FACTORES DE RIESGO CASOS (n=85)CONTROLES (n=93)Valor-p Edad en a\u00f1os, mediana (P 5-P95) 67 (25-85) 70 (25-86) 0,383 Sexo masculino, n (%) 46 (54,1) 48 (51,6) n (%) M\u00e9dicos Quir\u00fargicos Onco-hematol\u00f3gicos Intensivos UCI- Pedi\u00e1trica Pediatr\u00eda34 (40) 22 (25,8) 15 (17,6) 12 (14,1) 0 (0) 2 (2,3)30 (32,2) 35 (37,6) 12 (12,9) 12 (12,9) 2 (2,1)0,392 Microorganismos, n(%) Cocos grampositivos Bacilos n (%) 29 (34,1) 26 (27,9) 0,400 Insuficiencia, renal n (%) 27 (31,7) 23 (24,7) 0,297 Insuficiencia hepatica, n (%) 12 (14,1) 6 (6,4) 0,091 \u00dalcera por Presi\u00f3n, n (%) 12 (14,1) 19 (20,4) 0,267 Hipertensi\u00f3n, n (%) 51 (60) 58 (62,3) 0,746 Diabetes Mellitus, n (%) 32 (37,6) 40 (43) 0,466 Dislipidemia, n (%) 31 (36,4) 31 (33,3) 0,661 Inmunosupresi\u00f3n, n (%) 27 (31,7) 29 (31,1) 0,933 Sonda vesical, n (%) 66 (77,6) Ventilaci\u00f3n mec\u00e1nica, n (%) 34(40) 11(11,8) <0,001 Cat\u00e9ter Venoso Central, n (%) 54 (63,5) 45 (48,3) 0,043 Hospitalizaci\u00f3n previa en 6 meses, n (%) 32 (37,6) 32 (34,4) 0,653 Cirug\u00eda en el ingreso, n (%) 44 (51,7) 26 (27,9) 0,001 \u00cdndice Charlson, mediana (P 5-P95) 49 (57,6) 46 Sensibles, n (%) 11 (22,4) 15 (32,6) 0,243 Exitus, n (%) 16 (18,8) 13 (13,9) 0,382Tabla 1 Resultado de las comparaciones de los potenciales factores de riesgo a una bacteriemia secundaria a una infecci\u00f3n del tracto urinario entre casos y controles.Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al. Rev Esp Quimioter 2019;32(4): 311-316314calizaci\u00f3n Quir\u00fargica y las Infecciones del Tracto Respiratorio, las BNS m\u00e1s frecuentes y prevalentes en los hospitales [9, 10]. Estos 85 casos, supusieron un 24% del total de BNS del pe - riodo a estudio, siendo las segundas BNS m\u00e1s prevalentes en nuestro hospital, por detr\u00e1s de las bacteriemias nosocomiales secundarias a infecciones de localizaci\u00f3n quir\u00fargica (ILQ) que representaron el 28,5% [11]. En Espa\u00f1a, seg\u00fan el estudio EPINE del a\u00f1o 2017, estas bacteriemias fueron un 11,83% del total de BN, siendo las m\u00e1s prevalentes [7]. En Europa, seg\u00fan el in - forme European Center for Disease and Control (E-CDC) [12] las BNS-ITU supusieron un 8% del total de BN (28,8%), siendo las BNS m\u00e1s prevalentes. En nuestro hospital, el porcentaje de prevalencia es menor que en Espa\u00f1a y Europa [11]. Con estos datos podemos afirmar que las BNS-ITU supo - nen un porcentaje no despreciable con respecto a las BN, sin embargo, constituyen un grupo de infecciones poco estudiado y la bibliograf\u00eda referente a ellas es muy escasa. Por ello, hemos realizado un estudio de casos y controles para determinar los factores predisponentes para que un paciente con infecci\u00f3n del tracto urinario desarrolle una bacteriemia nosocomial. Para ello, hemos recogido todos los casos de BNS-ITU en el per\u00edo - do de estudio y hemos apareado nuestros controles seg\u00fan el a\u00f1o de infecci\u00f3n y el servicio, adem\u00e1s de los factores de riesgo no modificables como son la edad y el sexo. La edad ha sido descrita como factor de riesgo para la adquisici\u00f3n de BNS-ITU [4, 13, 14]. Seg\u00fan un estudio realizado por Griebling et al. [15] las mujeres presentan un mayor riesgo de padecer una ITU, sin embargo, a la hora de desarrollar una bacteriemia secundaria en nuestro estudio no existieron diferencias de sexos, al igual que en el trabajo de Greene et al. [16]. En nuestro estudio, los microorganismos predominantes fueron los bacilos gramnegativos, seguidos de los cocos gram - positivos (especialmente de los Enterococcus spp.) y levaduras. Este porcentaje es similar al encontrado por otros autores [13, 14, 17]. En el estudio presentado por de Saint et al. [4] aunque los bacilos gramnegativos fueron globalmente los microorga - nismos m\u00e1s frecuentes, si se desglosa por especies, los mayo - ritarios fueron los Enterococcus spp. tanto en la serie de casos como en la serie de controles, siendo m\u00e1s frecuentemente ais - lados entre los casos (30,2% vs. 22,3%, p= 0,011). Chang et al. [2] obtuvieron un predominio de los Enterococcus spp. (29%) seguidos de Candida spp., (20%), teniendo los pacientes con bacteriemias por Candida spp. un riesgo 3,4 veces mayor de sufrir exitus que los pacientes con bacteriemia por Escherichia coli. En nuestra serie se produjo un 18,8% de exitus, de los cuales 10 (62,5%) ten\u00edan infecci\u00f3n causada por bacilos gram - negativos. Diversos autores refieren porcentajes de mortalidad asociados a una infecci\u00f3n BNS-ITU que var\u00eda entre el 7,5% [13] y el 16,2% [18]. Se ha identificado que el uso de dispositivos invasivos, co - mo la sonda vesical, como factor de riesgo para el desarrollo de bacteriemia [4, 18] y sepsis [19]. En nuestro estudio, en el an\u00e1 - lisis univariante obtuvimos que el uso de sonda no se asociaba a mayor riesgo de desarrollo de bacteriemia; pero sin embargo, 51,7% de los casos hab\u00edan sometido a cirug\u00eda en el ingreso, frente al 27,9% del grupo control (p< 0,001). No se encontraron diferencias significativas en cuanto al consumo previo de antibi\u00f3ticos ni se obtuvieron diferencias en cuanto a la sensibilidad de los tratamientos emp\u00edricos aplica - dos en ambos grupos de pacientes. En la tabla 3 se muestran los resultados del ajuste del modelo de regresi\u00f3n log\u00edstica en el an\u00e1lisis multivariante. Los pacientes con ventilaci\u00f3n mec\u00e1nica y los que tuvieron un pro - ceso quir\u00fargico durante el ingreso presentaron un riesgo supe - rior de desarrollar BNS. DISCUSI\u00d3N Las BNS-ITU son, junto con las BNS a Infecciones de Lo -Microorganismo n (%) Escherichia coli 29 (31,8) Klebsiella spp. 18 (19,7) Pseudomonas aeruginosa 16 (17,5) Enterococcus spp. 13 (14,2) Candida spp. 6 (6,5) Staphylococcus coagulasa negativos 3 (3,2) 2 (1) Enterobacter cloacae 1 (1) Fusobacterium nucleatum (1) Proteus mirabilis 1 (1) Serratia marcescens 1 (1)Tabla 2 Distribuci\u00f3n de los microorganismos en los pacientes con BNS-ITU 2010-2014 El modelo arranca lleno con los potenciales factores: D\u00edas pre-bacteriemia, Insufi - ciencia hep\u00e1tica, Ventilaci\u00f3n mec\u00e1nica, Cat\u00e9ter venoso central, Cirug\u00eda al ingreso, e \u00cdndice Charlson, como potencialmente explicativos de la bacteriemia secundaria. El modelo converge a los 6 pasos reteniendo s\u00f3lo a la Ventilaci\u00f3n mec\u00e1nica y la Cirug\u00eda al ingreso.Tabla 3 Resultados del ajuste del modelo de regresi\u00f3n log\u00edstica multivariante a los potenciales factores de riesgo considerados en el estudio para el desarrollo de BSI- ITU que alcanzan significaci\u00f3n en su comparaci\u00f3n univariante entre casos y controles Factor OR(IC95%) p-Valor Ventilaci\u00f3n mec\u00e1nica 4,6 (2,1-10,3) <0,001 Cirug\u00eda en el 2,8 (1,4- 5,5) 0,003Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al. Rev Esp Quimioter 2019;32(4): 311-316315retrospectivo, no pudimos determinar si a todos los pacientes que padecieron un episodio de bacteriemia se le solicit\u00f3 cultivo microbiol\u00f3gico de otras muestras cl\u00ednicas para poder descar - tar infecci\u00f3n en otra localizaci\u00f3n, pudiendo tener un exceso de clasificaci\u00f3n de bacteriemias primarias quedando as\u00ed las BNS-ITU infradiagnosticadas. Otra limitaci\u00f3n, es que el estu - dio se realiz\u00f3 en un \u00fanico centro hospitalario, y para conocer mejor la epidemiolog\u00eda de las BNS-ITU en los hospitales de ni - vel terciario ser\u00eda necesario realizar un estudio multic\u00e9ntrico. La tercera limitaci\u00f3n es el escaso n\u00famero de controles. Esto es debido a que en nuestro planteamiento decidimos aparear los controles seg\u00fan el tipo de microorganismo, ya que al ser un factor no modificable podr\u00edamos observar si encontr\u00e1bamos otros factores de riesgo modificables para la prevenci\u00f3n de las BNS-ITU. En conclusi\u00f3n, y a pesar de estas limitaciones, creemos que nuestro estudio tiene importantes implicaciones cl\u00ednicas. Observamos que los dispositivos invasivos, como el cat\u00e9ter venoso central y la ventilaci\u00f3n mec\u00e1nica, que no hab\u00eda sido estudiada previamente, se comporta como un factor de riesgo para la adquisici\u00f3n de una BNS-ITU. La cirug\u00eda en el episodio, que tampoco hab\u00eda sido estudiada previamente, supone tam - bi\u00e9n un factor de riesgo. Adem\u00e1s, la bacteriemia asociada a ITU causa un aumento significativo de la estancia hospitalaria. Por ello, consideramos que es necesario conocer los factores de riesgo para la aparici\u00f3n de estas infecciones, para poder prevenir su aparici\u00f3n y mejorar la seguridad de los pacientes hospitalizados. FINANCIACI\u00d3N Los autores declaran que no han recibido financiaci\u00f3n pa - ra la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener conflicto de intereses. BIBLIOGRAF\u00cdA 1. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Du - comble T et al. 2016;13(10):e1002150. doi: 10.1371/ journal.pmed.1002150. Chang R, Greene MT, Chenoweth CE, Kuhn L, Shuman E, Rogers MA et al. Epidemiology of hospital-acquired urinary 2011;32(11):1127-9. doi: 10.1086/662378. 3. World Health Organization. 2003. Prevenci\u00f3n de las infecciones nosocomiales: gu\u00eda pr\u00e1ctica / revisores : G. Ducel, J. Fabry y L. Ni - colle, 2a ed. Ginebra : Organizaci\u00f3n Mundial de la 20 December 2018]. Avaliable from: http://www.who.int/iris/hand invasivos, como la ventilaci\u00f3n me - c\u00e1nica y el cat\u00e9ter venoso central si eran factores de riesgo significativos para el desarrollo de una BNS-ITU, lo que podr\u00eda estar relacionado, ya que se trata de pacientes ingresados en las unidades de cuidados intensivos, con la patolog\u00eda de base y gravedad de estos pacientes. La insuficiencia hep\u00e1tica, al igual que en el trabajo de Greene et al. [16] se comport\u00f3 como un factor de riesgo. Encontramos diferencias significativas respecto a la es - tancia hospitalaria. Aquellos pacientes que desarrollaron bac - teriemia permanecieron m\u00e1s d\u00edas de estancia desde el ingreso hasta el desarrollo de la misma y posteriormente desde \u00e9sta \u00faltima hasta el alta. En el estudio de Greene et al. [16] la estan - cia hospitalaria media tambi\u00e9n fue significativamente superior en los casos que en los controles. Esto puede significar un au - mento del gasto sanitario, tal y como describieron Riu et al. [21] en un estudio sobre el impacto econ\u00f3mico del desarrollo de bacteriemia seg\u00fan el foco de infecci\u00f3n y la sensibilidad an - tibi\u00f3tica. En dicho estudio, observaron que las BNS-ITU por mi - croorganismo sensibles supon\u00edan un coste adicional de 6.786 \u20ac y hasta 13.299 \u20ac en el caso de bacteriemia por microorganis - mos multirresistentes. No encontramos diferencias significativas en cuanto al tratamiento previo con antimicrobianos a diferencia de otros estudios, como el de Saint et al. [4], Greene et al. [16] y Ro- gers et al. [22]. en los cuales describieron que el uso de an - tibi\u00f3ticos era un factor de riesgo protector para el desarrollo de bacteriemia. Por ello, la importancia de aislar e identificar el microorganismo productor de la infecci\u00f3n para adecuar el tratamiento antibi\u00f3tico y no aumentar el desarrollo de resis - tencias bacterianas. Padecer diabetes no se comport\u00f3 como un factor de ries - go para desarrollar BNS-ITU, similar a lo descrito por Greene et al. [16] a diferencia del trabajo de Saint et al. [4], que obser - varon que aquellos pacientes con diabetes ten\u00edan mayor pro - babilidad de desarrollar BNS-ITU. Tampoco encontramos dife - rencias en los pacientes con insuficiencia renal, a diferencia de otro estudio [16], que si encontraron diferencias significativas. En nuestra serie la terapia con inmunosupresores no fue esta - d\u00edsticamente significativa, a diferencia de otros autores que la describen como un factor de riesgo asociado para desarrollar BNS-ITU [4,14]. Seg\u00fan el an\u00e1lisis multivariante, s\u00f3lo dos factores se com - portaron como factores independientes asociados a padecer un episodio de bacteriemia nosocomial, el haber sido sometido a un proceso quir\u00fargico en el episodio y llevar un dispositivo de ventilaci\u00f3n mec\u00e1nica. En el trabajo publicado por Chang et al. [2] la cirug\u00eda en el episodio hab\u00eda sido descrita en el 84% de los pacientes con BNS-ITU y Bishara et al. [18] describen que un 12% de la poblaci\u00f3n a estudio proced\u00eda de un servicio quir\u00fargico; sin embargo no ha sido estudiada como factor de riesgo en otros trabajos de casos-control [5, 18]. La ventilaci\u00f3n mec\u00e1nica como factor de riesgo no hab\u00eda sido estudiada pre - viamente [5, 16 18]. Una de las limitaciones de nuestro estudio es que, al ser Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al. Rev Esp Quimioter 2019;32(4): 311-3163164. Saint S, Kaufman SR, Rogers MA, Baker Lipsky Chenoweth CE, Weinstein SM, Mirrett S, Reimer LG, Parmi- giani G, et al. cultures in the 1990s: evaluation the - Informe global de Espa\u00f1a. Sociedad Espa\u00f1ola de Medicina Preventiva, Salud P\u00fablica e Higiene, 2017. A, Luzzaro F, Lombardi G, Toniolo A. A two year analysis of risk factors and outcome in patients A, Miguel MA, Ramos MJ, Pedroso Y, Lecuo - na M. Epidemiological - survey of infections J Urol. 2005;173(4):1281- 7. PMID: 15758783. 16. Greene MT, Chang R, Kuhn L, Rogers MA, Chenoweth CE, Shuman E et al. E, San Juan R, Munoz P, Voss A, Kluytmans J. on behalf of the Co-operative Group of the Study Samra Z, H, et al. Five-year prospective study of bacteraemic urinary tract in - fection in a single Clin C. of a urinary catheter pre - Terradas R, Sala M, Garcia-Alzorriz E, Castells X et al. Incremental cost of nosocomial bacteremia according to the focus of infection and antibiotic sensitivity of the causati - ve microorganism in a university hospital. Medicine (Baltimore). 2017;96(17):e6645. doi: 10.1097/MD.0000000000006645. 22. Rogers MA, Blumberg N, Heal JM, Kuhn L, Greene MT, Shuman E et al. Role of transfusion in the Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).en la prescripci\u00f3n del TAR durante el ingreso hospitalario as\u00ed como solicitar anal\u00edticas de CV y linfocitos CD4 a todos los pa - cientes VIH ingresados en el Hospital. Palabras Clave: VIH, hospitalizaci\u00f3n, mortalidad. Hospital admission and mortality causes of HIV patients in a third level hospital ABSTRACT Introduction. The aim of this study is to describe the HIV population admitted to a tertiary level a third level Hospital. Inclusion criteria: Patients 18 years with a prescription of diagnosis of HIV known or of were as 79.7% were male; Age patients that were admitted to hospital during 2016-2017 were the 13.52%. The main on ART treatment prescription during hospital ad -RESUMEN Introducci\u00f3n. El objetivo del presente trabajo es describir el perfil de los pacientes VIH que ingresan en un hospital de tercer nivel as\u00ed como analizar las causas de ingreso hospitalario y de mortalidad durante el mismo. Material y m\u00e9todos. Estudio observacional, retrospecti - vo llevado a cabo en un Hospital de tercer nivel. Criterios de inclusi\u00f3n: Pacientes 18 a\u00f1os con prescripci\u00f3n de tratamiento antirretroviral (TAR) y diagn\u00f3stico de VIH conocido o descu - bierto durante el ingreso. Como motivo de ingreso hospitalario se utiliz\u00f3 el diagn\u00f3stico al alta de cada paciente. Se recogieron variables cl\u00ednicas, anal\u00edticas as\u00ed como las causas de exitus. Resultados. En el periodo de estudio ingresaron un to - tal de 162 pacientes VIH. Cumplieron los criterios de inclusi\u00f3n 128, de los cuales 8 fueron diagnosticados como VIH de novo. Un 79,7% fueron varones; edad 50,29\u00b19,81 a\u00f1os. El principal diagn\u00f3stico al alta (38,3%) fueron ciertas enfermedades in - fecciosas y parasitarias (Clasificaci\u00f3n CIE-10) y dentro de esta clasificaci\u00f3n, las infecciones directamente relacionadas con el VIH fueron las mayoritarias (24,1%). Las tasas de mortalidad de los pacientes VIH 18 a\u00f1os que ingresaron en el Hospital (a\u00f1os 2016 y 2017) fue del 13,52%. Las causas de muerte m\u00e1s fre - cuentes fueron ciertas enfermedades infecciosas y parasitarias seguidas de neoplasias. Conclusiones. Nuestros resultados enfatizan la necesidad de seguir reforzando el diagn\u00f3stico precoz de VIH as\u00ed como la profilaxis primaria de Pneumocysitis jirovecii en los pacientes VIH. Insistir en la adherencia al TAR desde las consultas de se - guimiento de especialista en enfermedades infecciosas y en las consultas de atenci\u00f3n farmac\u00e9utica, concienciar a los cl\u00ednicos Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel Hospital Regional Universitario de M\u00e1lagaRoc\u00edo Asensi-Diez Cristina Fern\u00e1ndez-Cuerva Juan Jos\u00e9 Alcaraz S\u00e1nchez Isabel Mu\u00f1oz-Castillo Correspondencia: Roc\u00edo Asensi-Diez Hospital Regional Universitario de M\u00e1laga. Avenida CP.29010. 13 April 2019Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326318m\u00e1s elevadas en este grupo de pacientes que en la poblaci\u00f3n general y parece ser causada por infecciones no relacionadas con el VIH [10]. En los pacientes con TAR, las principales causas de morta - lidad no son infecciosas, si no enfermedades cardiovasculares (CV), enfermedad renal avanzada, enfermedad hep\u00e1tica des - compensada y c\u00e1ncer no relacionado con VIH [11]. Respecto a las enfermedades CV, destacan en incidencia el infarto agudo de miocardio y el ictus [12] que son m\u00e1s prevalentes que en individuos no portadores de VIH. Esto se debe a que la infecci\u00f3n por VIH produce una inflamaci\u00f3n cr\u00f3nica que incrementa la edad biol\u00f3gica y el desarrollo de enfermedades CV [13] y pese a que el TAR reduce la inflamaci\u00f3n, los marcadores siguen siendo m\u00e1s elevados que en pacientes no infectados [12]. En pacientes sin TAR, las principales causas de muerte son las complicacio - nes infecciosas debido a la inmunodeficiencia, siendo la tuber - culosis la m\u00e1s frecuente. En pa\u00edses de Europa del oeste se est\u00e1 produciendo un incremento de la incidencia de tuberculosis por microorganismos multirresistentes [14]. La complejidad del paciente VIH con y sin TAR provoca que las causas de ingreso hospitalario sean variadas. Destacan las causas infecciosas, relacionadas con VIH como la tuberculosis o no relacionadas, como neumon\u00eda y bacteriemia. Tambi\u00e9n se producen ingresos por causas no infecciosas: desnutrici\u00f3n, al - teraciones respiratorias, digestivas, cardiovasculares, renales, psiqui\u00e1tricas, hep\u00e1ticas, neurol\u00f3gicas y hematol\u00f3gicas [10]. El objetivo del presente trabajo es describir el perfil de los pacientes VIH que ingresan en un hospital de tercer nivel as\u00ed como analizar las causas de ingreso hospitalario y de mortali - dad durante el mismo. MATERIAL Y M\u00c9TODOS Estudio observacional, retrospectivo llevado a cabo en un Hospital de tercer nivel. Criterios de inclusi\u00f3n: Pacientes 18 a\u00f1os con prescripci\u00f3n de TAR y diagn\u00f3stico de VIH conocido o descubierto durante el ingreso y que ingresaron en cualquier unidad cl\u00ednica del hospital excepto ginecolog\u00eda y obstetricia. Periodo de estudio: Enero 2016 a Diciembre 2017. Criterios de exclusi\u00f3n: Aquellos pacientes VIH cuya duraci\u00f3n de ingreso fue <24 horas debido a la imposibilidad de recoger suficientes datos cl\u00ednicos y/o anal\u00edticos durante su estancia hospitalaria o bien, aquellos fugados antes de aclarar el motivo de su estancia hospitalaria. La informaci\u00f3n se recogi\u00f3 de las historias cl\u00ednicas electr\u00f3 - nicas y del registro de dispensaci\u00f3n a pacientes externos del Servicio de Farmacia: ATHOS-Prisma\u00ae Variables empleadas: Para la recogida de datos se elabor\u00f3 una base de datos en Excel que inclu\u00eda: 1. Variables demogr\u00e1ficas: edad y sexo 2. Otras variables: - Variables cl\u00ednicas: n\u00famero de ingresos en el periodo de estudio, n\u00famero de ingresos previos al periodo de estudio en mission as well as requesting viral and CD4 Keywords: HIV, Mortality, Hospitalization INTRODUCCI\u00d3N Seg\u00fan los datos de la Organizaci\u00f3n Mundial de la Salud de 2017, el VIH afectaba a 36,9 millones de personas de todo el mundo de los cuales 35,1 millones eran adultos. Actualmente nos encontramos en una \u00e9poca en que el acceso generaliza - do a combinaciones efectivas de tratamientos antirretrovirales (TAR) ha permitido disminuir la mortalidad asociada al VIH en un 59% a nivel mundial. A pesar de esto, desde el inicio de la epidemia, 35,4 millones [25,0 millones - 49,9 millones] de personas han muerto a causa de enfermedades relacionadas con el SIDA [1]. Seg\u00fan el informe de vigilancia epidemiol\u00f3gica del VIH/ SIDA en Espa\u00f1a (situaci\u00f3n hasta el 30/06/2018), hasta el 30 de junio de 2017 se hab\u00edan recibido, desde las 17 comunida - des aut\u00f3nomas (CCAA), Ceuta y Melilla, la notificaci\u00f3n de 3.381 nuevos diagn\u00f3sticos de VIH en el a\u00f1o 2017, lo que representa una tasa de 7,26 por 100.000 habitantes sin ajustar por retraso en la notificaci\u00f3n [2]. En el periodo 2011-2017, la neumon\u00eda por Pneumocystis jirovecii ha sido la enfermedad definitoria de SIDA m\u00e1s fre - cuente (28,4%), seguida de la tuberculosis de cualquier locali - zaci\u00f3n (20,6%) y de la candidiasis esof\u00e1gica (12,6%) [2]. En el a\u00f1o 2016 se produjeron en Espa\u00f1a un total de 410.611 fallecimientos, de los cuales 498 (1,2 por 1.000) fueron por VIH y SIDA. De \u00e9stos, 385 (77,3 %) se produjeron en hom - bres y 113 (22,7%) en mujeres. La tasa de mortalidad global por VIH y SIDA fue de 1,1 por 100.000 habitantes [3]. El TAR debe iniciarse en todos los pacientes con infecci\u00f3n por VIH-1, con o sin sintomatolog\u00eda, y con independencia del n\u00famero de linfocitos CD4+ [4]. Los primeros meses del TAR se consideran clave ya que las tasas de mortalidad son m\u00e1s altas durante el primer a\u00f1o de tratamiento [5]. En pa\u00edses desarrollados, se calcula que la mitad de pacien - tes con VIH tienen 50 a\u00f1os, por lo que cada vez tienen mayor n\u00famero de comorbilidades, entre las que destacan depresi\u00f3n, hipertensi\u00f3n arterial, dislipemia, insuficiencia renal, fractura \u00f3sea y diabetes mellitus que aparecen hasta diez a\u00f1os antes que en personas no infectadas y en mayor n\u00famero [6,7,8].. Sobre estos pacientes tambi\u00e9n influyen factores del estilo de vida, la obesidad, el tabaco y alcohol. En ciertos casos se producen coinfecciones por otros microorganismos, como el caso de virus de hepatitis B y hepatitis C. A esto, hay que sumarle que los pacientes con TAR se ven expuestos a la toxicidad a largo plazo de los f\u00e1rma - cos utilizados, lo cual puede enmascarar otras comorbilidades. Las toxicidades m\u00e1s frecuentes del TAR son dislipemia, resistencia a la insulina, y diabetes mellitus, y en el caso del tenofovir disoproxilo problemas renales y p\u00e9rdida de masa \u00f3sea [9]. Pese a que la esperanza de vida actual en pacientes VIH con TAR ha aumentado, las cifras de mortalidad siguen siendo Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326319Se recogi\u00f3 solamente el principal diagn\u00f3stico al alta, ad - miti\u00e9ndose m\u00e1s de uno en los casos en los que el curso de la hospitalizaci\u00f3n no se entendiera sin la suma de diferentes factores. No se incluyeron en esta clasificaci\u00f3n aquellos que fallecieron durante el ingreso, incluy\u00e9ndose as\u00ed en una clasi - ficaci\u00f3n a parte, la cual analizaba la principal causa de mor - talidad del episodio de hospitalizaci\u00f3n. Para clasificar la causa de mortalidad se utiliz\u00f3 la Estad\u00edstica de Defunciones seg\u00fan la Causa de Muerte. Esta estad\u00edstica se realiza siguiendo los crite - rios establecidos por la OMS en la CIE-10. Este dato se recogi\u00f3 del informe de defunci\u00f3n registrado en la historia cl\u00ednica de cada paciente. A la hora de clasificar la causa de mortalidad \u00fanicamente se recogi\u00f3 el motivo principal que llev\u00f3 al mismo, a diferencia de los diagn\u00f3sticos al alta, en los que se admitieron varios por ingreso hospitalario. An\u00e1lisis estad\u00edstico. El an\u00e1lisis de los datos fue descriptivo. Los valores de las variables fueron expresados como medias \u00b1 desviaci\u00f3n est\u00e1ndar (DE), medianas y rangos o porcentajes. Se consider\u00f3 que no exist\u00edan problemas \u00e9ticos en la realizaci\u00f3n del estudio, ya que se trat\u00f3 de un trabajo observacional, en el que la informaci\u00f3n recopilada se consider\u00f3 confidencial y se utiliz\u00f3 \u00fanica y exclusivamente en el \u00e1mbito profesional. RESULTADOS En el a\u00f1o 2016 ingresaron 21.755 pacientes 18 a\u00f1os en nuestro hospital excluyendo ginecolog\u00eda y obstetricia, de los cuales 85 pacientes fueron VIH. En 2017 ingresaron 20.832 pa - cientes, de los que 77 fueron VIH. Las tasas de ingreso por tanto fueron 0,39 y 0,37 respectivamente. En el periodo de estudio ingresaron un total de 162 pa - cientes con registro desde admisi\u00f3n como VIH excluyendo gi - necolog\u00eda y obstetricia. Cumplieron los criterios de inclusi\u00f3n 128, de los cuales 8 fueron diagnosticados como VIH de novo. Los 120 restantes ya estaban diagnosticados con anterioridad. Por lo que el n\u00famero total de pacientes reales ingresados fue de 170. La distribuci\u00f3n de pacientes en funci\u00f3n al tiempo que llevaban diagnosticados de VIH viene reflejada en la tabla 1. Un 79,7% fueron varones; edad 50,29\u00b19,81 a\u00f1os. Todos fueron ingresados al menos una vez por un periodo de tiempo 24h en el periodo de estudio (a\u00f1os 2016-2017). Se analizaron en total 250 ingresos hospitalarios de los cuales 11 fueron excluidos. La mediana de la estancia hospita- laria fue de 8 d\u00edas (2-86), presentando una mediana de ingre- so por paciente de 1 (1-15) durante los 2 a\u00f1os que abarc\u00f3 el estudio. La mediana de ingresos/paciente en nuestro centro ante - rior al periodo de estudio fue de 3 (0-32) ingresos. De los 120 ya diagnosticados de VIH, no se dispone de da - tos acerca de los a\u00f1os que hab\u00edan pasado desde el diagn\u00f3stico en 6 pacientes. La media de a\u00f1os diagnosticados de los 114 restantes fue de 13,85\u00b16,52 a\u00f1os. La tabla 1 muestra la distri - buci\u00f3n de pacientes en funci\u00f3n al tiempo que llevaban diag - nosticados de VIH. Se considera \"diagn\u00f3stico en el \u00faltimo a\u00f1o\" nuestro centro, unidad cl\u00ednica de ingreso, d\u00edas de hospitali - zaci\u00f3n, diagn\u00f3stico previo de VIH y en caso afirmativo, a\u00f1os diagnosticado de VIH, ingreso a la unidad cl\u00ednica del hospital por urgencias o programado desde consulta, diagn\u00f3stico al alta como motivo de ingreso, profilaxis con trimetoprim-sulfame - toxazol prescrita en receta electr\u00f3nica y causa de mortalidad en caso de producirse. - Variables anal\u00edticas: carga viral (copias/ml) aprox. 6 me - ses antes del ingreso y durante el/los ingreso/s, cifra de lin - focitos CD4 (c\u00e9lulas/\u00b5L) aproximadamente 6 meses antes del ingreso y durante el/los ingreso/s y coinfecci\u00f3n con virus de la hepatitis C (VHC). En aquellos pacientes que tuvieran m\u00e1s de un ingreso hos - pitalario durante el periodo de estudio y por tanto pudieran tener m\u00e1s de una determinaci\u00f3n de niveles de CV y de linfocitos CD4, se consider\u00f3 una \u00fanica medida de CV y CD4. En estos pa - cientes se consider\u00f3 la media de sus niveles de CV y de linfoci - tos CD4 resultante de todos los ingresos. - N\u00famero pacientes 18 a\u00f1os y n\u00famero de pacientes 18 a\u00f1os VIH y n\u00famero de exitus en el hospital en los a\u00f1o 2016 y 2017 exceptuando el servicio de ginecolog\u00eda y obstetricia. Datos extra\u00eddos de la unidad de documentaci\u00f3n y archivo del Hospital. - Variable de adherencia. El c\u00e1lculo se realiz\u00f3 con la si - guiente f\u00f3rmula: % adherencia = n\u00famero de unidades de me - dicaci\u00f3n ARV total dispensada/N\u00famero de unidades de medi - caci\u00f3n ARV prevista*100. Se consideraron unidades previstas las necesarias para cumplir el tratamiento en los d\u00edas incluidos desde la primera dispensaci\u00f3n hasta la \u00faltima en el periodo de tiempo conside - rado para el c\u00e1lculo. Definimos como buena adherencia un % 95 en los 6 me - ses previos al ingreso hospitalario en el periodo de estudio. Una adherencia por encima del 95% es necesaria para mantener una supresi\u00f3n virol\u00f3gica \u00f3ptima [15-18]. Los datos se recogie - ron de los episodios de dispensaci\u00f3n de la consulta de atenci\u00f3n farmac\u00e9utica a pacientes externos de nuestro hospital. En el caso que un paciente tuviera m\u00faltiples ingresos hospitalarios, lo cual podr\u00eda traducirse en una infraestimaci\u00f3n del porcentaje de adherencia al no acudir a la consulta a recoger su medica - ci\u00f3n durante el tiempo de hospitalizaci\u00f3n, se determin\u00f3, que en aquellos pacientes cuyos ingresos hospitalarios distaban menos de 6 meses el uno del otro, se aceptar\u00eda como % de adherencia el correspondiente al promedio de los 6 meses previos a la pri - mera de las estancias hospitalarias. Como motivo de ingreso hospitalario se utiliz\u00f3 el diagn\u00f3s - tico al alta de cada paciente. Asumimos el diagn\u00f3stico al alta de cada ingreso hospitalario como el diagn\u00f3stico primordial de toda la estancia del paciente en la unidad de hospitalizaci\u00f3n, pues nos proporcionaba mayor informaci\u00f3n que aquel que se recog\u00eda en el primer d\u00eda de ingreso como motivo de ingreso hospitalario. El diagn\u00f3stico al alta se identific\u00f3 a trav\u00e9s de un c\u00f3digo recogido en Clasificaci\u00f3n internacional de enfermeda - des, CIE-10 dividido a su vez en 20 categor\u00edas [19]. Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326320aquellos pacientes que llevan diagnosticados menos de un a\u00f1o en el momento del ingreso hospitalario. La distribuci\u00f3n de los ingresos en las distintas unidades del Hospital viene reflejada en la tabla 2. En el 66,5% de los casos los pacientes ingresaron a trav\u00e9s del servicio de urgencias del hospital, mientras que el 33,5% restante lo hizo de forma programada por su consulta de se - guimiento de atenci\u00f3n hospitalaria. El diagn\u00f3stico al alta de aquellos pacientes VIH ingresados durante 24 horas en nuestro hospital, y no fallecidos durante el mismo, se recogi\u00f3 en la tabla 3. Recogimos como subclasifi - caci\u00f3n dentro del grupo de ciertas enfermedades infecciosas y parasitarias aquellas asociadas a la enfermedad por el virus de la inmunodeficiencia humana (tabla 4). El principal diagn\u00f3stico al alta con un 38,3% de los diag - n\u00f3sticos fueron ciertas enfermedades infecciosas y parasitarias y dentro de esta clasificaci\u00f3n, las infecciones directamente re - lacionadas con el VIH fueron las mayoritarias con un 24,1%. De los diagn\u00f3sticos al alta clasificados como enfermedades del sis - tema respiratorio, encontramos 22 diagn\u00f3sticos de neumon\u00edas de origen infeccioso de un total de 39 que no incluimos dentro de la categor\u00eda B20-B24 de enfermedad por el virus del VIH ya que no se trataba de neumon\u00edas causadas por Pneumocystis o tuberculosis. Cuando analizamos la subclasificaci\u00f3n enfermedad por virus de la inmunodeficiencia humana del diagn\u00f3stico al alta, encontramos que el 48,4% de los diagn\u00f3sticos fueron por tu - mores onco-hematol\u00f3gicos seguido de enfermedad por VIH resultante en otras infecciones bacterianas (tabla 4). En total un 47,66% (N=61) de los pacientes incluidos ha - b\u00edan padecido o padec\u00edan infecci\u00f3n por el virus de hepatitis C. De ellos, 42 (68,85% estaban a\u00fan infectados durante el periodo de estudio) y 19 (31,14%) hab\u00edan sido ya tratados y estaban curados. Los datos de CV y linfocitos CD4 en los 6 meses previos al ingreso y durante el ingreso en el periodo de estudio vienen reflejados en la tabla 5. Cabe destacar que un 6,25% pacientes (N=8/128) fueron diagnosticados de novo. La mediana de CV de los pacientes diagnosticados de novo fue 219.009,48 (697,64 - 1.000.000) copias/ml. Respecto a los niveles de linfocitos CD4 durante el ingreso, los 8 pacientes diagnosticados de novo ten\u00edan una me - diana de linfocitos CD4 de 45 (22-483) c\u00e9lulas/\u00b5L. De los 98 pacientes de los que ten\u00edamos datos de linfo - citos CD4 en los 6 meses previos al ingreso, 25 pacientes te - n\u00edan niveles de CD4 <200 cel/\u00b5L y de estos, solo el 40% (N=10) hab\u00edan recibido profilaxis para la infecci\u00f3n por P. jirovecii con trimetoprim-sulfametoxazol. En cuanto a la adherencia al TAR, de los 120 pacientes con diagn\u00f3stico previo de VIH conocido al ingreso, 22,5% (N=27) de ellos recog\u00edan fuera de nuestro centro por lo que no dis - ponemos de datos de su adherencia; el 13,66% (N=16) hab\u00edan abandonado el tratamiento en los 6 meses previos al ingreso. La mediana de adherencia de los pacientes restantes: 81,67% A\u00f1os desde el diagn\u00f3stico de VIH N\u00famero de pacientes % Diagn\u00f3stico > 1 a\u00f1o y < 20 a\u00f1os 62 48,44 Diagn\u00f3stico 20 a\u00f1os 47 36,72 Diagn\u00f3stico de novo 8 6,25 Sin datos del tiempo desde el diagn\u00f3stico 6 4,69 Diagn\u00f3stico en el \u00faltimo a\u00f1o 5 3,91 TOTAL 128 100,00Tabla 1 Distribuci\u00f3n de pacientes en funci\u00f3n al tiempo que llevaban diagnosticados de VIH Unidad de ingreso N\u00famero ingresos N=239 % Enfermedades Infecciosas 134 56,07 Hematolog\u00eda y Hemoterapia 28 11,72 Cardiolog\u00eda 12 5,02 Aparato Digestivo 10 4,18 Cirug\u00eda Digestiva 9 3,77 Oncolog\u00eda 7 2,93 Neurolog\u00eda 6 2,51 Cirug\u00eda Cardiovascular 5 2,09 Traumatolog\u00eda 4 1,67 Cuidados Paliativos 4 1,67 Cirug\u00eda Pl\u00e1stica 4 1,67 Neurocirug\u00eda 4 1,67 Nefrolog\u00eda 3 1,26 Medicina Interna 2 0,84 Cirug\u00eda General 2 0,84 Salud Mental 2 0,84 Neumolog\u00eda 2 0,84 Otorrinolaringolog\u00eda 1 0,42 TOTAL 239 100Tabla 2 Distribuci\u00f3n de los ingresos en las diferentes unidades del Hospital. (N=98) fue del 98% (43-100). De ellos, 42,85% (N=42) pacien - tes eran buenos adherentes ( 95%). Las tasas de mortalidad de los pacientes 18 a\u00f1os ingresa- dos en el hospital excluyendo ginecolog\u00eda y obstetricia, en los a\u00f1os 2016 y 2017, fueron 5,93% y 6,46%, respectivamente. Las tasas de mortalidad de los pacientes VIH 18 a\u00f1os que ingresaron en el Hospital excluyendo ginecolog\u00eda y obstetricia en los a\u00f1os 2016 y 2017 fue del 13,52% (23/170). En el a\u00f1o 2016 la tasa de mortalidad fue de 10,22% y en el a\u00f1o 2017 fue Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326321Respecto a la adherencia de estos pacientes, 21,74% (N=5) hab\u00edan abandonado el TAR previo al ingreso en que fallecen, 17,39% (N=4) eran pacientes que fueron diagnosticados de novo de VIH durante el ingreso, del 13% (N=3) no tenemos da - tos de la adherencia al ser de otros centros. De los 11 restantes, 26,10% (N=6) eran buenos adherentes ( 95%) y 21,74% (N=5) ten\u00edan una adherencia <95%. DISCUSI\u00d3N El acceso global al TAR en la \u00faltima d\u00e9cada ha llevado a disminuciones sustanciales en la morbilidad y mortalidad re - lacionadas con el VIH, especialmente en los pa\u00edses de ingresos medios-bajos en los que la prevalencia es mayor. Sin embargo, se estima que el VIH fue la sexta causa m\u00e1s com\u00fan de perdida de vida a nivel mundial [20]. Las tasas de ingreso de los a\u00f1os 2016 y 2017 fueron 0,39 y 0,37 respectivamente, tasas m\u00e1s bajas que la reportada en otros estudios como el de \u00c1lvarez Barreneche MF et al (2017) [21]. La media de edad de nuestro estudio es m\u00e1s alta, 50,29 \u00b1 9,81 a\u00f1os, que la reportada en ese trabajo que fue de 37 a\u00f1os (30-49). En nuestro estudio, observamos que la unidad mayoritaria de ingreso de los pacientes VIH fue Enfermedades Infecciosas, seguida de la unidad de Hematolog\u00eda y Hemoterapia. El moti - vo de ingreso mayoritario, clasificado en nuestro estudio como de 17,94%. Un 86,95% eran hombres (N=20) con una media de edad \u00b1 desviaci\u00f3n est\u00e1ndar de de 52 a\u00f1os \u00b18,15. Estos 23 pacientes supusieron un total de 58 ingresos (23,20% de los ingresos totales) durante los dos a\u00f1os que abar - c\u00f3 el estudio, con una mediana de ingresos por paciente de 1 (1-8). 4 de estos pacientes fallecidos fueron diagnosticados de VIH durante el tiempo de estudio, 3 de ellos muriendo durante su primer y \u00fanico ingreso hospitalario y 1 durante su segundo, distanciado 15 d\u00edas del ingreso en el que fue diagnosticado por primera vez. Las unidades principales de ingreso Paliativos y Cirug\u00eda Or - top\u00e9dica y Traumatolog\u00eda cada uno con 1,72% (N=1). Las causas principales de mortalidad clasificadas por ca - p\u00edtulos de la clasificaci\u00f3n CIE-10 se encuentran en la tabla 6. Los datos de CV y linfocitos CD4 en los 6 meses previos al ingreso y durante el ingreso en el periodo de estudio de los pacientes que fallecieron est\u00e1n reflejados en la tabla 5. Un 17,39% (N=4/23) de los pacientes que fallecieron durante el ingreso fueron diagnosticados de VIH de novo. La mediana de CV de estos pacientes durante el ingreso fue de 81.633,25 copias/ml (39.507 - 1.000.000) y la de linfocitos CD4 fue de 68 c\u00e9lulas/\u00b5L (12-130). N\u00ba diagn\u00f3sticos % Ciertas enfermedades infecciosas y parasitarias 98 38,1 Enfermedad por virus de la inmunodeficiencia humana 62 24,1 Enfermedades del sistema respiratorio 39 15,1 Enfermedades del sistema circulatorio 30 11,7 Enfermedades del sistema digestivo 22 8,6 Traumatismos, envenenamientos y algunas otras consecuencias de causas externas 13 5,1 Tumores (neoplasias) 11 4,3 S\u00edntomas, signos y hallazgos anormales cl\u00ednicos y de laboratorio, no clasificados en otra parte 11 4,3 Enfermedades del sistema genitourinario 8 3,1 Enfermedades de la sangre y de los \u00f3rganos hematopoy\u00e9ticos, y ciertos trastornos que afectan el mecanismo de la inmunidad 7 2,7 Enfermedades de la piel y del tejido subcut\u00e1neo 5 1,8 Enfermedades del sistema osteo-muscular y del tejido conjuntivo 4 1,6 Factores que influyen en el estado de salud y contacto con los servicios de salud 3 1,2 Enfermedades endocrinas, nutricionales y metab\u00f3licas 2 0,8 Trastornos mentales y del comportamiento 2 0,8 Enfermedades del o\u00eddo y de la ap\u00f3fisis mastoides 1 0,4 Causas externas de morbilidad y de mortalidad 1 0,4 TOTAL 257 100Tabla 3 Diagn\u00f3stico al alta. Clasificaci\u00f3n CIE-10.Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326322las principales causas de hospitalizaci\u00f3n fueron tuberculosis pulmonar, candidiasis oral, neumon\u00eda por P. jirovecii y encefa - litis por Toxoplasma. La elevada contribuci\u00f3n de ingresos hos - pitalarios y mortalidad observada en nuestro centro debidos a enfermedades infecciosas y parasitarias pone de manifiesto la importancia de la profilaxis con trimetoprim-sulfametoxazol y la vacunaci\u00f3n frente a neumococo y meningococo para pa - cientes portadores de VIH. En nuestro estudio resulta llamativo que s\u00f3lo el 40% (10/25) de pacientes con niveles de linfocitos CD4<200 c\u00e9lulas/\u00b5L tuvieran prescripci\u00f3n de trimetoprim-sul - fametoxazol como profilaxis contra la infecci\u00f3n por P. jirovecii a pesar de que las Gu\u00edas [23] recomiendan profilaxis primaria en pacientes con linfocitos CD4+ <200 c\u00e9l/\u00b5l (AI). Esto nos lleva a concluir la necesidad de reforzar, desde las consultas cl\u00ednicas y de atenci\u00f3n farmac\u00e9utica, la profilaxis primaria contra P. ji- rovecii en pacientes con niveles de linfocitos <200 c\u00e9lulas/\u00b5L. Respecto a los datos anal\u00edticos de los 120 pacientes conoce - dores de su status de portadores antes del ingreso llama la aten - ci\u00f3n que 69 pacientes ten\u00edan la CV indetectable 6 meses antes de la estancia hospitalaria, permaneciendo solo 47 indetectables en el periodo de estudio. De los 128 pacientes VIH ingresados no se determin\u00f3 la CV en el 27,50% de los casos. Respecto a los niveles de CD4 en los 6 meses previos al ingreso, la mediana de CD4 de los pacientes de los que se dispon\u00eda de informaci\u00f3n disminuye. Estos resultados ponen de relieve la importancia de conocer el estatus de ser portador de VIH en admisi\u00f3n y por parte de los cl\u00ednicos para pedir determinaciones de CV y linfocitos CD4 sea cual sea la unidad cl\u00ednica de ingreso hospitalario. Solo 8 pacientes (6,25%) fueron diagnosticados de novo durante el ingreso hospitalario en los dos a\u00f1os que abarc\u00f3 el diagn\u00f3stico al alta, seg\u00fan la clasificaci\u00f3n CIE-10 (a\u00f1o 2016) fue ciertas enfermedades infecciosas y parasitarias (38,3%) inclu - y\u00e9ndose dentro de esta clasificaci\u00f3n la enfermedad por el virus de la inmunodeficiencia humana (24,1%) como diagn\u00f3stico al alta mayoritario. Estos datos coinciden con los reportados del metaan\u00e1lisis de Ford N et al (2015) [22] donde se analizaron las causas de hospitalizaci\u00f3n y de mortalidad seg\u00fan la clasificaci\u00f3n CIE-10 (a\u00f1o 2010) de 313.006 adultos y 6.182 ni\u00f1os correspondientes a 99 estudios y concluye que las principales causas de hos - pitalizaci\u00f3n fueron la enfermedad relacionada con VIH e in - fecciones bacterianas en todas las regiones geogr\u00e1ficas, siendo tambi\u00e9n las causas m\u00e1s frecuentes de mortalidad. Este estudio refiere que en Europa, tras las enfermeda - des relacionadas con VIH e infecciones bacterianas, las causas m\u00e1s frecuentes de ingreso fueron enfermedades respiratorias (14%), desorden psiqui\u00e1trico (13%), enfermedad cardiovascular (12%), renal (11%) y hep\u00e1tica (10%), asemej\u00e1ndose en parte a nuestros datos, donde el 15,18% de los ingresos fue debido a enfermedades del sistema respiratorio, seguido de enfermeda - des del sistema circulatorio (11,67%) y enfermedades del siste - ma digestivo (8,56%). En nuestro estudio, en lo referente al motivo de ingreso (diagn\u00f3stico al alta) en la categor\u00eda de enfermedades relacio - nadas con el VIH, destacan los tumores onco-hematol\u00f3gicos seguidos por otras infecciones bacterianas, neumon\u00eda por P. ji- rovecii, s\u00edndrome caqu\u00e9ctico, enfermedad por citomegalovirus, infecci\u00f3n por micobacterias y candidiasis. Estos datos coinciden en parte con el metaan\u00e1lisis de Ford N et al (2015) [22] donde Tabla 4 Sub-clasificaci\u00f3n del diagn\u00f3stico al alta: enfermedad por virus de la inmunodeficiencia humana. Sub-clasificaci\u00f3n del diagn\u00f3stico al alta: enfermedad por virus de la inmunodeficiencia humana. N\u00ba ingresos % Enfermedad por VIH, resultante en linfoma de Burkitt 12 19,3 Enfermedad por VIH, resultante en otros tipos de linfoma no Hodgkin 9 14,5 Enfermedad por VIH, resultante en otros tumores malignos 9 14,5 Enfermedad por VIH, resultante en otras infecciones bacterianas 6 9,7 Enfermedad por VIH, resultante en neumon\u00eda por Pneumocystis jirovecii 4 6,5 Enfermedad por VIH, resultante en otras enfermedades infecciosas o parasitarias 4 6,5 Enfermedad por VIH, resultante en s\u00edndrome caqu\u00e9ctico 4 6,5 Enfermedad por VIH, resultante en enfermedad por citomegalovirus 4 6,5 Enfermedad por VIH, resultante en infecci\u00f3n por micobacterias 3 4,8 Enfermedad por VIH, resultante en candidiasis 3 4,8 Enfermedad por VIH, resultante en otras infecciones virales 1 1,6 Enfermedad por VIH, resultante en encefalopat\u00eda 1 1,6 Enfermedad por VIH, resultante en sarcoma de Kapossi 1 1,6 Enfermedad por virus de la inmunodeficiencia humana [VIH], sin otra especificaci\u00f3n 1 1,6 Total 62 100Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326323de 45 (22-483) c\u00e9lulas/\u00b5L y la mediana de CV de 219.009,48 (697,64 - 1.000.000) copias/mL. Tal como ocurre con la mor - talidad, se ha reportado que las tasas de ingreso hospitalario descienden con el aumento del recuento de CD4 y que se no - tifican mayores tasas de ingreso hospitalario en pacientes con recuento de CD4 <100 c\u00e9lulas/\u00b5L. Los bajos niveles de CD4 ade - m\u00e1s predicen el riesgo de reingreso hospitalario, mientras que el uso del TAR se ha asociado con mejoras en la supervivencia, incrementando los niveles de CD4 y reduciendo el n\u00famero de estudio, dato m\u00e1s bajo que el reportado en el estudio de \u00c1lva - rez Barreneche MF et al (2017) [21] con un 22% y en del de Ford et al (2015) [22] con un 30% de los ingresos hospitalarios. Esto es debido probablemente a que nuestro estudio se circunscribe a un solo hospital regional de tercer nivel dentro de un pa\u00eds desarrollado donde el acceso a las pruebas de determinaci\u00f3n y el acceso al TAR son gratuitos. De hecho, de los 8 pacientes de los que no se conoc\u00eda el status de portador de VIH la mediana de los niveles de CD4 fue Sin datos Diagnosticados con datos (N=100) Indetectable CV (mediana, rango)6 meses previos (120 pacientes diagnosticados)20 pacientes (16,67%) 69 pacientes (57,50%)31 pacientes (25,83%) 345 copias/ml (37 - 1.183,34) Sin datos Diagnosticados con datos (N=95) Durante ingreso (128 pacientes)33 pacientes (25,78%) 47 CD4 (mediana, rango)Sin datos Diagnosticados con datos (N=98) 6 meses previos (120 pacientes diagnosticados)22 pacientes (18,33%)442,69 cel./\u00b5L (1-1.994) Sin datos Diagnosticados con pacientes)38 pacientes (31,66%)257,50 cel/\u00b5L datos Indetectable CV (mediana, rango)6 meses previos (19 pacientes (52,63%)5 pacientes (26,31%) 626,50 copias/ml (161-1.183,34) datos con (N=20) datos con meses previos (19 pacientes diagnosticados)4 pacientes (21,05%)353 cel/\u00b5L (27-1.085) Sin datos Diagnosticados con Durante ingreso (23 pacientes)3 pacientes (13,04%)130 cel/\u00b5L (12-608)Tabla 5 Niveles de CD4 y carga viral de los pacientes y exitus 6 meses antes del ingreso y durante el mismo. Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326324Tabla 6 Causas de mortalidad. N\u00ba de pacientes % Ciertas enfermedades infecciosas y parasitarias 7 30,43 Neoplasias 5 21,74 Enfermedades del sistema respiratorio 4 17,39 S\u00edntomas, signos y hallazgos anormales cl\u00ednicos y de laboratorio, no clasificados en otra parte 3 13,04 Enfermedades del sistema circulatorio 2 8,70 Enfermedades del aparato digestivo 2 8,70 Total 23 100,00 ingresos hospitalarios por causas debida al VIH [22]. La cifra de linfocitos CD4+ es el indicador fundamental del estado inmu - nol\u00f3gico. Sirve para estadificar la infecci\u00f3n por el VIH, evaluar el riesgo de comorbilidad, la vulnerabilidad a determinadas in - fecciones oportunistas, la necesidad de su profilaxis y su even - tual discontinuaci\u00f3n [24]. Respecto a las tasas de mortalidad observadas en nuestro estudio, un 13,52% de los pacientes fallecieron en el hospital en el periodo de estudio. Estos % de mortalidad son m\u00e1s altos que los observados en otros estudios [21,25] con tasas del 5,4% o del 2,6%, sin embargo se aproximan a los datos reportados por Ford et al (2015) [22] con tasas globales de mortalidad en adultos del 20%. Esta \u00faltima tasa de mortalidad procede de un metaan\u00e1lisis que engloba m\u00faltiples estudios realizados a nivel mundial, incluyendo pa\u00edses sub-desarrollados como \u00c1frica. Podr\u00edamos justificar estas tasas de mortalidad mayores que las de otros estudios debido a la situaci\u00f3n geogr\u00e1fica de nuestro Hospital, siendo un hospital de referencia de tercer ni - vel que recibe pacientes no s\u00f3lo de la provincia y Melilla, si no que a la poblaci\u00f3n de derecho se suma tambi\u00e9n la de la pobla - ci\u00f3n flotante originada por el turismo, que aumenta especial - mente en los meses de verano y la de la poblaci\u00f3n inmigrante. Adem\u00e1s, 4 de los pacientes que fallecieron, fueron diagn\u00f3sticos de novo, 2 pacientes fueron diagn\u00f3sticos recientes (<6 meses) y otros 2 fueron pacientes que no estaban en seguimiento en nuestro Hospital. De los 15 pacientes restantes, que eran se - guidos por la unidad de enfermedades infecciosas de nuestro hospital, 4 hab\u00edan abandonado el TAR. De los pacientes que fallecieron, en los seis meses previos al ingreso la CV fue indetectable solo en el 43,48%, observando como la mediana de CV aumenta debido fundamentalmente a los 4 diagn\u00f3sticos de novo que se produjeron durante el ingre - so hospitalario. Respecto a los niveles de linfocitos CD4 en los 6 meses previos al ingreso, la mediana disminuye durante el ingreso hospitalario por el mismo motivo. Los resultados refle - jan que los pacientes diagnosticados de novo y que fallecieron, ingresaron en el hospital con un sistema inmunol\u00f3gico muy deteriorado y con un avanzado estado de la enfermedad. Esto nos lleva a reflexionar que en Espa\u00f1a habr\u00eda que reforzar las pol\u00edticas de diagn\u00f3stico precoz ya que el diagn\u00f3stico tard\u00edo y la presentaci\u00f3n tard\u00eda dan como resultado una alta morbilidad y mortalidad [20]. La mayor causa de mortalidad fue la de ciertas enferme - dades infecciosas y parasitarias lo cual coincide con las princi - pales causas de mortalidad encontradas en otros estudios [21, 22, 25]. En cuanto a la adherencia al TAR, de los pacientes con diag - n\u00f3stico previo de VIH conocido al ingreso y que se dispon\u00eda de datos, s\u00f3lo un 42,85% eran buenos adherentes. De los que mu - rieron, s\u00f3lo un 26,10% ten\u00edan buena adherencia y un 21,74% hab\u00edan abandonado el tratamiento, lo que nos lleva a pensar que hay que reforzar desde el diagn\u00f3stico la importancia de la adherencia al TAR. De hecho, en las Gu\u00edas GESIDA [24] subrayan que la adherencia inadecuada es la primera causa de fracaso terap\u00e9utico. Entre los factores asociados con una adherencia imperfecta destacan: mala relaci\u00f3n m\u00e9dico-paciente, consumo de drogas, enfermedad mental, deterioro neurocognitivo, bajo nivel educativo, barrera idiom\u00e1tica, falta de apoyo social, com - plejidad terap\u00e9utica y efectos secundarios del tratamiento. Por el contrario, el apoyo emocional, la capacidad para incluir la medicaci\u00f3n en las actividades de la vida diaria y la comprensi\u00f3n de la importancia del cumplimiento terap\u00e9utico son factores que predicen una adherencia correcta. El cumplimiento descri - be la calidad en la ejecuci\u00f3n del tratamiento prescrito; aspectos vinculados al TAR, como el acceso y la persistencia en el mismo son esenciales para su \u00e9xito. Nuestro estudio tiene como limitaci\u00f3n el car\u00e1cter retros - pectivo y limitado a pacientes VIH con prescripci\u00f3n de TAR, de hecho, cabe destacar que 34 pacientes VIH no tuvieron pres - cripci\u00f3n de TAR en sus ingresos en el Hospital o bien se trat\u00f3 de pacientes fugados. Por tanto, no se han podido analizar las causas de ingreso hospitalario de todos los pacientes VIH que ingresaron en el hospital en el periodo de estudio. En conclusi\u00f3n, nuestros resultados enfatizan la necesidad de seguir reforzando el diagn\u00f3stico precoz de VIH, reforzar la profilaxis primaria de P. jirovecii en los pacientes VIH con nive - les de linfocitos CD4<200 cel/\u00b5L tanto en consulta como ingre - sados y al alta hospitalaria. Reforzar la adherencia al TAR desde Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-326325las consultas de seguimiento de especialista en enfermedades infecciosas y en las consultas de atenci\u00f3n farmac\u00e9utica. Hay que concienciar a los m\u00e9dicos para prescribir el TAR en los ingresos hospitalarios de los pacientes VIH as\u00ed como so - licitar anal\u00edticas de CV y linfocitos CD4 a todos los pacientes VIH ingresados en el Hospital, sea cual sea la unidad cl\u00ednica de ingreso. FINANCIACI\u00d3N Los autores declaran que no han recibido financiaci\u00f3n pa - ra la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener conflicto de intereses. BIBLIOGRAF\u00cdA 1. Estad\u00edsticas mundiales sobre el VIH y el SIDA - Hoja informativa de 2018. Consulta [Enero 2019]. Disponible en: http://www.unaids. org/en/resources/fact-sheet . 2. Vigilancia 30/06/2018. Consulta . Mortalidad por VIH/SIDA en Espa\u00f1a. A\u00f1o 2016. 1981- 2016. Consulta 4. Documento de consenso de Gesida/plan nacional sobre el sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Enero 2018). Consulta [Enero 2019]. Disponible en: http://gesida-seimc.org/category/ guias-clinicas/antirretroviral-vigentes/. 5. Brennan AT, Maskew M, Sanne I, Fox MP. The interplay between CD 4 cell count, viral load suppression and of antiretroviral therapy on mortality in 2013. 18(5): 619-631. DOI: 10.1111/tmi.12079. Epub 2013 Feb 18 6. Maciel RA, Kl\u00fcck HM, Durand M, Sprinz E. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV- uninfected matched controls, aged 50 years sectional study. International of Infectious Diseases, 2018. : 30-35. DOI: 10.1016/j.ijid.2018.02.009. Epub 2018 Feb 21. 7. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli E et Cotte L, Pugliese P, Cheret A, Bernaud C et al. Ageing with HIV: do Allard SD. Current challenges in the G, Zona S, Menozzi M, Carli Bormann AM, Erlandson KM, Huppler Hullsiek AC by Age KM, HupplerHullsiek K, Justice AC et Adjudicated morbidity mortality by age for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, and Latin America. AIDS. 2017; 31(3):375-384. DOI: 10.1097/QAD.0000000000001333. 15. health problems. https://icd.who. 2013 Causes of Global, re specific a systematic analy - sis for the Global Disease Lancet 2015; 385: \u00c1lvarez Barreneche MF, Restrepo Castro CA, Hidr\u00f3n Botero A, Villa Franco JP, Trompa Romero IM, Restrepo Carvajal L et al. Hospitalization causes and outcomes in HIV patients in the late 2017 Nov 13; 14(1):60. DOI: 10.1186/s12981-017-0186-3.Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al. Rev Esp Quimioter 2019;32(4): 317-32632622. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. Causes of hospital admission among people living with HIV world - wide: a systematic review and meta-analysis. Lancet HIV. 2015. 2(10):e438-44. DOI: 10.1016/S2352-3018(15)00137-X. Epub 2015 Aug 11. 23. Ministerio de Sanidad, servicios sociales e Igualdad. Documento de prevenci\u00f3n y tratamiento de infecciones oportunistas y otras coin - fecciones en pacientes con infecci\u00f3n por VIH. Actualizaci\u00f3n Mayo 2015. Consulta [Febrero 2019]. Disponible en: http://gesida-seimc. org/wp-content/uploads/2017/02/gesida-guiasclinicas-2015-In - feccionesOportunistasyCoinfeccionesVIH.pdf . 24. Documento de consenso de Gesida/plan nacional sobre el sida res - pecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n Enero 2019). Consulta [Febrero 2019]. Disponible en: http://gesida-seimc.org/ wp-content/uploads/2019/01/gesida_DC_TAR_2019_v_final.pdf 25. Gonzalez Singh S, Kilayko V. All- in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Prevalencia de micoplasmas genitales y respuesta al tratamiento de descolonizaci\u00f3n en pacientes de reproducci\u00f3n humana asistida RESUMEN Introducci\u00f3n. Se han publicado estudios que demues - tran mayores tasas de \u00e9xito en las t\u00e9cnicas reproducci\u00f3n asistida (TRA) en parejas no infectadas por micoplasmas. El objetivo de este estudio fue determinar la prevalencia de los micoplasmas genitales en muestras de orina del miem - bro masculino de las parejas incluidas en el Programa de Reproducci\u00f3n Asistida en nuestro \u00c1rea Sanitaria realizando un tratamiento descolonizador con el fin de incrementar la calidad del semen, mejorar las tasas \u00e9xito de la embriotrans - ferencia y minimizar los efectos adversos sobre la gestaci\u00f3n. Material y m\u00e9todos. Participaron parejas incluidas en el Programa de Reproducci\u00f3n Asistida durante 2016. La de - tecci\u00f3n de los micoplasmas se realiz\u00f3 por PCR en tiempo real. En los casos positivos, la pareja fue tratada con anti - bi\u00f3ticos hasta la erradicaci\u00f3n del microorganismo. Los anti - bi\u00f3ticos fueron: azitromicina, doxiciclina, levofloxa - cino, moxifloxacino y estudiados, fueron positivos: Ureaplasma urealyticum 15,1%, Mycoplasma hom - inis 3,9%. Azitromicina fracas\u00f3 en el 50% de los casos y doxiciclina en el 10,2%. Con levofloxacino solo en 2 de 5 se consigui\u00f3 la erradicaci\u00f3n de U. urealyticum . Conclusiones . El cribado de rutina de los micoplas - mas genitales puede ser \u00fatil para mejorar la calidad del semen. Esto permitir\u00eda simplificar los procedimientos de fertilizaci\u00f3n in vitro e incrementar las tasas de \u00e9xito en la implantaci\u00f3n de los embriones y en la gestaci\u00f3n, especial - mente con la aplicaci\u00f3n de t\u00e9cnicas diagn\u00f3sticas r\u00e1pidas y espec\u00edficas como la PCR en tiempo real. Palabras clave: Mycoplasma fertilisation by ART in couples who were not by . in couples who were treated with antibiot - ics to eradicate the infection. The aim of this study was to de - termine the prevalence of genital mycoplasmas in urine sam partners in the Assisted Reproduction Program (ARP) in our healthcare area so that, positive cases can be treated prior to the use of ART in order to increase the quality of semen, improve the and This ARP during Mycoplasma detection using real-time PCR. com - pared to 10.2% for doxycycline. Of the 5 cases treated with could be useful in order to increase the quality of semen which could simplify the fast, real de Compostela, Spain 2Clinical Microbiology Unit. University Clinical Hospital of Santiago de Compostela, Spain.Ernesto Veiga1 Mercedes Trevi\u00f1o2 Bel\u00e9n de Compostela. c/ Ram\u00f3n Baltar s/n. 15702- Santiago de Compostela, The first fraction of urine (10-15 mL) was collected from males after at least 2 hours without urinat - ing. Urine was collected under the same conditions for the Briefly, a 224 or 129 bp frag - ment of the glyceraldehyde-3-phosphate dehydrogenase (gap) gene by melting curve analysis. In the same way, a 187 bp long fragment of 16S RNA gene was applied for ing to manufacturer\u00b4s information. The sensitivity of the test is 10 extracted concen - trating the sample by centrifuging 2 mL of urine for 20 min - utes at 14,000g [14]. After discarding the supernatant, 200 \u00b5L were dox - ycycline. Quinolones were used when first line treatment failed. Statistical analysis. All statistical analyses were carried out using SPSS v. 20.0 (IBM Corp., Armonk, NY). Statistical sig - nificance was set at p< 0.05. RESULTS A total of 205 couples were enrolled in the study. The age range was 24 to 54 years in men and 23 to 39 in women, with a median age of 36 years for men and 35 years for women. Most men were Caucasian ( n= 201). Other ethnic 2) and Gypsy ( 2). 33 (16.1%) males tested positive by real-time PCR (2.9%) the placenta and/or embryo in preg - nant spp. [6, 7]. In - creased also in couples infected fetus newborn can have genital mycoplasma suggests a role for routine screening and - dergoing infertility treatment [10-12]. It therefore seems rec - avoid the ensure of these bacteria [13]. With the advent of sensitive and prevalence of genital mycoplasma as well as the control of the efficacy of the antibiotic treatment can be determined. This study presents the results after human reproduction program at University Hospi - tal Complex of Santiago (CHUS), in Santiago de Compostela, Spain. MATERIALS AND METHODS Patients. This study included couples enrolled in the as - sisted human reproduction program carried out by the Assist - ed Human Reproduction Unit at CHUS during 2016. Couples provided their informed consent after approved by the competent Research Ethics Committee and by the hos - pital's management (reference number 2015/493). The screen in male 7-14 after initiating treatment. Both members of the couple had a microbiological test 3-4 weeks after completing the treatment. Couples failing anti - biotic treatment were prescribed alternative antibiotics un - til both members had negative post-therapy microbiological tests. No patient was on antibiotic treatment at least, three months prior to collection of the sample. As part of the study protocol prior to in vitro fecundation, all couples 400 for 7 days as M. hominis was detected in the post-treatment test (couple # 104). The cases of M. hominis infection (6/7 in coinfection, 86%) were both 2 were members of the same couple) (table 3). The statistical analysis showed that the - p< 0.01) in both men and women. Treatment efficacy was independent of age. However, the age range was too small to observe significant DISCUSSION M. hominis and Ureaplasma [15, 16]. There is evidence that the use of semen infected with Ureaplasma spp. for cases for U. urealyticum Treatment failed in females, 2 couples), including 12 pa - tients treated with a single oral dose of azithromycin 1 and 4 patients treated with doxycycline 100 mg/12h p.o. for 7 days. One of the couples (couple # 61) who tested negative for U. urealyticum initial treatment with doxycycline treated (moxifloxacin 400 mg p.o. for 7 days). 2 results of cycle administered after failure of the initial treatment. One of the 12 couples who failed treatment with azithromycin withdrew from the program. The remaining - ples were treated with doxycycline 100 mg/12h p.o. for 7 days. There was only one case of therapeutic failure, which was treated alternatively with levofloxacin (500 mg/day, 7 days). As the remained positive, she was prescribed vaginal clindamycin 100 mg/day for days. Her post-treatment test was negative. Doxycycline proved ineffective in 4 of the 19 couples treated initially. In these cases, levofloxacin (500 mg/day, 7 days) was used as an alternative. Only one patient remained PCR-positive for U. urealyticum. This patient was vaginal clindamycin 100 for 3 days; she required a second course combined a Negative 12 Negative 25 Negative 28 Negative 29 Negative 31 Negative 36 Negative 39 Negative 43 Negative 46 Negative 48 Negative Doxycyclin Levofloxacin104 Negative MoxifloxacinaNegative 106 Negative higher rate failure against Ureaplasma spp. in women, as compared to men, and this difference was spp. and M. hominis [35], but our results do not support this, as therapeutic failure occurred in 40% of patients treated with levofloxacin. Nevertheless, in view of the small number of cas - es, we cannot draw any firm conclusions in this regard. Moxi - floxacin has been reported to be a powerful antibiotic against M. hominis [35] and indeed, it was a successful alternative in our series for one couple In decided to as azithromycin, cycline can vaginal in high local drug - deed, eradication of Ureaplasma spp. was achieved in one case. More assays are necessary to know the effect of probiotics on the success of the antibiotic treatments. Treatment efficacy was independent of age, even though the age range was too small to observe significant in of the cases (from 3% to 10,6%) which means cost savings of 7% for summary, consider that genital mycoplasma routine could be useful in order to increase the quality of se - men which could simplify in real-time PCR significantly re - duces time to initiation of treatment and can be used to assess its efficacy. Doxycycline was other hand, eradication of genital mycoplas authors, as strongly technics in - stead of intracytoplasmic which more labori - ous, other hand, the washing procedures used for semen preparation prior to IVF are efficient to eliminate mycoplasmas, as treatment may in the ART protocol. techniques such as real-time are antibiotic use and have much higher sensitivity [20]. Our study found that 15.1% of the males were colonised by Ureaplasma spp. and 3.9% by M. hominis (practically all of whom were coinfected Ureaplasma spp.). figures are somewhat lower than reported in studies, in prevailed on genital mycoplas - ma prevalence has been to geographical and methodological differences [25]. Unlike other publications which report rates of up to 5% [21, 26], there were no positive cases of M. genitalium in our patients. This could be explained M. hominis with age [27], asymptomatic and, possibly, more con - servative sexual behaviour. Besides the benefits that the eradication of genital my - coplasma can [28]. to the recommendations of therapeutic guide - lines, macrolides are the treatment of choice for Ureaplasma spp. infections, with doxycycline or levofloxacin as alterna - tives. For M. hominis, the treatment of choice is doxycycline, with quinolones as an alternative [29, recommended these members the couple when the male was positive. antibiotic against strains [31-33]. However, the in in the treatment recommend - ed for sexually transmitted infections (1 g single dose; www. vademecum.es) revealed the low efficacy of this macrolide. For this reason, after the initial results, doxycycline was used as the first choice b.i.d. p.o., 7 days). Some reports have that periods [34], and this could be the reason behind its low efficacy in our series. Pos - sibly, also could contribute L, Chakroun N, Sellemi A, Zna - infection in pregnancy: to screen or Perinat Med. 2017; 45 (5): 505-15. doi: Allan WR, Stenzel D, Lawrence and Ureaplasma urealyticum are detect - The effecct ME. The Impact of Bacterial Infec - tions on Human Spermatozoa. International Journal of Zhioua A, Bahri O. In the case of patients who do not eliminate colonization in the first treatment regime, the benefit of initiating succes - sive alternative and possible undesirable effects no conflicts of interest. CONSENT All patients included in - formed consent document. REFERENCES 1. Domingues D, Noguera F, and Tavira L. Papel que desempe\u00f1an mi - coplasmas en las infecciones humanas. Act Med W. Association of abnormal vaginal and species as risk in R, Droz S, M, Dona V, Bodmer T, et al. Antibiotic susceptibility and sequence type Ureaplasma Z, hominis 10.1016/j.gofs.2018.03.014. 20. Acosta Codina Grau MG, Matas Andreu L, Meseguer Peina - do MA. Diagn\u00f3stico microbiol\u00f3gico de las infecciones por Myco - plasma spp . y Ureaplasma spp . Procedimientos en Microbiolog\u00eda Cl\u00ednica Cap 40. Recomendaciones de la Sociedad Espa\u00f1ola de En - fermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. 2011. 21. Andrade-Rocha FT. and R. Ureaplasma urealyt a position statement from the European STI Guidelines Editorial Board. J Nowicka Go and in susceptibility C, Roth-Kleiner M, Vasile - et al. Treatment of genital mycoplasma in colonized pregnant women in late pregnancy is associated with a lower rate of pre - mature labour Muir P, Evans C, Radkliffe K. On behalf of the clinical effectiveness group of the British Association for Sexual Health and HIV. 2015 UK national Guideline on the man - agement of non-gonococal antimicrobiana. Barcelona: Ed 2017. 31. Redelinghuys \u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).ommendations, but only to give multidisciplinary opinion on topics that could be particularly debatable or controversial. The paper reviews the main vaccine-preventable adult diseas - es, their clinical and economic impact, the possibilities of reducing them with vaccination programmes and nursing, was new vaccines were discussed and we speculated on the future in this field. Finally, particularly relevant ethical aspects in decision-making regarding which must be faced by both individuals and states. We have tried to summarize, at the end of the presenta - tion of each question, the environment of opinion that was agreed with all the members of the table. Key words: adult vaccines, vaccination, prevenci\u00f3n de infecciones en adultos: art\u00edculo de opini\u00f3n sobre la situaci\u00f3n en Espa\u00f1a RESUMEN El calendario de vacunaci\u00f3n infantil es bien conocido y generalmente bien implementado en los pa\u00edses desarrollados. ABSTRACT The childhood immunization schedule is well infections incom plete and generally very deficient. In order to assess the situation of adult vaccination in Spain, the Fundaci\u00f3n de Ciencias de la Salud has brought to - gether a series of experts in different fields, including doctors, nurses, representatives of authorities and journalists to deal with this issue. The format was that of a round table in which a se - ries of questions previously formulated by the coordinators were to be answered and debated. The document presented is not an exhaustive review of the topic, nor is it intended to make rec -Vaccines for the prevention of infections in adults: an opinion on 1Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Instituto de Investigaci\u00f3n Sanitaria Grego - rio Mara\u00f1\u00f3n, and CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain. 2Pneumology Service. Hospital de la Princesa. Coordinator COPD strategy of the National Health Service. Madrid. Spain 3Service of Preventive Medicine and Epidemiology. University Hospital Vall d'Hebron. Barcelona. Spain. 4Department of Microbiology. University of Valladolid. Department of Microbiology. University Hospital R\u00edo Hortega, Valladolid. Spain 5National Federation of Liver Transplant Patients (FNETH) 6Public Health of the Canary Islands Health Service. Spanish Association of Vaccinology. Spain 7Ciencias de la Salud Foundation. Madrid Spain. 8National Association of Health Reporters (ANIS) 9Vaccination Programs. Subdirecci\u00f3n de Promoci\u00f3n de la Salud y Vigilancia en Salud P\u00fablica. Ministry of Health. Madrid. Spain 10Spanish Society of Geriatry and Gerontology. (SEGG). Spain 11Working group Immunology. Spanish of and Community Pharmacists (SEFAC). Madrid Spain. 12Faculty of Nursing Spain 13Complutense Clinical Microbiology and Infectious Disease Department. Hospital Gregorio Madrid. Spain. 14Institute Choiseul. Madrid. Spain. 15Department of Microbiology. University of Valladolid. Department of Microbiology. University Hospital, Valladolid.Spain 16Health Preservation and Prevention Department. Catalonia Health Service. Barcelona, Spain. 17Ciencias de la Salud Foundation. Madrid. SpainEmilio Bouza1 Julio Ancochea-Berm\u00fadez2 Magda Campins3 Jos\u00e9 Jos\u00e9 Carmen Magro11 Gloria Mirada12 Patricia Mu\u00f1oz13 Eduardo Ra\u00fal Ortiz de Lejarazu15 Luis Urbiztondo16 Esteban Palomo17 Correspondence: Emilio Bouza Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n. C/ Dr. Esquerdo, 46 28007 Madrid, Spain Phone: +34- 504 49 06 E-mail: emilio.bouza@gmail.com Esteban Palomo Director. Fundaci\u00f3n de Ciencias de la Salud. C/ Severo Ochoa, 2, 28760 Tres Cantos. Madrid Phone in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364334belong. This document is not held in Madrid on April the 18th, 2018 and this document reflects the main questions, answers and conclusions of the meeting updated by the literature available up to May 2018. METHODS Before the meeting, the different participants were sent related to the situation of vaccines for adults in Spain, in general terms or in relation to some vaccines in particular. Some questions especially pulsed the vision of these problems on the part of particular groups as the nurses, the associations of transplanted patients, the health economists or position attitudes the press. Each accepted question was introduced and presented by one of the panel members and then discussed by all the participants trying to reach a common or document, conveniently edited and referenced, was sent all panel members for correction and final approval. QUESTION 1.- What are most prevalent vac - cine-preventable diseases in adults? Exposure: The important diseases preventable - ble [1]. Among them are several that do not currently rep resent a problem in the developed widespread use of vaccines among the population, so we will not address them in this text. Examples are measles, rubel - mumps, tetanus, diphtheria, polio as recent is a clear risk of outbreaks of these diseases. WHO does not include in its list other diseases, also preventable by vaccines, but which either Por varias razones,no ocurre lo mismo en el caso de las va - cunas destinadas a prevenir las infecciones en adultos, en los que la cobertura vacunal es incompleta y generalmente muy deficiente. Con el fin de evaluar la situaci\u00f3n de la vacunaci\u00f3n de adul - tos en Espa\u00f1a, la Fundaci\u00f3n de Ciencias de la Salud ha reunido a una serie de expertos en diferentes campos, incluyendo m\u00e9d - icos, enfermeras, representantes de asociaciones de pacientes, gestores sanitarios, economistas, autoridades sanitarias y periodistas para discutir este asunto. El formato fue el de una mesa redonda en la que una serie de preguntas, formuladas previamente por los coordinadores, deb\u00edan ser contestadas y debatidas. El documento presentado no es una revisi\u00f3n ex - haustiva del tema, ni tiene por objeto hacer recomendaciones, simplemente pretende dar una opini\u00f3n multidisciplinar sobre aspectos que pueden ser debatibles o controvertidos. El doc - umento revisa las principales enfermedades de los adultos que pueden prevenirse con vacunas, su impacto cl\u00ednico y econ\u00f3m - ico, las posibilidades de reducirlos con los programas de vacu - naci\u00f3n y las dificultades para llevarlos a cabo. Se discuti\u00f3 el papel de la enfermer\u00eda, la farmacia, los servicios de salud, las asociaciones de pacientes y la propia administraci\u00f3n sanitaria para cambiar la situaci\u00f3n actual. Se evaluaron las perspecti - vas para nuevas vacunas y se especul\u00f3 sobre el futuro en este campo. Por \u00faltimo, se discutieron los aspectos \u00e9ticos especial - mente relevantes en la toma de decisiones con respecto a la vacunaci\u00f3n, que deben ser afrontados tanto por los individuos como por los estados. Hemos intentado resumir, al final de la presentaci\u00f3n de cada pregunta, la opini\u00f3n que representaba el consenso de to - dos los miembros de la mesa. Palabras clave: Vacunas adultos, Vacunaci\u00f3n, Gripe, Hepatitis reducing Infectious Diseases during paediatric age and for the rest of life do not need to be highlighted. However, despite the large number that affect adults, and the availabil - ity of vaccines for many of them, adult vaccination is often neglected. This negligence may be as well as to health-care professionals, and the ad - ministration. In order to examine the situation of this problem in Spain, the Fundaci\u00f3n de Ciencias de la Salud has brought together, at a round table, both experts in different aspects of the sub - ject as well as representatives of affected communities and the were asked a series of previously agreed questions to review the state of the art of each subject, with particular emphasis on the situation in for opportunities improvement. The opinions expressed by each of the speakers are their own and do not necessarily rep - resent those of the Institution or Institutions to which they Measles Rubella Mumps Poliomyelitis in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364335caused by the incidence, some risk factors and the morbidity and mortality associated with them. Whenever pos - sible, we have used figures provided by the CDC in order to harmonize them and recognizing that incidence and vaccination system ( Bacillus anthracis , plague, Q fever) is not yet available. We will mention here, by way of example, seven infections that are vaccine-preventable but remain a challenge for adults in the developed world. The selection is based on the recent recommendations of the North American on Immunization Practices (ACIP). These infections are, follow - ing the same order of the mentioned recommendations, those Estimation of cases chronic heart and lung disease, serious cases of meningitis.[15, 16]Table 2 prevention infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364336ease and others, stand out for their magni The number of deaths attributable to notifiable infectious diseases in Spain in 2015 is estimated to be close to 28,000. The recommendations of vaccines for adults are provided by the Health Department of the United States of America [3]. Despite evidence of a drastic reduction in and mortality of vac - cine-preventable diseases since the late 19th century [23-25], American adults, as an exam - ple reluctance to use vaccines, low priority on the list of individual concerns, cost, problems of access to vaccines and other [26-28]. It is estimated that since 1924, more than 100 million cases of smallpox, measles, polio, mumps, ru - bella, hepatitis A, diphtheria and pertussis have been prevent - ed. Considering the period from 1980 to the present day, the reductions in incidence and mortality caused by some of the aforementioned diseases exceed 90% and in some cases 99%. and vaccination is considered an efficient and potential for substantial reductions that could be in the different diseases could be summarised as follows: Influenza A study of 18 elderly cohorts in the United States of America that collected 713,872 observational persons/-sea - sons estimated the effectiveness of Influenza vaccines as fol - lows: There was a 27% reduction in the risk of hospitalization for pneumonia or Influenza and a 48% [29] reduction in the risk of death for those vaccinated. These figures were main - tained for different age groups and risk subgroups. A historical cohort of England and Wales in people over 64 years of age compares the rates of acute respiratory - people vaccinated against - son-years) and in unvaccinated people (1,534,280 person/ years). The reduction in hospitalization was 21% and the death rate was reduced by 12% [30]. Gross et al [31], a meta-analysis of 20 cohort studies, estimate respiratory infections, in pneumonia ranged from 32% to 45%; between 31% and 65% in preventing hospital deaths caused mentioning. It is estimated that \"the flu\" in the Unit - ed States represents an annual expenditure of 10,400 million US dollars only as direct medical an expenditure attributable to influenza of 56.7 million euros per million in - habitants [18]. In the case of pneumococcus, the cost of an episode of pneumonia, meningitis and bacteraemia has been - lion annually, which increases by an additional US$ 324 million in the case of antimicrobial resistance [20]. Finally, the cost of bacterial meningitis in the event of sequelae has been estimat - ed at \u00a3160,000-\u00a3200,000 in the first year after the episode and \u00a3590,000 - \u00a31,090,000 per person for the rest of his life, assum - ing that the patient survives to the age of 70 years [21]. Conclusion: At present, in the developed world, the 7 adult in - fections that could benefit most from a strict vaccina - tion schedule are those caused by: of - eases in Spain published in Incidence of vaccine-preventable diseases in the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-36433711, 16 and 18 [40-43]. These results 5 years of follow-up [44]. A vaccination with tetravalent vaccine, recommended then only for girls between 11 and 12 years of age, with a res - cue for women between 13 and 26 years of age, was intro - duced in 2006 in the United States [45]. Other recommendations have been added to this, that take into account that there is an older population that can benefit from this vaccine and that men are not excluded from these benefits. However, information is being collected gesting capacity de - creases when applied to populations over 19 years of age. To the 2 and 4 serotypes vaccines, a 9-serotype vaccine has been added more recently. For all the above reasons, the current recommendations for vaccination against HPV in the US ideally indicate it be - tween 11 and 12 years old, in both boys and girls, with a po - tential rescue until the age of 26 for those who did not receive it previously and particularly for groups at risk such as men who have sex with men or immunocompromised men [ 45]. In Spain, the current recommendations of vaccination against HPV indicate 12 years old girls ( vaccinate only girls, with 2 doses ) and some risk groups adult women (HIV, ICs (non-HIV) & conizated), in 13 autonomous regions [46]. The CDC of the United States of America estimates, with data from 2008-2012, that about 30,700 episodes of cancer per year, 19,100 in women and 11,600 in men, can be attribut - ed to HPV and that a correct bivalent or tetravalent vaccine, to which an additional 3,800 cases could be added if vaccinated with new serotypes, which would add up to a prevention mours if HPV vaccination is properly implemented, in States America [47]. Population studies in Denmark and Australia seem to assumptions [48-52]. Hepatitis B virus In European the prevalence of chronic HBV is estimated at 0.5-0.7% of the general population. It is estimat - ed that cirrhosis will develop in 20-30% of infected another 25% developing hepatocarcinoma [8, 9, 53]. Hepatitis B vaccine is not strictly considered an adult vac - cine since it must be administered at paediatric age. It is rec - ommended in adults only for those not previously vaccinated in which there is a medical, occupational or behavioural risk factor or in non-immunized adults who lack these conditions and wish to be protected. The incidence of Hepatitis B in devel - oped societies is already very low since the beginning of child - hood vaccination in 1991. It is estimated that the decrease in incidence has been 82%. Despite this, in 2015, the incidence of acute hepatitis B was 2.6 cases per 100,000 people aged 30-39 in the USA [54, 55]. Medical indications not previously vaccinated, are primarily chronic renal or Influenza, between 43% and 50% in preventing deaths from any respiratory cause and between 27% and 30% in pre - venting deaths from any cause. Herpes Zoster In Western countries, the incidence of shingles is approx - imately 11 cases per 1,000 inhabitants over 80 years of age/ year, compared to 1 to 3 episodes in people under 50 years of age [27]. A study carried out in the United States shows that approximately 1 million cases of Zoster episodes occur in adults per year and that a high proportion of them developed post-herpetic neuralgia [5]. Lal and colleagues conducted a clinical trial in 18 nations on patients 50 years with two doses of VZV vac - cine two months apart, the results of which were stratified by decades of age (50 to 59, 60 to 69, and 70 years). Of a total of 15,411 participants, 7,698 and 7,713 participants received respectively. During a fol - low-up time of 3.2 years, herpes zoster was confirmed in 6 and 210 participants in the respective groups (incidence, 0.3 vs. 9.1 per 1,000 people/year). Overall, vaccine efficacy was 97.2%. Adverse effects were minimal and there were no dif - ferences between the two groups. In another prospective and comparative study, that enrolled (mean 75.6 years), observed over an average peri - od of 3.7 years, the efficacy of the vaccine in protecting from episodes of zoster in patients over 70 years was 91.3% paradigm of infection as a cause of cancer as in the case of the Human Papillomavirus (HPV). Infectious agents are estimated to cause 17.8% of all cancers in the world and their main agents are Helicobacter pylori (5.5% of the total), Hepatitis B and C virus - es (4.9%), EBV (1%), HIV along with Herpes viruses (0.9%) and HPV (5.2%) [6]. The last decade of the last century and the first decade of the present one have served to demonstrate the relation - ship between HPV and cervical cancer in women, a cancer that constitutes the second cause of death by neoplasia for women in the world [6, 34-38]. In a paper published in 2015, looking for HPV on tissues archived with different forms of human cancer, HPV was pres - ent in 91% of cervical cancers, in 69% of cancers, 89% and 93% of anal cancers in men and women respectively and 72 and 63%, respectively, of oropharyngeal cancers in men and similar design, clinical tetravalent HPV intro duced. After a follow-up of 40 months, it showed of and the persistence of HPV types contained in the vaccine that were 6, Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364338sodes of infection. Of the 12 existing capsular groups, A, B, C, W, X and Y are the cause of most IMI episodes. IMI episodes are usually grouped into three life stages: childhood, adoles - cence, and a third group in people over the age of 65. The classic quadrivalent vaccines include polysaccharide antigens from serogroups and induce specific antibody responses in more meningitidis serogroup B, which is nev - ertheless the cause of more than 50% of meningococcal in - fections in different parts of the world, today. There are two vaccines against N. meningitidis type B on the market that are recommended not only for children but also for adults with anatomic or functional asplenia, components, people being antigens from the that recent introduction, the long-term this vaccine is still scarce. In outbreak situations there has been a 42% reduction in expected cases. In the UK, the efficacy of 4CMenB has been estimated at 83% after the administration of the two doses [63, 64]. In a recent systematic review, and adolescents in whom seroconversion occurs at 30 days versus the 4 respectively: 92% for adverse events in patients receiving the 4CMenB vaccine was viduals), type b H. influenzae type b is a well-known cause of meningitis and other invasive infections, usually accompanied by bacte - raemia. Most of them occur in children in whom the vaccine is recommended. In 2012, the rate of invasive Hib disease in Europe in children under 5 years of age was 0.19/100,000 chil - dren. In the United States, after the introduction of the vac - cine, the incidence of the disease has been reduced by 99% [15, 66] and remains below 0.27 cases/100,000 in children un - der 5 years estimated by the Healthy People project for 2020 [67, 68]. This has of older adults [69-71]. In adults, the H. influenzae type b vaccine is recommend - ed only in immunosuppressed patients at high risk of acquir - ing this infection, including those with anatomic or function - al asplenia who are scheduled well as - tation. is not recommended for HIV-positive pa - tients at this time. In conclusion, with the data summarized indi - cations focus on health-care workers and security forces who may be exposed to blood or body fluids and people with risky behaviours such as parenteral drug users, those who have had more than one different sexual contact in the last 6 months, men who have sex with men and those who have had a recent Sexually Transmitted Infection (STI). The WHO aims to B by 2030, reducing chronic Hepatitis B infections by 90% and associated highlighted constitutes a very impor - tant cause and mortality, mainly in the popula - tions of children and adults over 50 years of age. The impact that conjugate pneumococcal vaccines have had on the evolution IPD in children is well known, with clear decreases in the overall incidence and par - ticularly those caused by serotypes included in them [11]. The impact that has been achieved in the reduction of IPDs in the adult population is not so well known. On this as - pect, a recent systematic review assesses the evolution of IPD between 2000 and 2016 using only articles written in English and collected in PubMed, finding 49 valid papers that met the selection criteria. Most of them came from Canada, the United Kingdom or the United States of America and showed statistically significant decreases been achieved in different situations and particularly benefited those PCV10 and PCV13 use in people over 65 years of age in Canada [12], with up to 21% reduction as an effect of the use of PCV7 and PCV13 in Israel statistical significance in other studies [59], one of them from Barcelona (Spain) [60]. In the latter case, mortality from IPD in people over 65 years of age did not change significant - ly (24 vs. 22%); but mortality dependent on cause disease one form or another, can vary between 10 and 40% of the epi -Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-3643391930s. No serious effect associated with it has been demon - strated but a hypothetical relationship between this product and autism or other neuropsychiatric diseases has caused a great damage to confidence Such an effect, we insist, was never but extremely rare. The and the CDC maintain a Vaccine Adverse Event Reporting System (VAERS) in the United States of America where manufacturers and phy - sicians report about 30,000 adverse effects annually [80-82]. In this specifically to the question posed in the adult population and in the vaccines that we have selected as the most relevant and most discussed at the present time. Influenza vaccine Influenza vaccination in adults, particularly in peo - ple over 65 years, has a somewhat higher incidence of local manifestations (30%) than in the younger population. There is no evidence that the presence of systemic manifestations after influenza vaccination is greater than in a population re - ceiving placebo. A special mention is the risk developing Guillain-Barr\u00e9 incidence in the general cases per million inhabit - ants. With some contradictory data, it is not clear that this rate is increased in the influenza vaccinated population nor that there is a causal relationship between these two problems [83]. A enza vaccination carried out with normal doses in young peo - ple or with high doses in the elderly. Although the volume of information is scarce, high-dose vaccine would reduce the risk of influenza by 24%, without clearly being associated with a in vast majority celiac disease, of which only one was possibly considered as related to the vac - cine [86]. This safety profile is maintained in women who are vacci - nated between the ages of 15 and 55 years in which no serious adverse events attributable to the vaccine were detected with - in an observation period of 10 years [87].sible to imagine the added protection that would result from adequate immunization coverage. American adults par ticularly poor immunization coverage against Influenza, hep - atitis and diphtheria/pertussis, in 29] could be avoided with the corresponding vaccines. One of the greatest risks is the association between influenza and pneumonia [28], vaccination reach 50%. The consequences of all this is that some 50,000 Ameri - cans die annually from diseases that could have been prevent - ed by vaccination and 99% of the deaths are in adults [27, 28]. In 2008, an estimated people from the vast majority of whom years of age [72] In terms of the reasons for this low coverage, in a recent survey, vaccines are perceived as a low health priority for both doctors and patients and to be vaccinated not the vast majority of employment situations. Many adults are not even aware that they need vaccines or the benefits of vac - cines, nor do they understand that booster doses of vaccines they have received in the past may be necessary. In general, adults are aware that there are vaccines for influenza or tet - anus, however, only 36% of those vaccinated for tetanus re - ceived a booster dose every 10 years. In the same survey, 56% of patients who knew there was a pneumococcal vaccine had not had it because \"the doctor did not recommend it\". Added to this is the fear of vaccines, punctures and their effects, and in some cases the high cost of vaccines not covered by public services or health insurers. Conclusion: The possibilities of reducing the problem vaccination in adults are always estimated to be above often more than 90%. savings in mortality would be immense if the vaccines were applied in all with an adequate vaccination calendar in adults. QUESTION 3.- What data vaccine tol - erance in adults? Exposure: Local reactions at the injection site of parenterally istered are common and may include pain, swelling, and erythema, usually of a moderate of short dura - tion. Systemic manifestations such as fever, irritability, or - omycin or gelatin as in the case of the MMR vaccine, or egg proteins and can produce an allergic reaction in people with to these substances. Anaphylactic reactions are estimated to occur in one out of every million doses ad - ministered [74]. Thimerosal is a mercuric compound used to prevent and viral contamination of vaccines, used since the Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364340is pain at the than 25% of vaccines. In much lower percentages there may be fever, ma - laise, headaches, arthralgias and myalgias, generally mild and of short duration. Suspicions of a link between vaccination against hepatitis B and multiple sclerosis, raised in France, have not been con - firmed in studies carried out in the United States of America [104-109]. In the case of the recombinant HBV vaccine using a new adjuvant (HepB-CpG), the adverse are similar to those for other vaccines [110], but suspicion has recently been raised that it may be associated with a higher incidence of my - ocardial infarction in one of to prevent IPD in adults over 50 years of age or with underlying diseases that justify the fact that for decades. - ty declines with age revaccination recommendation is under discussion. In a meta-analysis studies in vaccinated revaccinated patients [112], most of general adverse effects during vaccination and revaccination were few and limited in time, although they were more frequent during the second [113]. studies have of with the doubt of an increase in asthmatic reactions in some of the studies. The application of vaccines to patients who and are only given in adults if there is a particular risk of contracting this disease. This risk is particularly important in hyperendemic areas of meningococcal disease, in military personnel working in these areas, and for people frequently in contact with Neisseria meningitidis that have sex with men and patients in some areas where there is an epidemic outbreak of this disease in this population group. In addition to the classic vaccines, there are two vaccines against Neisseria meningitidis serotype B (Tru - memba \u00ae and Bexsero\u00ae) can be used in adults with risk factors as groups of adults who received the vaccine because they be [88, 89] during pregnancy is evidence of increased risk harmless vac - cines and there is no difference between them in the incidence of headache, dizziness [92]. for the prevention of Zoster in adults over years of age: an older live attenuated virus (ZVL) vaccine on the market, and recombinant produced in clinical trials, of RZV seen two clinical trials appears superior to ZVL. Zoster is estimated at whereas in the case of RVZ the protection was 90 to 97% over the age of 50 and data on immuno - suppressed individuals is limited. Safety data does not allow these vaccines to be indicated in individuals rheumatoid arthritis and other preferred for vaccinating contacts. There are no contraindications to RZV vacci - nation for people who have had a previous Zoster more than three years ago or who have received ZVL. The incidence consists primarily of local that activities - fever that only limit daily activities in 10.8% of cases. The duration of these side effects is usually less than 3 days and do not the vast of recip - ients second dose. The ZVL vaccine is administered in single doses and its local and systemic effects are qualitatively similar to those of RVZ. of acute retinal necrosis, uveitis or keratitis with ZVL have been between 6 strain, [102, 103]. B vaccine There recombinant hepatitis B vaccines cur - rently available on the market and all safe The most adverse with in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-36434148,277 cases in 2012 [128] [129]. In the United Kingdom there has also been a significant rebound in recent cases, which reached 12 episodes per 100,000 people aged 15 and over in 2012 [130]. There have also been major outbreaks of the dis - ease in South America, Asia, Africa, Australia and New Zealand with thousands of episodes published since 2008 and finally a severe epidemic that continues since 2008 in West Darfur [131-136]. In Spain, vaccination with whole cell vaccine began in 1975 and acellular vaccine was introduced in 2005. From 1998 to 2009, the numbers of whooping cough cases remained be - low 1.5 episodes/100,000 population. But, those numbers have risen dramatically in recent years and across all age groups [137]. The evolution of whooping cough in Spain between 1982 and 2016 shows a recent upturn in the number of cas - es reaching 17.9 episodes / 100,000 inhabitants in 2016 and growing since 2010. The upturn affects all age groups. Fernandez-Cano et al. analized the hospitalizated cases in Spain by whooping cough between 1997 and 2011, which amounts to 8,331, of which 92% were children under 1 year [138]. The overall mortality was 0.56%, the vast The causes for resurgence are the loss of natural and vaccinal immunity the lower antigenic potency of (DTaP), the immunity greater clinical suspicion, improvements in the the genetic changes of Bordetella pertussis that facilitate the escape from protection, along with the existence of strains with the - rier 71-85% [140], protect from disease but not from infection, do not prevent carrier status and allow transmission (experimental studies). They do not confer group immunity, do not immunity and produce response. Conclusion: been a clear increase in cases of whoop - ing cough over the last decade, affecting all population groups, including adults. The problem has multiple caus - es, one of which is the change to acellular vaccines, bet - ter tolerated but with less permanence of immunogenic capacity. Spain is no exception to the problem and has multiplied its incidence of pertussis more than 10 times in the last decade. QUESTION 5. - What has been the reality of the re - cent flu vaccination campaign in Spain? Exposure: The reality of the 2017-2018 flu campaign in Spain is that include local pain and erythema, with fever - nation, clear causal association between these vaccines and this syndrome has not been demonstrated [116, 117]. In the case of N. meningitis serotype B vaccine, admin - istration to adverse effects [118]. Haemophilus influenzae type b prevention of invasive disease caused by H. influenzae in adulthood. The most frequent reasons recipients and - 120]. malaise fever, little signifi - cance and short duration, adult vaccines have shown a very high degree of safety and a very low number of se - rious adverse effects. The generally related to such as gelatin cough by violent attacks of spasmod - ic cough that can last for weeks and are usually followed, in children, by post-episodium emesis. The only reservoir is hu - man and it is a highly contagious disease that can be fatal. Transmission in the close circle is very frequent but does not always translate into a symptomatic clinical picture. The introduction of a full-cell vaccine at the end of the 1940s, for use in children, dropped the incidence in the United States of America from about 250,000 cases per year in 1935 to about 1,000 cases per year in 1976 [122]. This vaccine was replaced by an acellular vaccine in 1997, better tolerated than the previous one, but against which the decreases at 5-10 years, resulting in adults we are resurgence this disease and in these circumstances; there are currently some 30 to 50 million cases of whooping cough in developing countries, of which some 300,000 cause death [127]. Some important out - breaks have occurred in the United States that have reached 25,827 episodes in 2004, 25,616 in 2005, 27,500 in and Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364342by Influenza A virus. (Spanish Influenza Surveillance System, April 2018). Despite this, the effectiveness of the vaccine has been reasonable with a certain cross-response. In Spain, inactivated vaccines modern tetrav - alent with two B virus lineages, in addition to subtypes H1 and H3 of type A influenza virus. The viruses recommended by the WHO in vaccines in existing mo - dalities. This has left approximately The explanation for the use of trivalent vaccines instead of quadrivalent ones lies fundamentally in the price differenc - es between them. Spain, like other countries, has a very con - servative stance in this regard. The WHO has noted that in the 2017/2018 season there were many hospitalizations among el - derly people caused by the influenza B virus of the lineage that was not included in the classic trivalent vaccines. Although price can be a barrier to implementation in countries with lim - ited resources, due to the higher price of quadrivalents, WHO considers that given the total costs to the health sector, quad - rivalent vaccines can prove to be cost effective [144]. As far as its general explanation is concerned, the health - care world tends to have a personal and simplistic knowledge about Influenza, which, together with a lack of trust in a vac - cine that is not absolutely effective, means that it is not linked, as in other to criteria of healthcare effi the - ical common chronic diseases. As for the challenges and possible future solutions, the first challenge in Spain lies in agreeing on a universal vaccina - tion indication or one almost similar to that of the USA, Cana - da or the UK. Only this indication has been shown to (>80% in healthy people) [146]. On the other hand, Spain, like many European countries, is far from the coverage targets and does not include among its indications that of children between 2 and 5 years that exist, for example, in Finland and the UK. In this sense, it is surprising that countries with very low coverage of influenza vaccination in classic population groups (chronically ill, elderly, etc.) rec - ommend children as a more gestural measure than fulfilled, since in many of them the influenza vaccine is not free or reimbursed [142].it has been a real \"perfect storm\" with declining vaccination figures, a multiple circulation of different types and subtypes of virus A, coupled with a predominance of type B command - ing the seasonal epidemic, aggravated by the almost absolute discordance between the that in the last seasonal epidemic lineage) admin - season. Spanish flu vaccination figures are known almost every year at the beginning of the following year's campaign, when the different Autonomous Communities provided their data to the Ministry of Health. For the umpteenth consecutive year since the 2009 pandemic, Spain shows a consecutive decrease in these figures. The only official global record available to Spain is for people over 65 years of age and indicates that the Spanish average for this population group stands at 55.5% coverage far from the 65.7% of the 2009-2010 flu season; maximum reached in the Spanish time series and twenty points away from the WHO set at 75% for 65 years. Only two Span - ish communities, Castilla y Le\u00f3n and La Rioja, have exceeded 60% of vaccination of their elderly. (Ministry of Health, Social Services and Equality, data from 2017). In this regard, WHO has that half European three older people [141]. In this sense, the recommendations of many of the more and more extensive, detailed and individual European coun - tries to like most countries, has included health care workers in its guidelines for influenza vaccination for years, but coverage in this strategic group is less than 40% and even lower. In general, there tends to be a certain parallel - ism workers and given community. Some publications have reliably demonstrated an association between this fact and also the priority population surveyed, the demonstrated risk of severe influenza in pregnant women and the additional protection of the new-born has had some different peculiarities with respect to others, such as the slightly earlier onset than other times, the prom - inence of the B virus over the A viruses and the presence of a lineage (Yamagata) different from the content of the seasonal vaccine (Victoria lineage). the vaccine (A/Hong Kong/4801). This vac - cine H3 virus has accounted for only a third of the infections Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter several years, the use of PCV13 seems to be justified in adults at higher risk, prevention of pneumo - disease based exclusively on use of vaccines [ 155]. In Spain, S. pneumoniae is in community-acquired pneumonia (CAP), causing up to of cases in some series. During the period 2003- 2007, a total of 75,932 deaths due to CAP were registered in adults aged 50 years or over and the incidence of CAP in our country in people over 65 is estimated at 14 cases per 1,000 person-years (IC95% 12.7-15.3) and increases with age (29.4 cases per 1,000 person-years in people over 85 years). In ad - dition, it carries an important burden, as up to 75% of cases require hospital admission [155]. We have the pneumococcal polysaccharide 23 vaccine (PPV23), indicated for active immunization prevention of S. pneumoniae disease in people older than 2 two (pre-filled are available, 7, 10 and 13 valents indicated for active immunization in children and adoles - cents aged 6 weeks to 17 years and for the prevention of IPD in adults 18 years and older. The vaccines in Spain are Synflorix \u00ae and Prevenar \u00ae [156]. In Spain it is estimated that approximately 50% of the population over 50 years of age has risk factors for pneumo - coccal mod - est reduction hospitalizations, ICU admissions, and death in elderly with CAP [158]. On the contrary, the impact of the use of conjugate vaccines in children on the incidence of disease by vaccine serotypes in adults has been demonstrated by C\u00e1mara et al [159]. The PPV23 has shown a good safety profile both as primary doses and after the ad - ministration of booster doses, but does not generate immune - er impact by acting on nasopharyngeal colonization. Prior to the introduction of PCV7 in children, a study in 10 European including adults, which was found acceptable in all countries. For Spain, the cost-effective - ness over was estimated at 9,187 euros. Using the CAPiTA study efficacy data, the CAPA study serotype coverage data and the CMBD 2010-13 incidence it determined that the of PCV13 in 5 years would hope to avoid in a cohort between 65 and 69 years of age 10,360 cases of IPD, 699 deaths, 14,736 years of life direct costs would represent an accumu -The next challenge is the of vaccines with elongated immunity in order to increase the immunizing po - tency and its spectrum of effectiveness against different virus - es, thus avoiding the problem of flu variation or lengthening the period of influenza revaccinations. These vaccines have been denominated by the WHO as NGIV (Next Generation In - fluenza Vaccines) that has elaborated and published some ob - jectives to 5 and 10 years. Some of them are easier to achieve and reach; others may require more Among these future are the cines\" claimed different authors [148, 149]. The approaches to these vaccines are multiple and not all have the same degree of experimental development. The viral targets against which they are directed include, in order of de - velopment, the M2 the chimera haemagglutinins, the inclusion of neuraminidase and nucleoprotein (NP), the anti - bodies against the stem of the haemagglutinin in serial admin - istration, etc. [150, 151]. Until these challenges are met, - enza in many European countries, especially This is the only way to increase the coverage in the elderly and people with chronic diseases and add other population groups with scarce or tes - timonial coverage (pregnant women and children) reaching at least the targets set by the WHO [153]. Until we reach the Holy Grail of an almost universal flu vaccine, there are quite a few preliminary goals to be met [154]. Conclusion: The proportion of people over the age of 65 vacci - nated against influenza in Spain continues to decline and is far from a coverage of more than 75% of the popula - tion WHO objectives. in populations such health care workers, pregnant women and children is regrettable and does not reach significant figures. There are very important challenges in the flu vaccination until the Holy Grail of an almost universal vaccine against this virus is reached. Vaccination of children is effective not only in the prevention of hospitalizations but also in in - direct herd immunity in older people before much greater coverage is QUESTION 6.- is Spain? Exposure: S. cause of - ty mortality worldwide and the pneumococcal potentially by with for the prevention infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364344systems vaccinology, use of And as types of recombinant the cold [162]. The antiviral vaccines that are at a more advanced level of research development include those aimed at the prevention of Simplex (HSV) and Vari - cella-Zoster Virus (VZV). At the same level of development are framed different flu vaccines, against Respiratory Syncytial Vi - rus (RSV), new modalities of triple virus (Measles-Rubella-Pa - rotiditis) and those aimed at the prevention of HPV and HIV, whose search is a relevant challenge, with high budgets and great media attention [163]. Of the \"emerging\" seems Ebola and Zika. Dengue is based on another flavivirus (yellow fever), which is attenuated and recombined with genes from the premembrane and the enve - lopes of wild strains of the different serotypes [164]. The Ebola outbreak has accelerated ment of vaccines, being an adenovirus from chimpan - zee (ChiAd3) that encodes the glycoprotein of the species Zaire (GP EBOV), which has become the vector of the same at an ad - vanced stage Zika is working on vaccines that can activate the response B and T aureus which includes several an - tigens, given its host adaptation systems that allow it to col - onize numerous niches and elude the immune system) stand infection strong research investment, Malaria, Chagas Disease and Leishmaniasis stand out, the latter being autochthonous in our country. Vaccines are developed vectors a heterologous vaccination strategy through induction by plasmidic DNA and a later re - inforcement with a viral vector (adenovirus) or with recombi - nant proteins adjuvated with IL-2 and cytokines will in Spain? The conventional \"usefulness\" refers to the capacity of a measure (in this case a vaccine) to serve or to be used for a specific purpose. The criteria that must prevail in order to implement \"useful\" vaccination strategies in our environment must assess the economic and social impact of prevention programs. To this end, at least two entities are in - volved that combine healthcare and preventive activity in each Regional Management of the health system: the \"Direcciones lated net saving of 3.8 million euros at constant prices (4.9 at current prices), being efficient for the National Health System of Spain. PPV23 is financed by all the Autonomous Communities in Spain, in risk groups and systematically for people over 60 years in each Autonomous Community. Only 5 Autonomous Communities (Castilla Le\u00f3n, Madrid, Galicia, Asturias and La Rioja) finance in their calendar the vaccination of adults with a valent conjugate vaccine from 60-65 years of age. The fact that it is not financed does not mean that it cannot be recommend - ed. In fact, the Ministry of Health, Social Services and Equality itself, in the review document published by the Working Group on Vaccination against pneumococcus in risk groups of the Presentation of Programmes and Registration of Vaccinations and approved by the Public Health Commission in June 2015, urges physicians that \"it possibil - ities of vaccination against pneumococcus (...)\". In those cases in which the vaccine recommended by the health authorities is the PPV23, it is necessary not only to inform that the choice of the vaccine obeys public health criteria, but that the PCV13 also exists and is marketed, which, although it is not contraindicated [156]. Conclusion: Invasive pneumococcal infection in morbidity and mortality in adults and the Although the polyvalent polysaccharide vac - has shown a modest and applied children have a greater impact on the adult population. The financing of these vaccines does not follow a homo - geneous pattern in the different Autonomous Communi - ties of Spain. QUESTION 7. - What is the future of Vaccine Clinical Research? Exposure: According to a report issued of manufacturers and almost three hundred vaccines are in them aimed at infectious diseases [160]. The dynamism of this field of knowl - edge is illustrated by the fact that access to PubMed through the terms a structured view of the topic, we will try to answer four questions. What vaccines are in Phase 3 clinical trials at present time? The field of infectious diseases includes vaccines against an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364345It is possible to introduce new vaccines from the modal - ities of economic evaluation in the field of health. These can be summarised in two types of techniques: analysis where the measurement of the effect is collected in monetary units (Cost-Benefit Analysis) and analysis of effect is collected in non-monetary units, where the Cost-Utility Analysis (CUA) is inscribed. Specifically, in a CUA (to which the second question referred) we compare two or more alternatives in relation costs results, expressed to the user's unit of measurement can this measure relates the years of life that the individual would en - joy (thanks to a health intervention) with the quality of life of that extra period [171]. A particularly attractive field will be to apply - uation models from a certain predisposition singular im - mune response, an adjusted of de - signing vaccines for each individual or group that are safer, easier to conserve/administer, of vaccines, proximately which infec - viral, and parasitic processes, and their future application will depend on very diverse factors that must consider the size of the problem, the effectiveness of the vaccine, its tolerance, and economic aspects of unquestionable im - portance. QUESTION of vaccines Spain? Exposure: Following the transfer of public health competencies from the State to the Autonomous Communities (AA.CC.), between 1979 and 1985, and through the General Health Law 14/1986, the \"Interterritorial Council of the National Health System, ICN - HS (Consejo Interterritorial del Sistema Nacional de Salud)\" was created as a permanent body for coordination, cooperation and communication between the State and the AA.CC. In this way, the Ministry of Health, Social Services and Equality coordinates and harmonizes health strategies in order to maintain equity and cohesion in access to health on Vaccination Programme and Registries, created in 1991, advises the Public Health Commission of the ICNHS from a scientific and technical point of view in making decisions on vaccination programmes in Spain and healthy adults is currently being re -Generales de Asistencia y P\u00fablica\" of the different Au - tonomous Communities. Among others, we could consider from the assistance assessment of the real burden of each disease, identified by the Basic Minimum Data Set to hospital discharge and scientific literature; and have a system of access to \"big-data\" that allows a quantification of the most prevalent by age segments and patient groups. From the managerial point of view, it is pertinent to implement economic evaluation studies with ro - In by the previous Herpesviruses. Among the bacterial ones, desirable foreseen - that system and budg - etary availability. Among the actors that will have a joint im - pact on its application and, consequently, on the reduction of the problems for its application, it is worth mentioning: Firstly, the Pharmaceutical Companies which, through - in exemplary behaviour in achieving recommendations and cov - erage that place us in paediatrics among the most [170], a special indications. Fourthly, the necessary involvement of the media in the dis - semination of truthful and responsible information in support should be highlighted. Finally, it is opportune to point out the role of the Health Authorities, who define the conditions of use and ensure access to vaccines protag and independence of the Regulatory Agencies, which evaluate and control their effectiveness, safety and quality. What impact will they have on the problems they aim to reduce? It is clear that the purpose of any vaccination strategy is to measure its capacity to reduce the burden of disease to be prevented, to reduce its morbidity and to avoid its potential for the prevention infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364346Should there be some others? At the moment, for differ - ent risk groups and healthy adults are in the final phase of the evaluation the and meningococcal disease will begin with 2018. What are the major differences between Autonomous Communities? In recent years, the the vac - cination schedule. Although there has also been joint work on the recommendations for certain vaccines in risk groups, some AA.CC have extended the age of vaccination and the use of certain vaccines to certain population groups. The main differences relate to the age of influenza vaccination, type of vaccination used for routine (HPV) vaccina - tion in certain risk groups. What can be improved and what is needed to do so? Some of the aspects to be improved in terms of vaccina - tion in general AA.CCs. Unilateral deci - sions different than those agreed in the ICNHS may cause con - fusion in the population and the healthcare workers. adopted the ICNHS, of which all the Autonomous Communities are a part. - In order to improve confidence in the decisions adopted necessary mechanisms for participation the of from the different stakeholders involved in vaccination, as well as great - er transparency and communication between them. - There is a need for greater awareness of the benefits that vaccination programs bring The authorisation of vaccines in Spain is mainly car - ried out at European Union level. Most of the vaccines authorised in Spain are for use in a wide range of ages including adults, with some exceptions authorised only for children or for the erderly. They are financed in any age group, as long as they are included into the current vaccination schedule, approved by the Interterritorial Council of the National Health System or the Autono - mous Communities, with few differences vaccination recom -viewed within the These are in the consultation phase, are expected to be agreed in adults authorised Spain. procedures, the latter coordinated at European Union (EU) lev - el and the most widely used at present. The Spanish Agency for Medicines and Health Products (AEMPS), existing under the Ministry of Health, Social Services and Equality, is the regula - tory body that participates together with the other EU coun - tries in the evaluation of medicines dossiers in Agency (EMA) [174-176]. Most of the vaccines authorized in Spain are for use in a wide range of ages including adults, with the exception of combined vaccines that contain high loads of diphtheria tox - oid and components against whooping cough (D and Pa), ro - tavirus vaccines (up to 24 or 32 weeks depending on the prod - uct), attenuated influenza (2 to 18 years), shingles (from 50 years of age and older), ten serotypes pneumococcal conjugate vaccine (6 weeks to 5 years of age) and H. influenzae type b (2 to 5 years of age) [177]. It is important to distinguish between the authorization and the recommendation of vaccines. In the evaluation for vaccine authorization, it is considered that the benefit/risk ra - tio is favourable. To establish vaccination is the of the disease to be prevented, the pattern and target group diphtheria (Td), influenza and pneumococcus (VPP23). Between the ages of 15 and 64, any contact with the health system should be used to review vaccination and up - date in of Td, MMR hepati - tis B, meningococcus C and HPV. - In addition, people of any age with risk conditions, the relevance of recommending DTap, hepatitis A, According to current legislation, referring to the portfolio of common services in the NHS, \"vaccinations are covered in all age groups and, where appropriate, risk groups, according to the current vaccination schedule approved by the ICNHS and the competent health administrations, as well as those that may be indicated, in general population or risk groups, for situations an opinion paper on the situation in Spain E. Bouza, et The ACIP recommends that booster doses for all adults older than 19 years in which a de - crease in immunity is suspected. In relation to polio, given the situation erad - ication of poliomyelitis, only transplant recipients who could exposed to travel or risk would require prevention with inactivated vaccine, in vaccination, and only a booster dose is recommended if risk of vaccine 10 or 13 valent, but it is interesting that the recommendations depend on the vaccines previously received and the order of the vaccinations. For those who have not previously received either of the two, we recommend first the conjugate followed by the 23 valent, at least 8 weeks apart [191]. For those who have previously received one or more doses of 23 valent vac - cine, a single dose of separate conjugate vaccine a minimum of one year after the 23 valent vaccine is recommended. Fi - nally, for those who have received previous conjugate vaccine and require other doses of 23 valent vaccine, a delay of at least 8 weeks from the administration of the conjugate, and not less than 5 years from the last dose of 23 valent, is desirable. The relatively low incidence of H. b pneu - monia in adult transplant recipients and the poor immunogen - ic response that occurs with the vaccine do not make this one an essential vaccine for this population group [192, 193]. The same occurs with in this popula - tion. adults, there a low meningococcal infection in SOT patients poorly known [194]. The vaccine is therefore reserved particular risk factors for When indi opt a vaccine All that are Anti-HBs negative high rate of related mortality [195-197]. Therefore, if after the usual three doses a rate of antibodies > 10mIU/ml is not reached in cycle be repeated. The response to HBV vaccine is quite varia - ble when done in post-transplantation and also in cirrhotic pa - tients, vaccinated at any time, which makes it necessary to - riodically re-check the level of protective antibodies [198-203]. With regard to Hepatitis A (HAV), - ry for all unvaccinated transplant whether children or risk of fulminant liver fail - ure when contracting hepatitis A in a SOT recipient. The anti - body response is also more limited in time than in the normal population and vaccination should therefore pri 9.- What is the vision on vaccination of a group of affected people such as patients with Solid Organ Transplants? of all, it would be appropriate highlight, as an idea for discussion, potential as a mechanism to avoid solid organ transplants (SOT). We do not know a pre - cise answer to this question, but it is enough to recall, as an example, that a substantial proportion of liver transplants are a consequence of the of hepatitis B and therefore potentially avoidable in almost 100% of cases. Preventing infection is a key element in SOT patients, since it is clear that infections contribute to the morbidity and mor to it. Immu - nization frank immunosuppression, also has its since, agents cannot be administered, adequate immune response being limited in some situations [178]. and National Societies have issued Guidelines with recommendations for Immunization in this population both in the paediatric age and for adults that in - clude their and etc.) will not able to receive if administration is made after transplantation. In the post-transplant period, vaccinations are generally avoided in the first two to six months after transplantation, during the period of maximum immunosuppression. An excep - tion to this rule is the case of Influenza, in which vaccination is justified after the first month post-transplant with inactivated influenza virus vaccines [181]. It is known that influenza is more severe in the popula - tion with SOT, [182]. - er than immunocompetent population and administra - tion of higher antigenic doses in this population is associated with a better immune response [183, 184]. A Spanish group has demonstrated the best efficacy of a second dose (booster) of inactivated flu vaccine, 5 weeks after the first, in the trans - planted population [185]. diphtheria and should be the as in the normal population, and vaccines are Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364348Health Authorities, in adults belonging to risk groups, and that these are as homogeneous as possible, and duly supported by sci - entific They must collaborate with the health-care authorities to ensure that the health professional is the first defender of vaccines and to provide agile mechanisms for con - sultation with those professionals who are better prepared in the field of prevention. In Spain there are several scientific so - cieties that have specific sections or working groups dedicated to vaccines groups. The Spanish Vaccinology Association (AEV) works specifically and monographically on the topic. It is a non-profit Medical-Scientific Association, constitut - ed under Law 191/1964, of 24 December. Its general objective is to protect health by means primary quality of life for citizens, with special reference to the child population and risk groups by age, immunocompromised people, people with occupational risks, international travel and basic diseases, increasing the quality of life of the population. The aims of the Association include: a) To disseminate scientific advances in the area of \"Artifi - cial, active and passive acquired immunity\" and to the vaccines and preparations infectious diseases. - cal, immunobiological research and cost-benefit analysis crite - ria in order to make judgments that may be useful for a ration - al use and in accordance with the socio-sanitary development in the aforementioned preparations, in the practice of Health Sciences professionals, both private practice and at the service of the Administrations. c) To expand the Vaccination Programs recommended by the Health-Care Authorities to the coverages, as well as to foment the evaluation of the same ones and to stimulate the Pharmacovigilance in the use of the and meetings in order to disseminate and update the knowledge that is being incorporated into Vaccinology, with expression of technological development in this field of Health Sciences. e) To promote research in Vaccinology, cooperating where necessary, in the Projects at the Design and Planning level, stimulating the streamlining at the level of the Clinical Re - search Ethics Committee of the Welfare Network. f) To raise awareness on the importance of the correct use of practices to social agents (politicians, media, general population) bearing in mind the competences of the different Public Administrations including Foreign Health. g) To establish relations with those National, International and International Scientific Societies with thematic affinity, as well as with the Health Administrations with competences in this professional or Regulatory praxis, creating meeting spac -With regard to it is a known fact that infection with this virus is associated with a risk of up to 100 times greater incidence of cervical neoplasms in transplanted women and anogenital who have vaccination criteria, whether they have been should receive the HPV vaccine. If they have transplanted, it is advisable to wait 3-6 months after the transplant. The immunogenicity of the HPV vaccine in this population not well known but the risks-ben - efits incline to the recommendation. In the future, indications may be extended to groups of transplanted adults who are not in the age ranges in which the vaccine is now indicated [179, 208-210]. RZV was nation and no safety concerns were identified [211]. At the time of writing this document, there is no recom - mendation for vaccination against Zoster with the recom - binant vaccine in the population with SOT, but at least two clinical trials are underway in this result of a clin - ical trial has just been published that proves its efficacy and good tolerance [213]. To conclude, we should remember that transplant patients diluted between the transplant of the family and community medicine that also follow the cases and transplant patient organizations. International da - ta show that there are clear opportunities to improve the im - plementation of schedule in this population [214, 215]. opinion also a frequent reason for omissions forgetfulness in the vacci - nation calendar of patients with SOT in our environment. Conclusion: Adult transplanted patients constitute a very par - ticular in ly, because the immune response is not the non-immunosuppressed Finally, some vaccines should be administered higher doses and at different rates. Despite the high level of the transplant system in Spain, there is an opportunity to improve coordination when implementing the for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364349In a study conducted in Israel, the role of the flu vaccine nurse in gaining acceptance of the flu vaccine among those [224]. In the case of the pneumococcal vaccine, a study carried out in Hong Kong, showed that a brief process of health educa - tion, only out by nurses, increased vaccination during hospital admis - sion for any reason, and so a CDC-sponsored study increased the vaccination rate from 19% to 74% after implementing a screening program and vaccination offer [226]. Another example of the potential nursing work in the ac - ceptance by school girls and their families, through a simple reminder call of the convenience of getting vaccinated against HPV [227]. This work may when it is carried out in particularly defenceless groups or in social exclu - sion. This is the case of vaccination against hepatitis B, where the role of nursing has also been shown to be by ensuring, through a follow-up programme, that patients complete their third dose of vaccine [228]. The literature collects a miscellany of situations in which the role of nursing is key in the global vaccination process, both in poor and developed countries and with vaccines of a different nature, including polio [229-231]. It seems, therefore, that this would be a very appropri - ate area, due to the characteristics we have mentioned, for the creation of consultations, or vaccine promotion groups, par - ticularly coordinated by not been find concrete in the professional literature the methodology) the clinical, eco introduction. Conclusion: Vaccination, and particularly adult vaccination, is one of the paradigms of the work and competence of nursing. Many studies demonstrate the effectiveness of nursing intervention in groups, with different vaccines and with different impacts. Nursing has to promote and manage all adult vaccines and their complete vaccination schedule, and in our opinion, this work is a very clear ar - ea for nursing consultations or working groups managed by nurses. QUESTION 12.- is the of adults? Exposure: The Community plays, or an essen - tial role in adult vaccination. Not only in aspects such the correct conservation storage also in all aspects related to tolerance and safety of There is the possibility of making a clear contribution to health edu -es between professionals of different levels and disciplines, for what is related to this scientific field. h) To cooperate in those Programmes of Health Dissemina - tion and Information and Education for Health (EPS) in which topics on vaccines and other immunobiological preparations of social, scientific or journalistic interest can be submitted for debate. i) To carry out Publications (printed, digital, Web), to sum - mon scholarships or aids for national and foreign research studies, to Prizes, or conducive to metializing the previous points. The activity of the Spanish Vaccinology Association is not restricted exclusively to promoting the scientific technical knowledge of its members but is open to any other possible beneficiary who meets the conditions and characters required by the nature of its own purposes. The activity of the Association may also consist of the collection and management of funds and patronage for the granting of Scholarships or Grants for studies and research, the organisation of Awards, Courses and Seminars, grants for all kinds of Governing Conclusion: several Scientific Societies that have spe - cific sections or working groups dedicated to vaccines in Spain. The Spanish Vaccinology Association (AEV) works specifically in the field of vaccines and its objectives are aimed at promoting knowledge, research and the appro - priate of vaccines as a means QUESTION 11.- What is the role of moting health with vaccines in adults? Exposure: Health promotion, as part of the comprehensive care pro - cess, is the essence of nursing. This - and social adaptation At any of levels, health education is a key instrument [216, 217]. The concept of nurs - ing care has also evolved from a disease-oriented care system to a preventive and health promotion system [218]. According to the World Health Organization at the 9th World Health Pro - motion Conference, \"getting vaccinated\" is one of the 12 tips for promo - tion and administration of vaccines, is very groups, the knowledge and skills of nurses, both graduated and school nurses, in the of vaccination, still offer op - portunities for improvement in both groups today and in ly countries adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364350from 72 to 93% of the candidates in one institution [244]. Similar experiences have been carried out in countries other than the United States [245-252], but we have not been able to find information on the activity and impact of promot - ing vaccination in departments and a in infection - tion and health education from ments, to promote the proper use of vaccines in adults. In the United States, a high percentage of these services have such programs, and the data in the litera - ture show a clear impact on vaccination rates and educa tional capacity. We have not been able to find data on the quantitative and Spain. QUESTION 13.- What is the economic value of vac - cines, as seen by a health economist? Exposure: The Choiseul Institute has recently produced proposing of which some aspects in the following lines. Health expenditure in Spain has been reduced to below 6% of Gross Domestic Product (GDP) in 2018 according to the General State Budget (not yet approved). This means that Spain is countries in \"per capita\" health-care spending but is in a second place that it shares with Italy. In a way, this situation is aggravated by the dispersion that exists - ferred to AA.CC. adds to the inequality between the different regions of Spain. On the other hand, it is interesting to note one of the problems that are not normally analysed, such as the effect on the economy of absenteeism due to illness. Although there is no very recent data, that provided by Eurostat in 2012 of the 13,000 million euros representing temporary incapacity says enough. An influenza episode, for example, results in a worker, on average, to take sick leave for five days. The cost of this incapacity represents more than 20% of health expenditure, part of which could be covered by prevention policies. This is where vaccines come in; an area which, like many others in health-care policy, has suffered significant cuts. Suffice around 1.8% of total pharma spending Spain. of vaccination in young is well known. In this chapter, Spain is among the most advanced countries in the with coverage above 95%. as a policy during all ages of life. And here, the situation is frankly improvable. It is enough to look at vaccination data for those over 18 years of age, or older. Cov -cation from the Community Pharmacy. This must be done not only in relation to the vaccines of regular use, but also in those that are needed occasionally as it is the case of some vaccines for travellers. If this is not the case, it is due, in our opinion, to the lack of necessary training and the necessary coordination with other structures. The health-care is changing significantly for the benefit of the patient, not only in Spain, but also in numerous countries of the European Union and beyond. The wide network of pharmacies distributed uniformly throughout Spain can undoubtedly help to vac - cination coverage of the adult population along with oth - er health-care centres. We must not forget that an average Spaniard goes to the pharmacy 7 times more frequently than to any other health centre or medical consult. At the Community Pharmacy, it is possible to identify and guide risk patients who may benefit from vaccination, strengthen the recruitment of people included in these risk groups by collaborating with other health professionals and involve the pharmacy in health education, transmitting truth ful clear on of vaccination to prevent different diseases. In addition, it is easy to carry out pharmacovigilance work from the Community Pharmacy. An - other important objective is to fight against the \"anti-vaccine\" philosophy from which some elements of the supposedly bet - ter educated classes are not free. The other area that we must discuss is the role of the Hospital Pharmacy Department in the immunization policy of the population. The hospital pharmacy is currently one of the points with the highest volume of data on patients in the hospital, not only from their own information but for being the coordinating node of many other databases to create and strategies based on and certain diseases can very well be done with a warning from the pharmacy servic - es. Taking advantage of admission is a perfectly feasible contribution. In of America, the - tion services\" or groups are well recent study esti - mates that they administer an additional 6.2 million doses of flu vaccine and 3.5 million additional pneumococcal vaccines each year evaluation that of them in the U.S. offer and promote the use of at least one vaccine that can be administered at the pharmacy itself [233- 235]. implemented from [236-243]. A example of influenza and invasive pneu - mococcal infection is a working group and a nurse prevention in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364351enormous economic effects other aspects that are undoubtedly very relevant. In all this, public authorities must be sensitive to the times. Conclusion: The money spent on vaccines should not be seen as an expense but as an investment. In strictly economic terms, it is estimated that every euro spent on vaccines has a return of 4 euros to a country's economy. Each pathogen against which a mated \u20ac44 to \u20ac226. The implementation of a of only 6 vaccines in the 72 poorest countries of the world would have the effect of preventing the death of 6.4 million children and 426 million episodes of illness in the next 10 years and would mean a saving of 151,000 million dollars, as productivity. QUESTION 14.- What is the role of the press in the promotion of Health through vaccines? Exposure: The role of the press in the vaccination of adults and children should focus on conveying to the population the im - portance of this fact and its repercussions as a major public health issue. The press should demand from the health author - ities, beyond information, a commitment to adopt measures to guarantee access for adults, on terms, all the neces - sary vaccines. Furthermore, it should call on the responsibility of scientific societies to promote the implementation of a ho - mogeneous adult vaccination schedule for the whole country. In addition to these general principles, it is also pertinent to comment on the news that leads to the dissemination of vaccine hoaxes, particularly via the Internet. In a study con - between July tweets, proving that many of them had origins similar to those that tried to influence the electoral process in 2016 in the United States of America. In general, they try to project the image of a public opinion much more divided than it actually is about the safety or insecurity of available vaccines. The study shows that the vast majority of American society believes that vaccines are effective. The reluctance of some parents to allow their children to be vaccinated is another issue in which the press can play a very important role, just providing proper information. In general, parents who do so tend to make three kinds of ar - guments: some believe that their children are at little risk of diseases such as polio, measles or tetanus because others are vaccinated already. Others believe that many of the diseases that vaccines prevent are not really too chick - enpox or measles the informa - tion and fleeing sensationalism, can do an extraordinary job in this sense as well [256-266]. In conclusion, we would like mention the laxity that professionals themselves have when it comes to getting vaccinated, an as - pect that requires special attention. The results of phase I of the DOVE study published in 2011 in the journal of Health Affairs conclude that with a package of only 6 vaccines, the death of 6.4 million children could be avoided over the following 10 years, to which should be add - ed the disappearance of 426 million episodes of disease. Eco - nomically, potential 72 poorest countries, 151,000 million dollars, the result - ing on diseases and greater productivity [255]. It has been proven that vaccination, a positive effects on the economy of any country. People with health produce less, consume less, increase public spending, affect in some way, on exports; in short, harm the production of goods and services of the country and, there - fore, deteriorate global wealth. The for every euro invested in health-care, a return of 4 euros is obtained and that 5 years of increase in life expectancy has an impact on the GDP of an annual 0.5% increase in developed countries. In Spain, it is estimated for every euro invested in vaccines, \u20ac22 person throughout his or her life is calculat - ed at a variable cost of between \u20ac443 and \u20ac3,953 per person at a cost of \u20ac226 new vaccines that address new problems. At this point, it is important to highlight the fact that the phar - maceutical industry is one of the most R+D-intensive, this be - ing necessary for the production of new solutions to specific health-care problems. One of them has to do, for example, with changes in the patterns of sexual rela - tionships increasingly younger ages and without the proper precautions, to which has been added the new problem that comes from the famous \"morning-after pill\", which is proven to be used without any medical control and which, in the long run, according to many experts, could have incidence in breast cancers. However, going back to vaccines, it is important to point out the HPV vaccine, which is now on the vaccination calendar for young women, but not for men. Giv - en the promiscuity in young people, the difference in criteria from one European country to another, the \"Erasmus effect\", and other considerations, this is a problem that, without being apparently serious, also affects boys in a multitude of health problems that affect the physical and, above all, the psycho - logical area. This is an aspect of vaccination policy that calls for review. This has for the prevention infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364352In fact, ethics has never questioned the type of service. The problems have started very recently. In the case of armies, one of the reasons has been the progressive complication and technification of military tasks, which can no longer be covered by non-specialized personnel, which has forced the professionalization not only of military command - ers but of the militia in general. But in addition to these reasons that we can call technical or professional, there are others that depend on culture. We live in a liberal culture, where perhaps the most appreciated value is freedom. It is, of course, about individual freedom, in such a way that all the orders coming from any instance out - side the person are questioned by principle. On the other hand, Western culture generally puts free - dom at the service of maximum utility or maximum personal interest. This means that the idea of the collective interest has lost much of its previous strength, and that today it clearly conflicts with the individual interest inasmuch as the search for that collective interest may result in some damage to the individual himself. Thus, the great moral conflict of compulsory vaccination is the conflict between the collective or common good and the individual good. As long as the protection of the former can put the latter at risk, there are criticisms that individual rights are being violated which are inviolable. The two values at stake or, in these cases, in conflict, are collective benefit vs. individual benefit. In all classical ethics it was assumed that the first of these values had priority over the second. Aristotle says it at the beginning of his Politics , and it became an undisputed principle, which was self-evident. It was a clear \"deontological principle\", which was soon justified by criteria of natural law and even divine law. But as of the 18th century, a new approach was devel - oped, not deontological but \"teleological\"; that of utilitari - anism. The only moral obligation is to maximize utilities, and therefore the question is whether the utilities of the individual benefit are superior to those of the public benefit or not. Act Utilitarianism calculates utility \"act by act\". This means an individual's vaccination must be calcu - lated both for the community and for the individual himself. If the vaccine entails serious risks, even if its probability is very low, it is normal that the usefulness of vaccinating a single individual is socially or collectively very small, and that the usefulness of avoiding the individual risk of secondary effects may be greater. Knowingly or not, this is how most objectors to social vaccination reason. There is another utilitarianism called Rule Utilitarianism. It seeks to optimize the usefulness of each act, but of each norm or rule. In rule says that collective vaccination has a great social bene - fit, even though it may entail some individual risks, which, in some very extraordinary cases, may become serious. But Rule Utilitarianism does not easily The result is that the rational utilitarianist will look for others to act according to Rule Utilitarianism whilst he decides accord -point out that the press is an excellent vehicle for transmitting public demands to the political class, which must legislate on the financing of vaccines so that their application is feasible for all those who need them. Conclusion: The role of the press in the subject of vaccination is potentially multiple. It must contribute to disseminating truthful and rigorous information to the population, - the acceptance of essential Public Health meas - ures. The media must contribute to the elimination of hoaxes and misinformation pressure in favour of making legislative decisions that, as in the case of vaccines, have a great impact on individual and collec - tive health. has raised ethical issues from the very begin - ning. But this does not mean that these problems have always been the same. Quite the opposite is true, that each era has posed its own problems. When Jenner fine-tuned antivariolic vaccination - cedure and wanted to spread it generalize it to the whole population, the problem arose as to whether it was correct to inoculate, in healthy people, a very serious disease and from which more than 30% of those affected died. This was the great debate in the final years of the 18th century and the first decades of the 19th century. In the middle of that century another problem arose. Faced with the century, Jaime Ferr\u00e1n fine-tuned his controversial vaccine. Here the de - bate was mainly scientific, and the question was whether this vaccine was effective and safe enough to be extended to the whole population. Today there is no question about the effectiveness and safety of vaccines. But it happens that, precisely because they are effective, they have side effects, which in some cases can be serious. And the problem that arises is whether the State can make a vaccine obligatory, which, although there is no doubt that it has a clear collective benefit, can nevertheless be harmful at an individual level. For obvious reasons, in the following lines we are going to focus on the analysis of this last problem, that of the obligato - ry nature of vaccines. Until very modern times it was never doubted that the State had the power to oblige people to provide services, not only financially or in terms of goods, but also personally or in terms of their own lives, in certain cases in which the good of the community was at serious risk. Such has always been the case of the obligatory nature of military service and of actively intervening in actions of war, even at the risk of one's own life.Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364353and Abrahamic root religions. This Western nat - uralism, which although it has been very positive in many as - pects of our culture, also highly problematic and negative consequences, such as the conversion of the order of nature into a criterion of morality. At present, this moral prejudice is at the basis of many of the \"ecological\" movements. But as ethics as deontological naturalism has been teleological utilitarianism, of which we have al - ready spoken, the moral obligations of human beings are not solely at optimizing individual benefits. We are social beings, we benefit from social life which, obviously, has the right to demand certain benefits by reciprocity. These must be as harmless as possible to individual goods, and that is why vaccines should be made compulsory only in exceptional cases. But we must all assume our duty to contribute to the common or collective good, even assuming, in exceptional cases, vital risks. Whoever does not act in this way must be seen for what he is, a \"non-solidarity\" subject, a \"profiteer\" or, simply, a \"free - 1714, a British physician and philosopher, Bernard Mandeville, published a famous book with the following title: The Fable of Bees, or How Private Vices Make Prosperity Public . It is a classic topic in liberal culture thereafter. Some time later, in 1759, Adam Smith brought to light his great book of ethics, the Theory of Moral Sentiments . In the part entitled \"From the wrote: rich consume barely more the and despite their natural selfishness and greed, even though they seek only their own convenience, even though the only aim they set them - selves is the satisfaction of their own vain and insatiable de - sires, they divide with the poor the fruit of all their properties. An invisible hand leads them to realize almost the same distri - bution of things necessary for life that would have taken place if the earth had been divided into equal portions among all its inhabitants, and so without pretending it, without knowing it, they promote the interest of society\". Hence the importance that this invisible hand ended up having in the other great work written by Adam Smith, this one on political economy, An investigation on the nature and cause of the wealth of na - tions , published in 1776. Does such an invisible hand exist? Does it fix everything? Does it make private vices contribute to public prosperity? Sometimes yes, but not in all cases. Both situations occur in the world of vaccines. In some of them, the pure individual interest in tackling the ills of the disease even not directly vaccinated and thus contributes to the collective benefit. This is the case of the Sabin vaccine against the polio virus. By seeking individual protection, the immunization of other These are win-win situations, studied game the - ory. It is unreasonable to collaborate on a collective good if one does not take personal advantage of it. The problem is that this is not always achieved, because there are times when it is necessary to lose something individually in order to maximize the collective benefit. The analysis of these situations has been worrying theoreticians for a long time, from Pareto to Nash. Mancur Olson's study of this type of social behaviour in his book The Logic of Collective Action: Public Goods and the The -ing to Act Utilitarianism. This is the case of the \"freeloader\", who takes advantage of the altruism of others to increase the usefulness of his own selfishness. For example, if everyone is vaccinated, my child will not be infected with the disease, and therefore I do not need to vaccinate him, thus avoiding dis - comfort and possible side effects. It is the same as when it is forbidden to fill swimming pools with water during a very dry summer, but a someone decides to fill his because this con - sumption is almost imperceptible, as long as the others respect the rule. I take advantage of the respect of the rule of others, at the same time that I decide not to respect it. What has been said about compulsory vaccination chang - es when vaccination is free, in such a way that it is advised but not obligatory. In those cases, which are the most frequent, the conflicting values are, in general, the balance between benefit and risk, that is to say, between the prevention of a potential serious disease on the one hand and the risk of sec - ondary effects of the vaccine on the other. These are obviously two distinct manifestations of non-maleficence: preventing something that is in our hands and that is maleficent on the one hand and, on the other hand, avoiding or not carrying out something that can be, though certainly with a low probability. This conflict is more apparent than real. This is due to the fact that clinical research into vaccines allows us to have sci - entific evidence that the benefit of the disease it prevents, or the harm it avoids, is far greater than the harm from the side effects of the vaccine itself, and this in the individual himself. Therefore, now we are not talking about collective benefit versus individual benefit, but we are comparing the individu - al benefit of getting vaccinated and avoiding a serious illness versus the benefit of not getting vaccinated and avoiding the side effects of the vaccine, whilst accepting the risk that the person may suffer a serious illness. This is therefore a utilitar - ian calculation, and not a \"Rule\" but an \"Act\". And it is clear that in vaccines, utilitarian calculus is always on the side of vaccinating, its benefits are much greater than the risks assumed. So far, we have appealed to the language of values and conflicts of values. We have approached analysis as a choice between different values. This is what is usually done in ethics. However, it is not the ideal procedure. The optimal solution is never in the extreme courses but in the intermediate ones. It is sometimes said that between vaccinating and not vaccinating, there are no intermediate courses. But that is not the case. This is a typical bias in the decision-making process promotion of responsibility. Most of the objections to vac - cination are due to false prejudices, which an adequate delib - eration allows, in most cases, to overcome. One of the most common prejudices is that of \"natural - ism\", i.e. natural is good and artificial is bad. This, however paradoxical it may seem, is in the collective unconscious of our culture. Ethics was born as a scientific discipline in Greece from this principle, which later reinforced an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364354ligatory vaccines in children, or Italy, where the presentation of the health booklet attesting to the application of the twelve types of vaccines required by law is required upon entry in - to kindergarten or school. The argument put forward by the Spanish scientific societies is that, with the current procedure, very high percentages of vaccination are achieved, even higher that achieved in some compulsory vaccination. This is a markedly consequentialist criterion. And while the consequences are an important factor in moral rea - soning, they are not the only one. There are also the principles; in this case, that of justice, the equitable distribution of bur - dens. We must not endorse voluntarism and altruism, which is basically a pure duty of justice. The invisible hand, as Adam Smith rightly said, gets \"almost\" the same distribution as jus - tice does. But only \"almost\". Conclusion: We receive many benefits from the community, and that is why we are also obliged to contribute to the col - lective good with different types of benefits. It is nec - essary to do everything humanly possible so that these are the least possible, not only in number but also in se - verity. But when it is necessary to distribute risks, it is not possible to trust everything to the voluntary will of those who, for whatever reasons, are willing to assume them freely and voluntarily. Because this, in a collateral way, encourages Public cannot be considered fair. When persuasive measures do not fully cover health objectives, as in the case of several vaccines, the only right thing to do is to make them ob - ligatory. The rest is a serious dereliction of duty. TRANSPARENCY DECLARATIONS/POTENTIAL CONFLICTS OF INTEREST The This publica - tion was financed by GSK and the authors have not received any fee for their collaboration. REFERENCES 1. World Health Organization . Global Vaccine Plan 2010-2020. Gene - va, 2012. 2017 2. World Health Organization. 16th Meeting of the SAGE Polio Working Group. http://www.who.int/immunization//sage/meet - ings/2017/april/1_Final_report_Clarke_april3.pdf 3. Kim DK, Riley LE, Harriman KH, P, Bridges CB. Recommended Immunization Schedule for Adults Aged 19 Years Bricout H, Clay Largeron N. Public health and eco - nomic impact of influenza Vaccin Immunother. 2016;12(9):2259-68. DOI: ory of Groups (1965) is a classic. The study of the case of the \"sponger\", \"stowaway\", \"parasite\" or free-rider, the one who tries to go unnoticed to take advantage of the collective ben - efit, without contributing to it in its aliquot part, also comes from the theory of games: \"If everyone gets vaccinated, then I don't have to, the germ won't be able to live and spread.\" The problem increases by degree when the individual loss does not consist so much in the discomfort of the very fact of vaccination, but as the possibility of some more serious and persistent effect on the life of the person being vaccinated. There is also a paradigmatic example of this: the human small - pox vaccine, which managed to eradicate this very serious dis - ease from the face of the earth. In addition to the discomfort inherent in its application, there were extremely rare encepha - litis, but with permanent 1980. The argument for requiring vaccination, even knowing that a small group of people would be harmed by it, was one of \"public health\". The risk had to be taken that individual health might be affected for public health reasons. It was a social benefit, a contribution to the collective good like others, including the obligation of military service or the defence of the country in the event of war. Today, in Spain, there is no vaccine that is compulsory. There is a very positive reason for doing so. The use of per - suasive methods is always preferable to coercive measures, es - pecially in our liberal societies, where it is getting worse and worse that someone has to suffer harm for reasons of public benefit. We all understand well and are willing to collaborate in win-win situations, but we resist by all means at our dis - posal those in which the collective good requires a sacrifice, sometimes serious, very are the lose-win situations. Someone has to lose, and we try by all means not to be us, although we are delighted to receive the positive social consequences generated by the sacrifice of others. The paradigmatic case is that of wars. With which we become, velis nolis, freeloaders. The ethical consequences of this type of behaviour are evident. We receive many benefits from the community, and that is why we are also obliged to contribute to the collec - tive good with different types of sacrifices. It is necessary to do everything humanly possible so that these are the least possi - ble, not only in number but also in gravity. But it is no longer so clear that the solution, when it is necessary to distribute risks, consists in trusting everything to the voluntary will of those who, for whatever reasons, are willing to assume them freely and voluntarily. Because this, in a collateral way, en - courages the proliferation of freeloaders. Public cannot be considered fair. When persuasive measures do not fully cover health ob - jectives, as in the case of several vaccines, the only right thing to do is to make them obligatory. The rest is a serious dere - liction of duty. This seems to have been understood by other countries, such as France, where there are currently eleven ob -Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364355and costs associated with Health Serv 2018;18(1):715.doi: 10.1186/ s12913-018-3529-4 21. Wright C, Wordsworth R, Glennie L. Counting the cost of meningo - coccal disease : scenarios of 22. Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP). Instituto de Salud Carlos III. Resultados de la Vigilancia Epidemiol\u00f3gica de las enfermedades transmisibles. In - forme anual 2015. Madrid, 2017. 23. Williams WW, Hickson MA, Kane MA, Kendal AP, Immunization policies Williams O'Halloran A, Kim DK, Summ. 2017;66(11):1- 28. DOI: 10.15585/mmwr.ss6611a1 United States: Recommendations, Barriers, and Measures to Improve Compliance: - nations. P t. PMC4959618 26. Esposito S, Durando P, Bosis S, Ansaldi F, Tagliabue C, Icardi G. Vac - cine-preventable diseases: from paediatric DOI: 10.1016/j.ejim.2013.12.004 27. Poland GA, Schaffner W, Hopkins RH, Jr., Health USDo, Human S. Immunization guidelines in the United States: new vaccines and new recommendations for children, adolescents, and adults. Vac - cine. 2013;31(42):4689-93. DOI: 10.1016/j.vaccine.2013.03.031 28. Anderson EL. Recommended solutions to the barriers to immuniza - tion in children and adults. Mo Med. 2014;111(4):344-8. 29. Nichol KL, Nordin J D, Nelson D B, Mullooly J P,Hak E. Effectiveness of influenza vaccine in Engl J Med. 2007;357(14):1373-81. doi: 10.1056/NEJMoa070844 30. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, Hall AJ. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Dis. 2004;190(1):1-10. DOI: 10.1086/421274 31. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123(7):518-27. 32. Lal H, Cunningham AL, Heineman TC. Herpes Zoster Subunit Vaccine Med. 7. DOI: 10.1056/NEJMc1508392 33. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domin - go J, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or N Engl J Med. 2016;375(11):1019-32. DOI: 10.1056/NEJMoa1603800 34. CJ, Shah KV. The causal re - lation between papillomavirus and cervical cancer. J P, Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged Years. Ann Intern Med. 2015;163(7):489-97. DOI: 10.7326/m15-0093 6. Parkin DM. The global health burden of infection-associated can - cers in the year 2002. J 2006;118(12):3030-44. DOI: 7. No authors cancer. Lan - cet. 1988;1(8588):756-8. 8. Schweitze A, Horn J, Mikolajczyk R, Krause G, Ott J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a sys - tematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-55. 9. Blachier M, Leleu H, Peck-Radosavljevic M, Valla F. The burden liver in Europe: data. J Hepatol 2013;58:593-608. 10. Thorrington D, Andrews N, Stowe J, Miller E, van Hoek AJ. Elucidat - ing the on pneumonia, sepsis otitis media hospital admissions in Eng - using a composite control. BMC 10.1016/j.vac - cine.2017.04.032 12. Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. vaccination programs Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quad - rivalent meningococcal vaccination C, Durrheim D, Esko - la J, Popul indicator of the Haemophilus type b (Hib) dis - vaccine era. Jama. 1993;269(2):221-6. 17. Putri WCWS, Muscatello DJ, MS, Newall AT. Econom - ic burden of seasonal influenza in the United States. Vaccine. 2018;36(27):3960-3966. C, R. Economic cost of community-acquired pneumonia, meningitis and bacteremia in an adult in Bogota, Colombia. Biomedica. 2014;34(1):92-101. DOI: 20. in healthcare utilization adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364356dence of cervical lesions in Danish women before after imple - mentation Nielsen TS, Dehlendorff C, Kirschner B, Junge J, et al. Trends in the incidence of National Australia. population-based HPV vaccination pro - gram on cervical abnormalities: a study. BMC Med. 2013;11:227. DOI: 10.1186/1741-7015-11-227 53. Prevention CfDCa. B. 2016. https://ww - wnccdcgov/travel/yellowbook/2016/infectious-diseases-relat - ed-totravel/hepatitis-b#4621 2 54. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis 55. Iqbal Baumgartner J, Gerard K, Pois - sant T, et al. Epidemiology of Acute Hepatitis B in the United Clin Combating hepatitis B and C to reach elimination by 2030 57. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, et al. Early impact of PCV7/PCV13 sequential introduction to the national 10.1016/j.vaccine.2015.01.030 Bruce MG, Singleton R, Bulkow L, Rudolph K, Zulz T, Gounder P, et al. I, Griffith B, McGeer A, Lovgren M, et al. Serotype distribution of invasive in Canada the Grau I, Ardanuy C, Benitez MA, Linares J, Pallares 2018;60(1546):73-82. 62. Wang NY, Pollard AJ. H, Beebeejaun K, Ribeiro S, Gray SJ, Borrow R, et al. Meningococcal Group W Disease in 10.1503/cmaj.070771 J, Rodriguez AC, Wachold - er S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907. DOI: 10.1016/s0140-6736(07)61416-0 38. Palma DA, Nichols BY, Lyu CW, et al. US assessment of HPV types in implica - Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical in RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a ran - quadrivalent human papilloma - ociety of Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic hu - man papillomavirus types 6/11/16/18 L1 virus-like mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacuna ciones/Calendario2018.htm 47. CC, Thompson TD, et al. Human Papillomavirus-Associated Cancers - an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-36435710.1056/NEJMoa071434 77. Godlee F, Smith J, Marcovitch K, Narwaney K, Breslin K, et al. Integration of data from a safety net health care system into the Vaccine Safety Datalink. Vaccine. 2017;35(9):1329-34. DOI: 10.1016/j.vaccine.2017.01.027 81. Izurieta HS, Moro RT. collaboration for ep - idemiological investigation of vaccine safety: countries? Use of a new - indicator for vaccine safety surveillance and Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of in - fluenza vaccination in specific Szwajcer A, Rabbani R, Zarychanski R, Abou-Set - ta AM, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review 85. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review Lim FS, F, Oh HM, Lee BW, et al. Comparative immunogenicity and safety of human AM, Poncelet S, et al. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine females vaccinated at Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, et al. Safety and im - munogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who (MSM). AIDS Res Ther. 2017;14:34. DOI: 10.1186/s12981-017- 0160-0 89. SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, et al. Efficacy, safety, and immuno - genicity of the human papillomavirus 16/18 AS04-adjuvanted vac -64. Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, et al. Meningococcal serogroup B strain of mul regional distri - bution and clinical characteristics in England, Wales, and North - ern Ireland, 2007-08 and 2014-15: a Bergamini M, Stefa - nati A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adoles - BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, et Wang X, MM, al. Invasive Haemophilus influenzae Disease Adults Dis. 2014;1(2):ofu044. DOI: 10.1093/ofid/ofu044 71. Livorsi DJ, Macneil JR, Cohn AC, Zansky S, Petit S, et al. Invasive Haemophilus influenzae in 2012;65(6):496-504. and techni - cians can enhance patient care even more once national pol - icies, priorities are aligned. 73. Spencer JP, Trondsen Pawlowski S. Vaccine Ad - verse Events: Separating Myth from et al. Adverse reactions to vaccines RD. An assessment of thimerosal use in child - hood vaccines. Pediatrics. 76. Thompson WW, et al. Early thimerosal exposure and neuropsychological out - comes at 7 to 10 years. N Engl J Med. 2007;357(13):1281-92. DOI: Vaccines for the prevention in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364358post-marketing safety experience. Vaccine. 2017;35(52):7231-9. DOI: 10.1016/j.vaccine.2017.11.013 Jr., Graham DJ, Guess JB, Johnson adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol. 1988;127(2):337-52. 105. McMahon of reactions to hepatitis B vac - cine in 43,618 persons. Am J Med. 1992;92(3):254-6. 106. Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vacci - nation of neonates and infants: emerging safety data from the Vaccine Adverse Reporting System. Pediatr Infect Dis MA, Olek MJ, Coplan PM, Bro - dovicz K, et al. Hepatitis B vaccination and the risk of multi - ple sclerosis. N Engl J Med. 2001;344(5):327-32. DOI: 10.1056/ nejm200102013440502 108. Hall A, Kane M, Roure C, Meheus A. Multiple sclerosis and hepatitis B vaccine? Vaccine. 1999;17(20-21):2473-5. 109. Confavreux C, Suissa V, Vukusic S. Vaccina - tions and the risk of relapse in multiple sclerosis. Vaccines in Multi - ple Sclerosis Study Group. N Engl J Med. 2001;344(5):319-26. DOI: 10.1056/nejm200102013440501 110. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR Morb Remschmidt C, Harder T, Wichmann O, Bogdan Falkenhorst P, Sundaraiyer V, Le Dren-Narayanin N, et al. Safety and immunogenicity of a 13-va - lent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An trial. vaccines: systematic review Organ. 2008;86(5):373-80. PMC2647448 Prymula R, Goldblatt L, Prymulova K, Ko - sina P. Immunogenicity and safety of a booster dose of the 13-va - lent pneumococcal 10-valent or 13-valent pneumococcal conjugate vaccine DOI: 10.1016/j.vaccine.2017.07.103 116. Centers for Disease Prevention to read - ers: Committee DOI: 10.1016/s1473-3099(16)30120-7 90. Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety of quadrivalent human Guillain-Barre Syndrome following quadrivalent human papillomavirus vaccine in Safety Datalink. Vaccine. 2017;35(43):5756-8. DOI: 10.1016/j. vaccine.2017.09.009 92. Costa APF, Cobucci RNO, da Silva JM, da Costa Lima PH, Giral - do PC, Goncalves AK. Safety 10.1155/2017/3736201 93. Sacks HS. In adults 70 years of age, an adjuvanted herpes zoster subunit vaccine reduced herpes zoster 2017;166(2):Jc5. 10.7326/acpjc-2017-166-2-005 Pagnoni MF, JE, et al. Safety and virus vaccine in adults infection with vari zoster and postherpetic neuralgia al. Efficacy, safety, and tolerability of herpes zoster vaccine in Infect Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine K, Hodge JA, Nduaka CI, et al. The Safety and Immunogenicity of Live Zoster Vaccination in 2017;69(10):1969- 77. 10.1002/art.40187 Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, An - nunziato PW, et al. Herpes zoster vaccine live: A 10year of Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364359lance pertussis data with changing diagnostic and immunization practices: the case of the state of Sao Paulo, Brazil. Gilmour R, Spokes P. Annual vaccine-preventable disease report for New South Wales, Australia, 2014. Western Pac Surveill Response J. 2017;8(2):5-11. DOI: 10.5365/wpsar.2016.7.3.006 C, Hozbor D. Increase in pertus - sis cases along with high prevalence of two emerging genotypes of Bordetella of whooping cough: notes from Dis. 2015;15(12):1480-4. DOI: parapertussis out - break in Bisham, Pakistan in 2009-2010: de Aragon MV. Increase of pertussis incidence in 2010 to 2012 after 12 years of low circulation in Spain. Euro Surveill. 2014;19(32). 138. Fernandez-Cano M. in S, Johansen K, Tsolova S, Brown C. How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal 2014/2015. Vaccine. 10.1016/j.vaccine.2017.12.019 143. Godoy P, Castilla J, Mayoral JM, Martin V, Astray J, Torner N, et al. Influenza vaccination of primary healthcare physicians may be associated with vaccination in their patients: a vaccination cover Fam 119. Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Preven - tion and control of haemophilus P, Davies EG, Avery R, Tomblyn al. 2013 IDSA clinical practice guideline for vaccination of Barenkamp SJ, Powers DC, Kennedy D, Irby-Moore S, et al. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines an Soc. HJ. Epidemiology of a small Pertussis outbreak in Kent county, Michigan. Public Health Rep. 1965;80:365-9. PMC1919641 124. Jenkinson D. Duration of effectiveness of pertussis vaccine: evi - dence from a 10 year community study. Br Med J (Clin Res Ed). Baraff Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vac - cines in the United States: Recommendations of the Advisory Com G, Gupta S, Campbell H. Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. Euro Surveill. an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364360158. Dominguez A, Soldevila N, Toledo D, Torner N, Force L, Perez MJ, Marimon E, Larrosa N, Quesada MD, Fon al. of journal.pone.0175224 160. Pharmaceutical Research and Manufacturers of America. VAC - CINES: HARNESSING SCIENCE TO DRIVE INNOVATION FOR PA - TIENTS. https://wwwphrmaorg/report/2017-state-of-vaccines . 2017;Assessed Infecc Microbiol Y, Takagi T, Kameoka M, Kawashita N. Dengue Vi - rus and Its Inhibitors: A Brief Review. Chem Pharm Bull (Tokyo). 165. K, Sebastian S, Spencer Hill AVS, Lambe T. Chimpanzee adenoviral Immune Re - sponses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development. Int J Environ Res Public Health. 2018;15(2). DOI: 10.3390/ijerph15020385 167. Goldmann O, Medina E. strategies to evade the host acquired im - mune trypanosomiases. Med Moreno-Perez Ortega Garces et al. [Immuni - sation schedule of the Pediatr (Barc). 2018;88(1):53.e1-.e9. DOI: 10.1016/j.anpedi.2017.10.001 Pascual CF, P\u00e9rez Rubio A, Eiros Bouza JM, Cort\u00e9s Lorenzo I. Cien cuestiones b\u00e1sicas de Econom\u00eda de la Salud y Evaluaciones Econ\u00f3micas. In: (ed). EA, editor. I. Valladolid: Iglesias Comunicaci\u00f3n; 2017. 172. Ministerio de Sanidad SSeI. Consejo Interterritorial. Introducci\u00f3n y marco legal. Ley 14/1986, de 25 de abril, General de Sanidad (LGS) y disposiciones de desarrollo. https://wwwmsssigobes/organizacion/ 1986. news/2018/6/is-european-region-ready-to-respond-to-next-in 28 June 2018. 145. Ortiz de Lejarazu R, Tamames S. [Influenza vaccination. Effective - ness of R, Donabedian A, Engelhardt OG, Katz JM, et al. Report on eighth WHO meeting on development of in - protective and AS. Chasing Seasonal In - fluenza - The Need for a Universal Influenza Vaccine. N Engl J Med. 2018;378(1):7-9. DOI: Kyncl J, De Lejarazu RO, et al. Influenza vaccination: key facts for general practitioners in Europe-a synthesis experts based on national guidelines and best practices in the United and DOI: 10.7573/ R, Kyncl J, Nitsch- Osuch A, Kuchar on seasonal influenza coverage Immunother. 2018:1-9. DOI: 10.1080/21645515.2018.1489948 154. Rudolph W, Ben Yedidia T. A universal influenza vaccine: where are we in the pursuit of this \"Holy Grail\"? Hum Vaccin. 2011;7(1):10-1. 155. Gonzalez-Romo F, Picazo JJ, Garcia Rojas A, Labrador Horrillo M, Barrios V, Magro MC, et al. Consenso sobre la vacunaci\u00f3n anti-neu - moc\u00f3cica en el adulto por riesgo de edad y patolog\u00eda de base. Ac - tualizaci\u00f3n 2017. Rev Esp Quimioter. 2017;30(2):142-68. PMID: 28198169 156. Ministerio Sanidad SSeI. Grupo de trabajo vacunaci\u00f3n frente a neumococo en grupos de riesgo 2015 de la Ponencia de Programas y Registro de Vacunaciones. Utilizaci\u00f3n de la vacuna frente a neu - mococo en grupos de riesgo. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. 2015. 157. Ochoa-Gondar O, Hospital I, Vila-Corcoles A, Aragon M, Jariod M, de Diego C, et al. Prevalence of high, medium and low-risk med - in adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 333-3643612014;16(6):871-7. AD, P, et al. decrease of anti-tetanus anatoxin and an - ti-pneumococcal preven - tion in Updated Santoro-Lopes G, Oliveira SS, da Silva EE, do Brasil P. Seroprevalence of antibodies against the three serotypes of po - liovirus and IPV vaccine Chou J, Glenn H, Castro-Malaspina H, Jakubowski AA, Durrbach A, Vallee JC, et al. Low Wagner D, P, Oppelt P, Petzold DR, et al. Long-term outcome of chronic B in heart trans - plant recipients. Transplantation. 1998;66(10):1347-53. 196. Pessoa MG, Terrault NA, Ferrell LD, Detmer J, Kolberg J, Collins ML, et al. Hepatitis after liver transplantation: management of allograft recipients following of hepatitis B prospective organ donor. Am J Transplant. 2001;1(2):185-91. 199. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liv -173. Espa\u00f1a. Gd. Real Decreto 1030/2006, de 15 de septiembre, por el que se establece la cartera de servicios comunes del Sistema Na - cional de Salud y el procedimiento para su actualizaci\u00f3n., 174. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Vacu - nas de uso humano autorizadas en Espa\u00f1a. . https://wwwaemps - gobes/medicamentosUsoHumano/vacunas/autorizadasEspana/ homehtm [consultado el of - E, Silveira F, Cordero E, Perez-Rome - ro et al. Five-year M, Slomovic J, Hoschler K, Ferreira V, Ashton P, et al. A Double-Blind, Randomized Trial of High-Dose vs Stand - ard-Dose Influenza in Adult Slomovic J, Hoschler K, Ferreira V, Ashton P, et al. A Double Blind Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine Bulnes-Ramos A, Aydillo T, Gavalda J, Moreno A, et al. Two Doses of Inactivated Influenza Vaccine Im - prove Immune Response KM, Nielsen AR, Worzella SL, Hayney adults: an opinion paper on the situation in Spain E. Bouza, et al. Rev 216. Formaci\u00f3n en Promoci\u00f3n y Educaci\u00f3n para la Salud. Informe del Grupo de Trabajo de Promoci\u00f3n de la Salud a la Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Octubre 2003. [Internet]. 2003. 217. Glosario de Promoci\u00f3n de la Salud (OMS). 1998. [Internet]. 1998. 218. Marco de competencias del CIE para la enfermera generalista. [In - ternet]. 2003. 219. Carta de Ottawa para el Fomento de la Salud. Primera Conferencia Internacional sobre Fomento de la Salud, Ottawa. [Internet]. 1986. 220. Organizaci\u00f3n Mundial de la Salud. Promoci\u00f3n de la Salud. 9\u00aa Conferen - cia Mundial de Promoci\u00f3n de la Salud, Shanghai (2016). Available at: http://wwwwhoint/healthpromotion/conferences/9gchp/es/ 2016. 221. Nikula A, minders on influenza immunization among seniors. Fam Med. 1989;21(6):433-7. 225. Chan SS, Leung DY, Leung AY, Lam C, Hung I, Chu D, education a ter - tiary H. Engaging parents 10.1016/j.vaccine.2014.06.026 Nyamathi A, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, et al. Effects of a nurse-managed program on hepatitis A and B vac - cine among MP, Tabbarah M, Hart JA, Fox DE, Raymund M, Wilson SA, et al. Office manager and nurse perspectives on facilitators of adult immunization. Am J Manag 230. Nowalk MP, Zimmerman RK, adult in diverse J, Lopez-San Roman A, del Campo S, Moreno N, et al. Response to hepatitis B virus vaccine in de Juanes JR, Gonzalez EM, Lopez A, Lumbreras C, Gomez R, et al. Hepatitis B vaccination results in 140 liver transplant Prevention through active or passive - munization: Recommendations F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl 1998;338(5):286- 90. DOI: 10.1056/nejm199801293380503 206. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized dur - ing an urban epidemic in the United States. Ann Intern Med. 1998;128(2):111-4. 207. Wilson L, Humar A. of quadrivalent human Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine de - an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364363245. Voidazan S, Morariu of Knowledge among Students of the University of Medicine and Pharmacy of Tirgu Mures, Romania. Acta Dermatovenerol flu vaccinations? Population influenza vaccine in a community pharmacy: A experience public Pub - lic 251. Banh HL. Alberta Olier E. Una Espa\u00f1a. Notas estrat\u00e9gicas del Instituto Choiseul ISSN 2444-4006. 2017. 254. Choiseul I. El impacto econ\u00f3mico de las vacunas. Madrid: Instituto Choiseul ISSN 2444-4006; 2017. 255. Stack ML, Ozawa S, Bishai DM, Mirelman A, Tam Y, Niessen L, et press. Bmj. 1993;307(6902):506. PMC1678807 257. Freed GL, Katz SL, Clark SJ. Safety of vaccinations. Miss America, the media, and public health. Jama. 1996;276(23):1869-72. 258. Cohn V. Vaccines and risks. The responsibility of the media, and Jama. 1996;276(23):1917-8. 259. Eavey RD. Vaccine safety, media reporting, and Miss America. Jama. 1997;278(4):290-1. 260. Anderson P. Another media scare about MMR vaccine hits Britain. Bmj. MC, Wood AL, LeBaron vaccine and the news media, 1987-2001. Jama. 2002;287(11):1455-62. 262. Dobson R. Media misled the public over the MMR vaccine, The physician's of - fice: can it influence adult immunization rates? Am J Manag Care. 2004;10(1):13-9. 232. Patel AR, Breck AB, Law MR. The impact of pharmacy-based im - munization services on the likelihood of immunization in the United States. J Am Pharm Assoc (2003). 2018. DOI: 10.1016/j. japh.2018.05.011 Kader MS, S, Buck PO, Rothholz MC. National survey of pharmacy-based immunization services. Vaccine. 2018. DOI: 10.1016/j.vaccine.2018.07.027 234. MW, Church D, Wenger L, Papastergiou J, Raman-Wilms L, Schneider E, et al. Pharmacy patron mul timodal approach to MB, Shah P, Marciniak MW, Brewer NT. Parents' willingness to get human papillomavirus vaccination for their ad children Prev Med. 2017;99:251-6. DOI: EE, Moose JS, Marciniak MW. Im - plementation of a vaccine screening program at an independent community pharmacy. J Am Pharm Influenza Vaccination Over Time in the United States. Am J Public Health. 2016;106(6):1099-100. DOI: 10.2105/ ajph.2016.303142 243. Rawson SJ, Conway JH, Addressing vaccine hesitan - cy an opinion paper on the situation in Spain E. Bouza, et al. Rev Esp Quimioter 2019;32(4): 333-364364Bmj. 2003;326(7399):1107. Howser J, Jones J, Poehling KA. Influenza vaccinations of young children increased Rubin DM. Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR rates CR, Shoup JA, Xu S, et al. Web-based Social Media Intervention to Increase Vaccine by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Comparaci\u00f3n de dos m\u00e9todos que eluden la lisis celular y la extracci\u00f3n de prote\u00ednas para la identificaci\u00f3n de bacterias crecidas en hemocultivos mediante espectrometr\u00eda de masas MALDI-TOF RESUMEN Objetivo. La espectrometr\u00eda de masas MALDI-TOF se utili - za com\u00fanmente para la identificaci\u00f3n r\u00e1pida de bacterias cre - cidas en hemocultivos (HC). Hemos comparado el rendimiento de dos procedimientos, uno que incluye un paso previo del en - riquecimiento en caldo coraz\u00f3n-cerebro y el otro un m\u00e9todo directo que usa tubos vacutainer con gel separador (DI), para la identificaci\u00f3n de bacterias a partir de hemocultivos mediante MALDI-TOF MS. Material y m\u00e9todos. Analizamos prospectivamente un total de 145 HC no consecutivos (68 con crecimiento de bacte - rias gramnegativas y 77 de cocos grampositivos). Resultados. Un total de 82% y 49% de los aislamientos fueron identificados correctamente a nivel de especie por los dos m\u00e9todos, respectivamente. Conclusi\u00f3n. El rendimiento del m\u00e9todo de pre-enriqueci - miento en caldo coraz\u00f3n-cerebro fue mejor que el del m\u00e9todo DI para la identificaci\u00f3n de la pr\u00e1ctica totalidad de las especies bacterianas incluidas en el panel de estudio. Palabras identification of bacteria from blood cultures (BC). We compared the performance of two procedures, one including a pre-enrichment step in brain heart infusion and the other a direct method using vacutainer separator gel tubes (DI), for identification of bacteria from blood cultures by MAL - DI-TOF MS. Material and methods. We first prepared a train - ing set of 20 simulated bacteremia specimens, including 10 Gram-negative and non-consecutive (validation Results. A total of 82% and 49% of isolates were cor - rectly identified to the of virtually all bacterial spe - cies in panels. Key words: INCLIVA, Valencia, Spain. 2Department of Microbiology, School of Medicine, University Valencia, Correspondence: David Navarro, Microbiology Service, Hospital Cl\u00ednico Universitario, and Department of Micro - biology, School of Medicine. Av. Blasco Ib\u00e1\u00f1ez laser desorption/ionization grown overnight on chocolate agar medium (BD) at 36 \u00b0C in air with 5% CO 2 using a Heracell 240i CO 2 incubator, (Thermo Fisher inocula were in sterile saline. The concentration - tive method prior to inoculation into the blood culture bottles. Next, a total of 145 non-consecutive BCs flagged as positive and collected between September patients set). study. All coagulase-negative staph - ylococci (CNS) included in and a DI method. For the former method, a volume of 50 \u00b5l of blood culture was in - oculated into a volume of 500 \u00b5l of BHI (Oxoid Limited, Hamp - shire, United Kingdom) in sterile vials and incubated at 36 \u00b0C in air with 5% CO 2 for 2-4 h. Then the vials were centrifuged at 13,000 rpm for 2 min, the supernatants discarded, and the pel - the latter method, a volume of 8.0 ml of BCs was trans - ferred with a syringe Jersey, USA) and centrifuged at 3,600 rpm for 15 minutes at room temperature. The supernatant was aspirated with caution to avoid disrupt - ing the formed pellet of bacteria present at the surface of the polymeric gel. Positive BCs were subcultured overnight on chocolate agar following our routine diagnostic protocol, the grow - bacteria from blood bacteria harvested following a [7] media. We previously developed a simple method by pos - itive BCs were subjected to short-term enrichment in brain that it outperformed - tion in blood agar in terms of efficiency and speed in identify - ing a wide array of bacterial species, in particular Gram-neg - ative bacteria [7]. Here, we compared the performance of our procedure with a DI method positive BCs MATERIAL AND METHODS first training of 20 simulated bacter - with protocol approved by our institutional review board. Bacterial isolates were spiked medium bottles, Dickinson and Company, New Jersey, USA) at 103 CFU/ml and incubated in automated Isolates in the panel in Brain Heart Infusion brothAccurate by direct processing of blood cultures no. of isolates (%) no. of isolates (%) All (20) 15 (75) 9 (45) Enterobacteriaceae (5) 5 (100) 5 (100) Escherichia coli (2) 2 (100) 2 (100) Klebsiella pneumoniae (2) 2 (100) 2 (100) Enterobacter cloacae (1) 1 (100) 1 (100) Pseudomonas aeruginosa (5) 2 (40) 0 (0) Staphylococcus aureus (5) 3 (60) 1 (20) Streptococcus/Enterococcus spp. (5) 5 (100) 3 (60) Enterococcus faecalis (2) 2 (100) 1 (50) Enterococcus faecium (1) 1 (100) 0 (0) Streptococcus pneumoniae (1) 1 (100) 1 (100) Streptococcus agalactiae (1) 1 (100) 1 (100)Table 1 Performance of two methods for identifying bacteria to the species laser desorption/ionization 2019;32(4): 365-369367from Biomeriuex, L'Etoile, France or BD 16S rRNA gene sequencing. RESULTS As shown in table species in the training set were successfully identified in 75% of cases after pre-cul - tivation in BHI and 45% of cases by direct BC processing. (P=<0.001 by a chi-square test). MS performed same target slide. for successful identification were met when the spectral score of at least one of the three spots was 2.0 (species level) and 1.7 (genus level), as in the panel (n) Time to positive culture after incubation (hours)Accurate in Brain Heart broth (hours)Accurate identification by direct processing of blood cultures no. of isolates (%) All (145) 12.3 119 (82) 2.9 72 (49) Enterobacteriaceae (58) 11.5 55 (94.8) 2.4 44 (75.8) Escherichia coli (31) 11.3 29 25 (7) 11.6 7 (100) 2.8 3 (42.8) Proteus mirabilis (4) 13.9 4 (100) 2.7 1 (25) Citrobacter koseri (1) 6.8 1 (100) 2.5 1 (100) Enterobacter kobei (1) 10.2 1 (100) 2.0 1 (100) Serratia marcescens (1) 6.9 1 (100) 2.5 1 (100) Non-fermenting Gram-negative rods (10) 13.6 7 (70) 3.8 6 (60) (9) 13.9 7 (77.8) 3.9 6 (66.7) Pseudomonas putida (1) 11.2 0 (0) 3.0 0 (0) Staphylococcus spp. (37) 12.8 24 (64.8) 3.4 5 (13.5) 1 13.5 7 (77.7) 3.2 1 (11.1) Staphylococcus (4) 12.0 2 (50) 3.4 0 (0) Staphylococcus capitis (2) 12.7 0 (0) 2.7 1 (50) Streptococcus (38) 33 4 (57.1) (5) 11.3 5 (100) 2.8 3 (69) Streptococcus anginosus (3) 13.3 3 (100) 2.7 0 (0) Streptoptococcus oralis (2) 13.1 2 (100) 2.0 0 (0) Enterococcus hirae (1) 11.0 1 (100) 3.5 1 (100) Streptococcus agalactiae (1) 11.9 1 (100) 3.0 1 (100) Streptococcus parasanguinis (1) 12.8 0 (0) 2.5 0 (0) Gemella morbillorum (2) 13.7 0 (0) 2.0 0 (0)Table 2 Performance of two methods for identification to the species level of bacteria laser desorption/ionization of isolates the species level, whereas only 49% could be identified by the DI method ( P=<0.001 by success - ful with all bacterial species included in the panel, except for Staphylococcus capitis (n=1). The DI method's performance was hampered by its failure to accurately identify large cocci, Staphylococcus were not accurately named to the ge - nus level by the ENR and DI methods, respectively. and used a performance disa - greement among these studies may be attributable to the use of different starting volumes of blood for pelleting bacteria (1 to 6 ml), the speed of the centrifugation steps to remove blood cells, the spectrum of bacteria subjected to analysis, the plat - form used for MALDI-TOF analysis, cell enhance efficiency [8]. This does not appear to be the case for Gram-negative bacteria, in particular for those belonging to Enterobacteriaceae , for which the DI method for identification of virtually all bacterial species included in the panels. The ma - nipulation that is inherent to the pre-enrichment method we propose entails the risk of contamination, although this was negligible in our series, perhaps due to the training of the per - sonnel in charge. In this sense, whether of positive blood a period, this practically minimizing the risk of contami - nations, would have resulted in a bacterial identification include lower risk of contamination by saprophytic bacteria. Whether or not the delay in bacterial identification has a tangible im - pact on patient outcomes remains to be investigated. Given the good performance of the DI method evaluated herein for the identification of pre-enrichment method, a mixed strategy, by which one method would be used the on Gram stain smear preparations may find its place in the work flow for positive blood cultures. ACKNOWLEDGEMENTS Estela Gim\u00e9nez holds a R\u00edo Hortega research contract from the Carlos III Health Institute (ISCIII) (Ref. CM16/00200). We thank BD for the kind donation of vacutainer gel tubes used in this to declare CONFLICT OF INTEREST The authors declare they have Spectrometry Use with C, Campo I, Esteban C, Pitart C, et al. A comparative study of two different methods of sample prepa - ration for positive the 3. La Direct laser desorption/ionization al. Strategy for G, Becker K. Rapid identification of microorganisms from positive blood cul - I, Gimenez E, Pascual T, Bueno F, Huntley D, Mart\u00ednez M, et al. Short-term by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC ac - curate detection of this pathogen is crucial for the use of ap - propriate antimicrobial therapy and the control of nosocomial spread. were compared with the \"gold standard\" test mecA Sensitivity and disk diffusion for respectively, 100 and II un microorganismo que fre - cuentemente coloniza la piel del hombre sano, pero que tam - bi\u00e9n est\u00e1 involucrado en infecciones tanto de origen comu -RESUMEN Introducci\u00f3n. En los \u00faltimos a\u00f1os se ha producido un incremento de las infecciones producidas por Staphylococcus aureus resistente a meticilina (SARM). En comparaci\u00f3n con las producidas por S. aureus sensible a meticilina (SASM), las in - fecciones por SARM requieren estancias hospitalarias m\u00e1s pro - longadas y presentan mayor mortalidad. La detecci\u00f3n r\u00e1pida de la resistencia a la meticilina por la adquisici\u00f3n del gen mecA que codifica la prote\u00edna fijadora de penicilina (PBP2a) es crucial para evitar la diseminaci\u00f3n nosocomial e instaurar una correcta terapia antimicrobiana. Nos proponemos evaluar el test inmu - nocromatogr\u00e1fico r\u00e1pido para la detecci\u00f3n de PBP2a directa - mente de colonias de S. aureus , PBP2a SA Culture Colony Test\u00ae (ICPBP2a). Material y m\u00e9todos. En 107 cepas de S. aureus se estudi\u00f3 la resistencia a meticilina mediante las siguientes pruebas: el sistema MRSA de cefoxitina, la ICPBP2a (AlereTM) y como m\u00e9todo de referencia, la detecci\u00f3n molecular del gen mecA . Resultados. La sensibilidad y especificidad para las prue - bas de detecci\u00f3n fueron para la difusi\u00f3n en agar con disco de cefoxitina 100% y 100% respectivamente, Vitek2\u00ae 100% y 100%, CHROMagarTM MRSA II 100% y 96%, y la ICPBP2a 98,25% y 100%. Conclusi\u00f3n. La inmunocromatograf\u00eda para la detecci\u00f3n de PBP2a es una t\u00e9cnica r\u00e1pida, f\u00e1cil y econ\u00f3mica. Resulta muy \u00fatil para el manejo de brotes hospitalarios. Palabras clave: PBP2a, Staphylococcus aureus resistente a meticilina, in - munocromatograf\u00eda.Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus Servicio de Microbiolog\u00eda. UGC Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva. Hospital Regional Uni - versitario de M\u00e1lagaRoc\u00edo S\u00e1inz-Rodr\u00edguez Inmaculada de Toro- Bego\u00f1a Palop-Borr\u00e1s Correspondencia: Bego\u00f1a Palop-Borr\u00e1s Servicio de Microbiolog\u00eda Hospital Regional Universitario de M\u00e1laga Avda. Carlos Haya, s/n 29010 M\u00e1laga E-mail: April r\u00e1pida la detecci\u00f3n de PBP2a en Staphylococcus aureus R. S\u00e1inz-Rodr\u00edguez, et al. Rev Esp Quimioter 2019;32(4): 370-374371De las 107 cepas de S. aureus se aislaron 93 (86,91%) de muestras cl\u00ednicas: 78 de sangre (83,87%), 4 abscesos 1 biopsia 4 broncoaspirados (4,30%), y 6 exudados de herida (6,45%). Y las 14 restantes de frotis nasales para estudio de portadores (13,08%). Las muestras se trabajaron seg\u00fan los protocolos norma - lizados del laboratorio que incluyen: Cultivo en medios no selectivos y espec\u00edficos y estudios de identificaci\u00f3n utilizando espectrometr\u00eda de masas MALDI TOF (Bruker\u00ae), y la sensibilidad mediante el sistema comercial automatizado Vitek2\u00ae (bioM\u00e9 - rieux). Los resultados de sensibilidad antimicrobiana se inter - pretaron siguiendo los criterios EUCAST 2015-2018. Adem\u00e1s, a todas ellas se les realiz\u00f3 siembra en medio cro - mog\u00e9nico CHROMagar MRSA II (BD Becton Dickinson) con lectura a las 24 y 48 horas, estudio de resistencia fenot\u00edpico utilizando m\u00e9todo de difusi\u00f3n con disco de cefoxitina, inmu - nocromatograf\u00eda para la detecci\u00f3n de PBP2a utilizando el test PBP2a SA Culture Colony y adem\u00e1s estudio molecular de de - tecci\u00f3n de gen mecA , para lo que se utilizaron 2 procedimien - tos: 52 cepas aisladas en muestras de sangre (a\u00f1os 2015-2017) se enviaron al Centro Nacional de Microbiolog\u00eda (CNM) para estudio de tipificaci\u00f3n. Y a las 55 cepas restantes se les realiz\u00f3 en el Laboratorio de Microbiolog\u00eda del HRU de M\u00e1laga el estu - dio molecular para la detecci\u00f3n del gen mecA. Inmunocromatograf\u00eda PBP2a SA. Se trata de un inmu - noensayo cromatogr\u00e1fico cualitativo para la detecci\u00f3n r\u00e1pida de la prote\u00edna de fijaci\u00f3n de la penicilina 2a (PBP2a) en co - lonias previamente identificadas, como ayuda para identifi - car S.aureus resistente a la meticilina (SARM). Se basa en la tecnolog\u00eda de membrana de nitrocelulosa donde se fijan los anticuerpos monoclonales recombinantes (rFabs) altamente sensibles y una prote\u00edna de control. Se realiz\u00f3 siguiendo las in - dicaciones del fabricante. Los resultados se leen visualmente al cabo de 5 minutos. M\u00e9todos moleculares. Del total de 78 cepas recuperadas a partir de hemocultivos, se enviaron 52 al CNM de Majadahonda (Madrid) donde se les realiz\u00f3, entre otras t\u00e9cnicas, una tipifica - ci\u00f3n del casete cromos\u00f3mico estafiloc\u00f3cico mec (SCCmec) me - diante una PCR m\u00faltiple que gener\u00f3 un patr\u00f3n de amplificaci\u00f3n espec\u00edfico para cada tipo estructural de SCCmec [11]. Las 55 cepas restantes se trabajaron en el Laboratorio de Microbiolog\u00eda del HRU de M\u00e1laga donde se les realiz\u00f3 en pri - mer lugar una extracci\u00f3n automatizada de ADN con el sistema Magcore\u00ae y una posterior PCR a tiempo real SmartCycler (Ce - pheid\u00ae) utilizando el kit RealCycler SAMAPV (Progenie Molecu - lar\u00ae) que detecta el gen mecA , la toxina leucocidina de Panton- Valentine (PVL) y el ADN (gen NUC) de S. aureus . RESULTADOS Del total de 107 cepas de S. aureus , se identificaron por m\u00e9todos moleculares 57 (53,27%) SARM y 50 (46,73%) SASM. nitario como hospitalario. Es una de las principales causas de infecciones en la piel, tejidos blandos y huesos, adem\u00e1s de bac - teriemias y sepsis [1]. S. aureus adquiere la resistencia a meticilina y a otros -lact\u00e1micos principalmente por el gen mecA, que codifica la producci\u00f3n de una prote\u00edna de uni\u00f3n a penicilina suplemen - taria, PBP2a o 2', que se expresa de manera homog\u00e9nea o heterog\u00e9nea, y menos frecuentemente por el gen mecC [2]. S. aureus resistente a meticilina (SARM) es un pat\u00f3geno nosoco - mial de gran importancia a nivel mundial y ha incrementado la frecuencia de infecciones adquiridas en la comunidad con una significativa morbi-mortalidad [1,3]. Distintos estudios indican que, seg\u00fan las tasas de morta - lidad, las cepas de SARM son m\u00e1s virulentas que las cepas de S.aureus susceptibles a la meticilina (SASM)[4]. Seg\u00fan los datos proporcionados por el ECDC en 2017, el n\u00famero de aislamientos invasivos de SARM es variable para los distintos pa\u00edses europeos (entre el 1% y el 44,4%), y dentro de estos, Espa\u00f1a se ha mantenido con cifras importantes del 25,3% y que han ido en ligero aumento en estos \u00faltimos a\u00f1os (22,1% en 2014, 25,3 % en 2015, 25,8% en 2016) [5]. En nues - tro medio es por tanto de crucial importancia el conocimiento de la susceptibilidad a meticilina para instaurar el tratamiento emp\u00edrico correcto, teniendo en cuenta que el uso de la vanco - micina, que ser\u00eda la alternativa en caso de SARM[6], se asocia con una tasa de mortalidad m\u00e1s alta que los -lact\u00e1micos en el tratamiento de la bacteriemia por SASM [7]. Adem\u00e1s, permite que los pacientes reciban una terapia antimicrobiana dirigida m\u00e1s r\u00e1pidamente con las implicaciones que conlleva en salud en infecciones graves como las bacteriemias por SARM [8,9]. Todos estos datos demuestran la importancia de la detec - ci\u00f3n temprana de estas cepas de SARM para instaurar un co - rrecto y r\u00e1pido tratamiento. Cl\u00e1sicamente, la sensibilidad a la meticilina se determina por las pruebas de susceptibilidad en disco o con m\u00e9todos automa - tizados, pero todos ellos necesitan al menos 24-48 horas para su realizaci\u00f3n a partir del aislamiento en placa de S.aureus [2]. La incorporaci\u00f3n de m\u00e9todos moleculares ha permitido agilizar es - tos resultados, pero se trata de m\u00e9todos caros y de mayor com - plejidad t\u00e9cnica. Los m\u00e9todos inmunocromatogr\u00e1ficos son una alternativa a los anteriores, ya que se trata de m\u00e9todos r\u00e1pidos y de f\u00e1cil utilizaci\u00f3n en el laboratorio de Microbiolog\u00eda [10]. En el presente trabajo evaluamos la incorporaci\u00f3n de PBP2a SA Culture Colony Test (Alere ahora Abbott) para la de - tecci\u00f3n de la meticilin-resistencia de S.aureus aislados en nues - tro laboratorio. MATERIAL Y M\u00c9TODOS Se han incluido en el estudio 107 cepas de S.aureus aisla - das a partir de muestras cl\u00ednicas y de frotis nasales para estu - dios de vigilancia de pacientes atendidos en el Hospital Regio - nal Universitario (HRU) de M\u00e1laga, en el periodo comprendido entre el 1 de agosto de 2015 al 31 de agosto de 2018. Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus R. S\u00e1inz-Rodr\u00edguez, et al. Rev Esp Quimioter 2019;32(4): 370-374372la excepci\u00f3n de uno de los aislamientos de SARM que resul - t\u00f3 indeterminado. Este hecho podr\u00eda deberse a que seg\u00fan el fabricante (Alere Technical Services), los resultados no v\u00e1lidos generalmente se deben a cantidades excesivas de PBP2a que se unen al conjugado y evitan que aparezca la l\u00ednea de control [12]. Otros autores [13] describen falsos positivos en pruebas realizadas a partir de hemocultivos con part\u00edculas de carb\u00f3n. En situaciones de brotes hospitalarios en los que es nece - saria una respuesta r\u00e1pida para evitar la diseminaci\u00f3n de este pat\u00f3geno, es de gran relevancia poder disponer de una t\u00e9cnica capaz de identificar estas cepas de una forma r\u00e1pida y sencilla, generando un gran beneficio en t\u00e9rminos socio-sanitarios ya que facilita aislamientos precoces y tratamientos eficaces. Las pruebas moleculares son \u00f3ptimas para este fin, pero requieren equipo, instalaciones adecuadas, personal capacitado para su realizaci\u00f3n y recursos econ\u00f3micos que no est\u00e1n disponibles en todos los hospitales. La utilizaci\u00f3n de cefoxitina en lugar de oxacilina como an - tibi\u00f3tico de elecci\u00f3n tiene la ventaja de ser mejor inductor de la expresi\u00f3n del gen mecA , y detecta mejor las poblaciones SARM de bajo nivel de resistencia, clasificadas err\u00f3neamente como SASM [2]. El sistema autom\u00e1tico Vitek2\u00ae presenta excelentes resul - tados y la ventaja de mayor rapidez frente al medio cromog\u00e9 - nico CHROMagar MRSA II y la difusi\u00f3n en disco de cefoxitina, ya que se obtienen los resultados a partir de las 7 horas [14]. CHROMagar MRSA II demuestra ser \u00fatil como t\u00e9cnica de screening en la b\u00fasqueda de portadores nasales de SARM, con lectura de las placas a las 24 y 48 horas, aunque la sensibilidad aumenta poco tras la reincubaci\u00f3n [15] pero a costa de la p\u00e9r - dida de eficacia. Algunos autores y con muestras de hemocul - tivos acortan este tiempo y obtienen id\u00e9nticos resultados a las 12 y a las 24 horas, 96 % de sensibilidad y 100% especificidad [16]. Las 2 muestras discordantes crec\u00edan en el medio cromo - g\u00e9nico pero, sin embargo el resto de pruebas eran negativas. Algunos autores [17] describen que la sensibilidad de estos me - dios disminuye cuando se trata de cepas heterorresistentes y la especificidad en cepas con CMI borderline. La principal debilidad que presenta esta prueba inmuno - cromatogr\u00e1fica es que s\u00f3lo est\u00e1 validada para su realizaci\u00f3n sobre colonias aisladas de S.aureus a partir de medios s\u00f3lidos, lo que retrasa la informaci\u00f3n 24 horas. Dupieux et al [9] la uti - lizaron con estafilococos coagulasa negativos demostrando la necesidad de inducci\u00f3n con cefoxitina para obtener buenos Entre los 57 aislamientos de SARM, se detect\u00f3 el gen codifican - te de la PVL en el 5,26% (2 abscesos, 1 biopsia). Los resultados obtenidos en el sistema Vitek2\u00ae tuvieron una concordancia del 100% con el m\u00e9todo de referencia. Las 57 cepas de SARM mostraban concentraciones de oxacilina 4 \u00b5g/ml y el test de cefoxitina positivo. La prueba de difusi\u00f3n con disco de cefoxitina present\u00f3 un halo de inhibici\u00f3n 21 mm en las 57 cepas de SARM. En el medio cromog\u00e9nico CHROMagar MRSA II crecieron 59 cepas (2 de ellas SASM) y no crecieron 48/50 SASM. 2 cepas identificadas como SASM crecieron en el medio cromog\u00e9nico (tabla 1). ICPBP2a fue positiva en 56/57 SARM y negativa en 50/50 SASM. Una de las pruebas realizadas result\u00f3 indeterminada. Del total de 106 pruebas consideradas como v\u00e1lidas coincidieron con los resultados obtenidos en el sistema Vitek2\u00ae y la prueba de difusi\u00f3n con disco de cefoxitina en el 100% de los casos (tabla 2). DISCUSI\u00d3N En los \u00faltimos a\u00f1os y con el fin de controlar la disemi - naci\u00f3n de SAMR en los hospitales fundamentalmente, se han implantado distintas t\u00e9cnicas r\u00e1pidas, como la ICPBP2a. El test inmunocromatogr\u00e1fico es de f\u00e1cil realizaci\u00f3n y al no necesitar ning\u00fan equipamiento espec\u00edfico es accesible a todos los tipos de laboratorios. Adem\u00e1s, los resultados son f\u00e1cilmente evi - denciables, de hecho, todos los resultados fueron v\u00e1lidos con n\u00ba de aislado Tipo de muestra Vitek2 OXA Disco Cefoxitina CHROMagar MRSA II IC PBP2a mecA PLV 31 Absceso S 0,25 S + - - - 34 Absceso S 0,25 S + - - -Tabla 1 Aislados discordantes S = sensible Prueba Sensibilidad Especificidad Disco Cefoxitina57/57 especificidad de las pruebas.Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus R. S\u00e1inz-Rodr\u00edguez, Disponible en: https://ecdc.europa.eu/en/publi - cations-data/surveillance-antimicrobial-resistance-europe-2017 6. Rao S N, Wang S K, Gonzalez-Zamora J, Hanson A P, Polisetty R S, and Singhm K. Improving 7. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD et al. Outcome of N, Alby K, Martin K E, Laux J, et al. Clinical Raulin O, Roure-Sobas Ch, Salord H, et al. Evaluation of a commercial im - assay R, Burnham C A D, Ford B A, Lawhon S D, McAllister S K, Lonsway D, et al. Evaluation of assay for rapid detection H. Lencastre. Multiplex PCR strategy for rapid identification of structural Barrett H L, Pasquale T R, DiPersio J R and File T M. Evaluation and use of a rapid Staphylococcus aureus assay by antimicrobial 10.2146/ajhp130118. 13. Heraud S, A M, Doleans-Jordheim A, Bes M, Tristan A, Vandenesch F, et al. Direct Identification of Staphylococcus au Castro- Mussot M E. Evaluaci\u00f3n de cuatro m\u00e9todos para la detecci\u00f3n de Staphylococcus aureus meticilino-resistente de muestras cl\u00ednicas en un hospital Mex 2012; 54:1-6. PMID: 22286822. 15. Wendt C, Boyce J M, Dickenson R, Eigner U, Schutt S and Fahr A E, and Singh K . Shorte - ned Time to Identify Staphylococcus Species from Blood Cultures resultados. Existen estudios que realizan la prueba a partir de muestra directa de hemocultivos positivos obteniendo buenos resultados [18]. Otros tambi\u00e9n los obtienen realizando la iden - tificaci\u00f3n por espectrometr\u00eda de masas (MALDI TOF, Bruker) a partir de microcolonias a las pocas horas del subcultivo de los hemocultivos positivos y la detecci\u00f3n de PBP 2a cuando se trata de S.aureus [19] produciendo resultados en unas cuantas horas de gran repercusi\u00f3n en el manejo del paciente. La inmunocromatograf\u00eda Alere\u00ae para detecci\u00f3n r\u00e1pida de PBP2a resulta ser por tanto una prueba de f\u00e1cil implementa - ci\u00f3n a nivel t\u00e9cnico [20], r\u00e1pida, segura y econ\u00f3mica que puede utilizarse en los laboratorios de Microbiolog\u00eda para confirmar la resistencia a meticilina mediada por el gen mecA . AGRADECIMIENTOS Los autores agradecen al Laboratorio de Infecciones intra - hospitalarias del Centro Nacional de Microbiolog\u00eda (Instituto de Salud Carlos III) por la tipificaci\u00f3n de las cepas enviadas y al Dr. Federico Rom\u00e1n Alonso, responsable del mismo por la revisi\u00f3n de las mismas. FINANCIACI\u00d3N Los autores declaran no haber recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener ning\u00fan conflicto de inte - reses. BIBLIOGRAF\u00cdA 1. Tong S Y C, Davis J S, Eichenberger E, Holland T L, Vance G. E, Ardanuy C, Torres C. Detecci\u00f3n fenot\u00edpi - ca de mecanismos de resistencia en microorganismos N, Nachamkin I. Evaluation of man of the European Antimicrobial Resistance Surveillance Network Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus R. Chander et Evaluation 10.1099/jmm.0.032219- 0. 18. Kong H, Tong L, Zhang W, Fu Y, Li X. Combined use of the Binax - NOW Staphylococcus aureus test with the Clearview for the detection of I, Burn S, McCormick J K, Schaus D, Lanni - gan R and Michael John Lamy B, Aissa N et al. of by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).susceptibility data of strains isolated from pregnant women as representation posible tasas de resistencia de Escherichia coli de bacteriurias asintom\u00e1ticas en gestantes a las de E. coli en ITU no complicada adquirida en la comunidad? RESUMEN Objetivos. El tratamiento en atenci\u00f3n primaria de las in - fecciones del tracto urinario no complicadas es generalmente emp\u00edrico sin solicitar urocultivo y basado en datos de resisten - cia sesgados procedentes de pacientes seleccionados, muchos de ellos con factores de riesgo de aislamiento de microorganis - mos resistentes. Con el fin de solventar el d\u00e9ficit de informaci\u00f3n sobre las tasas de resistencia reales en ITU no complicada, com - paramos el fenotipo antimicrobiano y genotipo de aislados de Escherichia coli procedentes de mujeres embarazadas con bac - teriuria asintom\u00e1tica (cultivo siempre realizado) con aquellos procedentes de mujeres con cistitis aguda no complicada (cul - tivo raramente realizado) de diferentes grupos de edad. Material y m\u00e9todos . Entre septiembre de 2017 y marzo de 2018 se recogieron aleatoriamente 103 orinas de mujeres embarazadas con edades entre 16 y 47 a\u00f1os con bacteriuria asintom\u00e1tica (BA) (n=42), mujeres no hospitalizadas en el mis - mo rango de edad con cistitis aguda no complicada (CANC) (n=31) y mujeres mayores de 47 a\u00f1os no hospitalizadas con CANC (n=30). La identificaci\u00f3n bacteriana se realiz\u00f3 por es - pectrometr\u00eda de masas y el antibiograma por microdiluci\u00f3n en caldo. La tipificaci\u00f3n gen\u00e9tica se llevo a cabo por electroforesis en gel por campo pulsado. ABSTRACT Objective. Treatment of uncomplicated urinary tract in - fections in primary care is generally empirical without request - urine factors the isolation of resistant microorganisms. In order to overcome the lack of information on the real resistance rates in uncomplicat - ed UTI, matic cystitis (culture rarely per - formed) groups. Material and methods. Between September 2017 and March 2018, 103 collected from preg - nant women 47 with asymptomatic bacteriuria (AB) (n=42), not hospitalized women in acute (UAC) (n=31) are no significant patients in - tween the three groups. Conclusions . We propose a simple model that could pro - vide better guidance for selection of empirical antimicrobial therapy for non-pregnant data on of Escherichia coli from asymptomatic bacteriuria in pregnant women E. coli in uncomplicated community-acquired UTI? 1Servicio Microbiolog\u00eda, Hospital Universitario de Getafe, Madrid, Spain. 2Laboratorio de Referencia e Investigaci\u00f3n en Resistencia a Antibi\u00f3ticos e Infecciones Relacionadas con la Asistencia Sa - nitaria, Centro Nacional de Microbiolog\u00eda, Majadahonda, Madrid, Spain. 3Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Phone: +34 916833541 report coli from asymptomatic bacteriuria in pregnant women to those of E. coli in uncomplicated community-acquired UTI?A. Asenjo, et al. Rev Esp Quimioter 2019;32(4): 375-378376lected. The samples were from women which, after their clinical history, met the inclusion criteria: - Pregnant women aged between 16 and 47 at the end of the first trimester or beginning of the second trimester with asymptomatic bacteriuria (AB), considering this term when of E. coli were isolated. - Not hospitalized in the same age range with uncompli - cystitis (UAC) coli . - Older than 47 hospitalized with UAC and the isolation of >103 UFC/ml of E. coli . From the first group, 42 strains of E. coli were collected, from the second, 31 and from the third, 30. Bacteria identification was performed using mass - ing genetic variation between the of the different patient addition, cumulative of adults from care with E. urine cul - tures during 2017 were obtained from our laboratory computer system. Data were introduced in a database created for the study. The PFGE were with InfoQuestFP, using a cut-off similarity, and the was calculated [8]. To test the statistically in ceptibility and genetic of the strains among the groups, the chi-square test or Fisher's exact test was performed. When the p-value was inferior to the alpha error (5%), a statistical significance was considered. The project was ampicillin with no signifi - cant differences between the different groups (table 1). Interestingly, when the susceptibility data of the total UAC strains of the study (n=103) are compared with differences observed in 0.008), cefotaxime (p=0.03), cotrimoxazole (p = 0.002), nalidix - ic acid (p = 0.01), ciprofloxacin (p = 0.001) and to gentamicin (p = 0.008) (table 2). We observed 90 unique PFGE-profiles (34 from E. coli isolates of the AB group, 29 from the strains of patients with UAC aged between 16 and 47, and 27 from strains of the group older than 47 with UAC). The diversity index of the set of E coli isolates was 87.38%. In table 3 the unique PFGE-pro -Resultados. hay diferencias significativas en la sensib - ilidad antibi\u00f3tica entre los grupos de pacientes. De igual forma, y seg\u00fan lo esperado, se observ\u00f3 una amplia diversidad gen\u00e9tica entre las cepas de E. coli estudiadas sin diferencias significati - vas entre los diferentes grupos. Conclusiones. Proponemos un modelo sencillo que po - dr\u00eda orientar mejor que los datos generales del hospital en la selecci\u00f3n del tratamiento antimicrobiano emp\u00edrico de mujeres no embarazadas con CANC, basado en extrapolar los datos de sensibilidad de cepas aisladas de mujeres embarazadas con BA como representaci\u00f3n de mujeres con CANC adquirida en la co - munidad. Palabras clave: ITU no complicada, Resistencia antimicrobiana, Treatment is generally empirical and ity data urine submitted to but selected patients complicated UTI or previ - ous failed treatments), most of them on biased resistance data, which are in most cases from strains that cause complicated or recurrent UTIs that have been shown to be more resistant [6]. Real and representative data are required. The guidelines for the management of pregnant women recommend to screen with urine culture for asymptomatic bacteriuria at the end of the first trimester or beginning of the second trimester [7]. This enables us to have reliable suscepti results of E. coli isolated in this population, which could be representative of the population with uncomplicated UTI of similar or higher age. The objective of the study, in order to overcome the lack of information on the real resistance rates in uncomplicated UTI, was to validate the hypothesis that there is no difference in population or susceptibility between E. coli pregnant women with from women with uncomplicated acute cystitis of different age groups. If so, a susceptibility pattern of E. coli causing uncomplicated September March 2018, 103 urines submitted the laboratory were randomly to coli from asymptomatic bacteriuria in pregnant women to those of E. coli in uncomplicated community-acquired UTI?A. Asenjo, et al. Rev Esp Quimioter 2019;32(4): 375-378377files found are reported separately by the of patients studied. There no significant differences in profiles. DISCUSSION provide data of uropathogens provided by laboratories are not representative of those of uncomplicated UTI, leading to an overestimation of local resistance rates and the consequent inappropriate use of antibiotics after the the cu - mulative laboratory UTI susceptibility data. Following our local patterns and according to the guide - lines recommendation not to use an antibiotic as empirical treatment in uncomplicated cystitis when of UAC. However, taking into account the results of this research, the options for empirical treatment in women with uncompli - cated UTI would be extended since all antibiotics could be used with the exception of ampicillin. There are no significant differences between the groups of without significant differences between isolates from women with AB and those from women with UAC acquired in the community regardless of patient's age. The genetic - most of the strains studied after performing the pulsed field in cystitis A limitation of the study is the small sample size, but it takes long time to recover strains of E. coli from pregnant women with ABU. We conclude that strains of E. coli from pregnant women with AB are similar in both genetic diversity and antimicrobi - al phenotype to those of women with UAC regardless of age. Given that E. coli urine isolates from all pregnant women AB we propose a reasonable, econom - ical and simple model that provide guidance for selection of empirical antimicrobial therapy women with UAC than do antibiogram data. This model is the susceptibility data of strains isolated from pregnant women with AB as rep - resentation of women with community-acquired UAC.Is it possible to coli from asymptomatic bacteriuria in pregnant women to those of E. coli in uncomplicated community-acquired UTI?A. Asenjo, et al. Rev Esp Quimioter Diseases Society of America guidelines genetic of pathogens Chemother. 2003;51:379-84. PMID:12562706 10. McNulty CA, Terry al. Department Urinary Antimicrobial resistance surveillance field electro - phoresis to molecular epidemiology. J Infect Dis. 1990;161:230-5. PMID:1967621FUNDING This study was supported in part by Fundaci\u00f3n Soria Mel - guizo. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. CONFLICTS OF INTEREST The authors declare that there are no conflicts of interest REFERENCES 1. de Cueto M, Aliaga L, Al\u00f3s JI, Canut A, Los-Arcos I, Mart\u00ednez JA, et al. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of Heginbothom M, Roberts Z, Dunstan F, Howard A, et al. When do general practitioners request urine R, et al. Interna - tional clinical practice guidelines for the treatment of acute un - complicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Taylor MB, Tan SL, Ee A, Chua C, Low A. What is true community-acquired urinary Infect Dis. DOI: 10.1007/s10096-003-0893- AB vs UAC (>47 Unique by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).mera vez a los 8 meses de edad con episodios de lesiones cut\u00e1 - neas urticariformes recurrentes, asociando, a la edad de 4 a\u00f1os, edema facial e infecciones conjuntivales y \u00f3ticas de repetici\u00f3n. Desde los 18 a\u00f1os experimentaba adem\u00e1s brotes autolimitados de artritis de grandes articulaciones, requiriendo a lo largo de su vida m\u00faltiples ciclos de tratamiento con esteroides. Tras la confirmaci\u00f3n gen\u00e9tica del diagn\u00f3stico de CAPS y con el objetivo de iniciar tratamiento inmunosupresor con anti-interleukina 1 (anakinra) se deriv\u00f3 desde la Unidad de En - fermedades Autoinmunes Sist\u00e9micas de la Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna a la Unidad de Vacunas del Servi - cio de Medicina Preventiva y Salud P\u00fablica del propio centro. Una vez all\u00ed, se revis\u00f3 la historia vacunal y se realiz\u00f3 una sero - log\u00eda basal. La paciente hab\u00eda recibido la vacunaci\u00f3n sistem\u00e1ti - ca infantil correcta para su edad. En la tabla 1 se presentan los resultados serol\u00f3gicos. Teniendo en cuenta lo anterior, y dado que la paciente no estaba recibiendo tratamiento inmunosupresor, se program\u00f3 la vacunaci\u00f3n inicial con vacuna triple v\u00edrica y hepatitis B. La vacuna frente al virus de la hepatitis A no fue administrada en Sr. Editor: Los pacientes con enfermedades autoinflamatorias sist\u00e9 - micas pueden estar en situaci\u00f3n de inmunosupresi\u00f3n, sobre todo como consecuencia de los tratamientos que precisan. Esto condiciona un mayor riesgo de padecer enfermedades in - fecciosas, habiendo sido ampliamente demostrado en la litera - tura cient\u00edfica el beneficio de la vacunaci\u00f3n en este grupo [1]. La seguridad de las vacunas es un hecho contrastado con una s\u00f3lida base de evidencia cient\u00edfica [2]. Los ensayos cl\u00ednicos, as\u00ed como los controles de calidad durante su fabricaci\u00f3n, hacen que se hayan convertido en f\u00e1rmacos seguros [3]. A pesar de lo anterior, el manejo de las vacunas en los pacientes inmunode - primidos debe llevarse a cabo en Unidades de Vacunas especia - lizadas. La monitorizaci\u00f3n de las reacciones adversas asociadas a la vacunaci\u00f3n es de especial inter\u00e9s para la Farmacovigilancia. En ocasiones, se han descrito reacciones adversas postvacunales en los pacientes inmunodeprimidos, por lo que la valoraci\u00f3n del beneficio-riesgo debe estar siempre presente [4]. Se plantea el caso de la reactivaci\u00f3n de la patolog\u00eda de base de una paciente tras la vacunaci\u00f3n con triple v\u00edrica (sa - rampi\u00f3n, rubeola y parotiditis) y vacuna frente al virus de la hepatitis B. La paciente deb\u00eda actualizar su calendario vacunal por ser candidata a tratamiento inmunosupresor: Se trata de una mujer de 22 a\u00f1os con diagn\u00f3stico cl\u00ednico de s\u00edndrome peri\u00f3dico asociado a criopirinas (CAPS), clasifica - do como fenotipo Muckle-Wells. Esta patolog\u00eda se caracteriza por una mutaci\u00f3n en el gen NLRP3 que se traduce en una ac - tivaci\u00f3n del inflamosoma con aumento en la s\u00edntesis de inter - leukina 1 beta (IL-1B), actual diana terap\u00e9utica de anticuerpos monoclonales como el anakinra, canakinumab y rilonacept [5]. En el caso de la paciente, la enfermedad se manifest\u00f3 por pri -Reactivaci\u00f3n del s\u00edndrome peri\u00f3dico asociado a criopirinas tras la vacunaci\u00f3n en una paciente candidata a inmunosupresi\u00f3n 1Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Vital \u00c1lvarez Buylla. Asturias. 2Unidad de Enfermedades Autoinmunes Sist\u00e9micas. Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna. Hospital Universitario Central de Asturias. 3Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Universitario de La Princesa. Madrid. 4Servicio de Alergolog\u00eda. Hospital Universitario Central de Asturias. 5Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Valle del Nal\u00f3n. Asturias. 6Servicio de Vigilancia Epidemiol\u00f3gica. Direcci\u00f3n General de Salud P\u00fablica. Consejer\u00eda de Sanidad del Principado de As - turias.Mar\u00eda Fern\u00e1ndez-Prada1 Jessica Rugeles-Ni\u00f1o2 Luc\u00eda Su\u00e1rez-P\u00e9rez2 Ismael Huerta-Gonz\u00e1lez6 Correspondencia: Mar\u00eda Fern\u00e1ndez-Prada. Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Vital \u00c1lvarez Buylla. Mieres, November 2018 Ant\u00edgeno Determinaci\u00f3n Varicela IgG Positivo Sarampi\u00f3n IgG Negativo Hepatitis B antiHBs Negativo (2,0 UI/ml) antiHBc total Negativo HBsAg Negativo Hepatitis A IgG 1 Serolog\u00eda basal (prevacunal). IgG: de superficie.Reactivaci\u00f3n del s\u00edndrome peri\u00f3dico asociado a criopirinas tras la vacunaci\u00f3n en una paciente candidata a inmunosupresi\u00f3nM. Fern\u00e1ndez-Prada, et al. Rev Esp Quimioter 2019;32(4): 379-380380CONFLICTO DE INTERESES Los autores declaran no tener ning\u00fan conflicto de inter\u00e9s. BIBLIOGRAF\u00cdA 1. Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla recommendations for the adult immunosuppressed patient: A of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed., Supplement. Washington D.C. Public Health Foundation, 2017. 3. Cunningham AL, Gar\u00e7on N, Leo O, Friedland LR, Strugnell R, Lau - p\u00e8ze B et al. Vaccine development: from concept to early testing. Vaccine 2016;34:6655-64. S. Varicela por virus vacunal en un paciente en tratamiento con metotrexato. Rev Esp Quimio - ter.2017;5:1-3. PMID: doi:10.1016/j.reu 6. Walker UA, Hoffman HM, Williams R, Kuemmerle-Deschner J, - momento por desabastecimiento y las antineumoc\u00f3cicas fueron descartadas al estar descrita la reactivaci\u00f3n del CAPS tras la administraci\u00f3n de la conjugada de 13 serotipos y polisa - c\u00e1rida de 23 serotipos [6]. A las 24 horas de la administraci\u00f3n de estas vacunas la pa - ciente experiment\u00f3 un cuadro cl\u00ednico caracterizado por fiebre de hasta 38\u00baC, artralgias y rash urticariforme generalizado, compa - tible con un brote de la patolog\u00eda de base. Se prescribi\u00f3 un ciclo corto de corticoides (deflazacort 30mg/d\u00eda en pauta descenden - te), persistiendo los s\u00edntomas hasta 6 d\u00edas. El cuadro se resolvi\u00f3 por completo a los 20 d\u00edas, aproximadamente, sin complicacio - nes ni secuelas. La figura 1 muestra el rash urticariforme inicial y la evoluci\u00f3n en d\u00edas sucesivos. De acuerdo con la paciente y el Servicio de Medicina Interna desde la Unidad de Vacunas, se decidi\u00f3 interrumpir el calendario de vacunaci\u00f3n programado A pesar de que existen publicaciones relacionadas con el empeoramiento del CAPS y la vacunaci\u00f3n antineumoc\u00f3cica y an - timeningoc\u00f3cica [6, 7], hasta el momento no se hab\u00edan descrito casos relacionados con las vacunas triple v\u00edrica y hepatitis B. Cabe la posibilidad de que la estimulaci\u00f3n del sistema inmune con la vacunaci\u00f3n en general, y no con ciertas vacunas espec\u00edficamente, provoque alteraciones en las personas con dicha patolog\u00eda. Inclu - so, en base a esta experiencia, los autores plantean que, dado que la paciente inici\u00f3 los s\u00edntomas a los 8 meses de edad, pero no fue diagnosticada hasta los 18 a\u00f1os, algunos de los brotes peri\u00f3dicos de la infancia y la adolescencia quiz\u00e1 hayan podido desencadenar - se en el contexto de la vacunaci\u00f3n sistem\u00e1tica infantil. Sin embar - go, esta hip\u00f3tesis resulta dif\u00edcil de confirmar. El caso fue notificado al Sistema de Farmacovigilancia (n\u00famero 03-600302). FINANCIACI\u00d3N Los autores declaran no haber recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. Figura 1 Secuencia cl\u00ednica postvacunal Rev Esp Quimioter 2019;32(3): 381-383381 \u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC brain was not any of occupying or increased intracerebral pressure. mild elevated level of 75 mg/dl, red blood cells of 17/mm3, white blood cells of 170/mm3, of which 65% were neutorophils, glucose level of 89 mg/dl with simultaneous blood sugar of 117 mg/dl and lactate dehydrogenase level of 64 U/L. The initial nocardiosis.Sir, Nocardia is the cause of various diseases such as cutaneous, ocular and central nervous system in both immunocompetent and im - mune-compromised patients [1]. The range of these diseases can be sub-clinical infection On the other hand over the several years the number of immunocom - promised patients are increased [1]. Nocardial meningitis is very rare and may be associated with or without a brain ab - scess. In this paper, we describe a man with Beh\u00e7et disease who was on corticosteroid, and experienced meningitis caused by Nocardia farcinica . A 38 years old fever, nausea, vomiting, frontal headache On admission the patient has 4oC, oxygen saturation de - gree was 92%. The forces of lower limbs had been decreased to 3/5. In eyes there was horizontal nystagmus and in left eye the movement of the globe to medial and lateral sides was dis - turbed; but no papilledema was seen in examination of both sides. The patient was a known case of Beh\u00e7et disease since 4 years ago, and was on 20 mg prednisolone daily since that time. At first, with this primary information; vancomycin, mer - ward, Department of Infectious Diseases, Infectious Diseases and Tropical Medicine Re - search Tropical Medicine Research Cen - ter, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: fatemeh.mohajeri183@gmail.comLetter to Editor Diffuse signal change as high in T2W at limited view of brain stem is seen involving pons and medulla without obvious mass effect meningitis in a case report and literature review Esp Quimioter 2019;32(3): 381-383382gle-organ infection is manifested as in hospitalized patients), followed high mortality rate [8]. In our cases we did not find any other site of infection in the body and therefore we concluded that \"isolated men - ingitis\" is the most probable diagnosis in this patient; which is really a rare incident. Although, isolated CNS infections, as abscesses involve - ment are reported [9]; but there any report of Isolated and /or pure nocardial meningitis similar to the bet - ter prognosis will be achieved in these patients. In declare CONFLICT INTERESTS The authors declare they have no of interest REFERENCES Conville PS, Byrer DE, Anderson VL, et al. Nocardia veterana as a pathogen in North J DOI: 10.3748/wjg.v21.i21.6491 3. Duque \u00c1IA, Salas PAO, Oviedo A, Ruales F. Meningo - encefalitis por Nocardia spp.: Reporte de un caso y revisi\u00f3n de la literatura. Infectio. 2014;18(3):109-15. AM, Righi E, Harris P, Paterson DL. Central nervous system nocardiosis in Queensland: a report of 20 cases and review of the literature. Medicine (Baltimore). 2016;95(46):e5255. 7. venography result was in nor - mal limit and magnetic resonance imaging high be suggestive for demyelinating or vasculitis disorders . after 10 days; the general condition of patient became better and improvement of headache achieved. Intravenous antibiotics were continued for 6 weeks in hospital and after that the pa - tient was discharged with oral antibiotics (cotrimoxazol, cefix - ime and amoxicillin-clavulanic acid) for up to 9 months. After that cotrimoxazol was continued for 3 months later. Now after one year the patient is on cotrimoxazol yet, and he has not any and dangerous and serious complications of the Beh\u00e7et's disease which is described in some papers [4]. One of the crite - ria for \"no our patient CSF culture and PCR were positive for infections, CNS fection is in to 44% [6]. Beaman et al. reported sin -Figure 2 Branched in a patient disease: case report and literature review Kiana Shirani, et Rev Esp Quimioter 2019;32(3): Extramedullary Spinal B, Arslanta A, Ay - A, et al. Multiple nocardial abscesses of by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).completed 12 weeks without remarkable side effects. There is no general agreement based on solid evidence regarding for how long should treatment after debridement and implant of PJI caused by rare microorganisms lacking months recurrence, and CRP values remain normal. Pasteurella is a genera of small gram-negative nonflagellated coccobacilli often found as part as the normal microbiota of oral and upper respiratory tracts of animals and humans. It is isolated from human infections associated to dog bites and 75% percent of cat bites. Humans acquire P. multocida not only through bites, but through scratches, even without skin or mucosal breakdown. Phenotypic are became infected by P. no adhesion/Flp pilus assembly cluster (tadZABCDEFG) are present in P. multocida . Homologs of the tad gene locus are also in many Pasteurellaceae, playing key biofilm formation, colonization, multocida vitro biofilm, case of PJI due to strain of P. multocida has been described [6]. In to try to evaluate phylogenetic the patient\u00b4s P. multocida and the cat\u00b4s sample Sir, A 92-year-old woman with a total knee arthroplasty performed 10 years ago was admitted with a story of 3 days of fever, pain and joint effusion in the left of that the patient which scratch and lick patients\u00b4 legs. An oral swab the CRP levels fell from 238 mg/L (normal range, 0-5 mg/L) in the day of surgery to 18 after twelve days, when she was discharged on oral levofloxacin. At the sixth week after surgery, CRP values had normalized, and the patient Burgos, Spain. 2Infectious Diseases Unit, Internal Medicine. Hospital Universitario de Burgos, Spain. 3Traumatology and Orthopedic Surgery. Hospital Universitario de Burgos, Spain.Maria Pilar Ortega Lafont1 Luis Buz\u00f3n Mart\u00edn2 Ledicia \u00c1lvarez Paredes1 Mar\u00eda Mora Fern\u00e1ndez3 Antonio Rodr\u00edguez P\u00e9rez3 \u00c1ngel Mor\u00e1n Rodr\u00edguez2 Correspondence: Maria Pilar Ortega Lafont Spain. Fax: 0034 947282722 Quimioter 384-386385easy recovery from joint effusion samples and a relationship with close contact with dogs The case presented represents, therefore, an archetypal example [8]. half were prosthesis removal. impression supported by the case presented. All of that samples from another cat not related to the index case and samples from another patient with P. multocida infection were collected, her the unrelated and her cat\u00b4s oral flora. Nevertheless, the distance between all of them, related and unrelated samples, was close (figure 1). Since 1975, only 32 cases of PJI due to P. multocida have been reported. Almost onset infections median time of 7.6 years after implantation, absence of documented in (cat 1) and another unrelated (patient 2 and cat 2) by None to declare CONFLICTS OF INTEREST there are REFERENCES Osmon and management Clinical Practice al. of Pasteurella isolates by species E, Vassena C, Manzi G, Drago L. A case of a late and atypical A. Prosthetic joint infection caused by Pasteurella multocida : a case by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).En este contexto se decide 50 mg/d\u00eda junto a tenofovir/emtricitabina 300/200 mg/d\u00eda. La paciente evoluciona favorablemente, con mejor\u00eda del labora - torio y siete semanas despu\u00e9s se documenta del Western blot reactivo. Se observ\u00f3 una excelente respuesta virol\u00f3gica con un descenso de la CV a 151 copias/ml (2.18 log10) y ascenso del recuento de linfocitos T-CD4 (tabla 1). Dos meses posteriores al inicio del TARGA present\u00f3 ame - norrea con test de embarazo positivo y ecograf\u00eda obst\u00e9trica que informaba gesta de 8 semanas. Se decidi\u00f3 continuar mis - mo esquema de tratamiento seg\u00fan las recomendaciones del momento, presentando CV indetectable durante todo el em - barazo, el cual curs\u00f3 sin intercurrencias cl\u00ednicas u obst\u00e9tricas, presentando parto vaginal a las 40 semanas de gestaci\u00f3n. Pa - ri\u00f3 un reci\u00e9n nacido masculino sano con estudios virol\u00f3gicos (PCR en ADN proviral) negativos al momento del nacimiento, a los 2 y 6 meses de vida. En virtud del beneficio cl\u00ednico sobre el paciente, la posibili - dad de disminuir el desarrollo de reservorios y el riesgo de tras - misi\u00f3n a terceros, las recomendaciones internacionales reco - miendan el tratamiento precoz de la infecci\u00f3n aguda por VIH, con un f\u00e1rmaco de alta barrera gen\u00e9tica y con eficacia frente a viremias elevadas como es el caso de nuestra paciente [3, 5]. Por la eficacia y perfil de seguridad que muestra dolutegravir frente a otros TARGA [6, 7], se decidi\u00f3 iniciar tratamiento con este f\u00e1rmaco con muy buena respuesta virol\u00f3gica (descenso de 4.9 log10 en 4 semanas) y cl\u00ednica (desaparici\u00f3n de los s\u00ednto - mas). Esto fue de suma importancia teniendo en cuenta que la paciente qued\u00f3 embarazada al poco tiempo del diagn\u00f3sti - co y comenzar la gestaci\u00f3n con supresi\u00f3n virol\u00f3gica reduce a <1% el riesgo de trasmisi\u00f3n vertical. La paciente fue asistida antes del alerta emitida por diferentes agencias regulatorias en funci\u00f3n de los resultados del estudio Tsepamo donde se docu - ment\u00f3 una potencial asociaci\u00f3n entre defectos del tubo neural y exposici\u00f3n a dolutegravir al momento de la concepci\u00f3n [9]. En este contexto se requiere de estudios prospectivos que con - firmen o refuten esta potencial asociaci\u00f3n con defectos con -Sr. Editor: A pesar de las intervenciones integrales para la preven - ci\u00f3n de la infecci\u00f3n por VIH y del impacto de la terapia antirre - troviral de gran eficacia (TARGA), todav\u00eda hay dos millones de nuevos casos de VIH en adultos cada a\u00f1o [1]. Esta incidencia es debido en gran parte a los fallos en la detecci\u00f3n de los casos agudos y, por lo tanto, en su tratamiento precoz [2]. La infec - ci\u00f3n aguda por VIH se define como el conjunto de fen\u00f3menos inmunol\u00f3gicos y virol\u00f3gicos que ocurren entre la adquisici\u00f3n viral y la emergencia de anticuerpos espec\u00edficos [3]. Presentamos el caso de una paciente femenina de 29 a\u00f1os que consult\u00f3 por s\u00edndrome febril de 3 semanas de evoluci\u00f3n. Al interrogatorio refer\u00eda cambio de pareja sexual reciente. En el examen f\u00edsico presentaba abdomen doloroso a la palpaci\u00f3n superficial en hipogastrio y el laboratorio evidenciaba leve tri - citopenia (tabla 1). Se interna para estudio y descartar patolo - g\u00eda quir\u00fargica. La ecograf\u00eda ginecol\u00f3gica no presentaba alteraciones y la tomograf\u00eda de t\u00f3rax, abdomen y pelvis presentaba m\u00faltiples adenopat\u00edas en regi\u00f3n inguinal y retroperitoneales. Al ingreso presenta resultados discordantes de serolog\u00eda de VIH, con test r\u00e1pido de VIH (Alere Determinetm HIV-1/2) ne - gativo, Elisa de 4a generaci\u00f3n positivo (Bayer\u00ae) y Western blot indeterminado (detecci\u00f3n exclusivamente de banda GP 160). Se realiza carga viral (CV) que informa >10.000.000 copias/ml (rea - liz\u00e1ndose t\u00e9cnicas de diluci\u00f3n se precisa su valor en 12.100.000 copias/ml, 7.08 log10), confirmando el cuadro como s\u00edndrome re - troviral agudo, estadio de Fiebing 2 [4]. A los 3 d\u00edas se repite test r\u00e1pido que resulta negativo y nuevo Elisa que resulta positivo con aumento de la relaci\u00f3n de positividad. La prueba de resis - tencia genot\u00edpica basal no evidencia mutaciones.Uso de dolutegravir en infecci\u00f3n aguda por VIH-1: primer caso reportado 1Unidad de infectolog\u00eda, Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina 2Laboratorio Central, Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina Franco Garibaldi1 Marcia Pozzati2 Claudia Rodriguez1 Diego Cecchini1 Correspondencia: Franco Garibaldi Hospital General de Agudos Cosme Argerich, Almirante Brown 240, Buenos Aires 1155AHD, Argentina. Accepted: 11 March 2019Uso de dolutegravir en infecci\u00f3n aguda por VIH-1: primer caso reportado F. Garibaldi, et al. Rev Esp Quimioter 2019;32(4): 387-389388BIBLIOGRAF\u00cdA octubre 2018] 2. Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, et al. HIV prevention 2020: a framework for delivery and a call for action. Lancet HIV. 2016;3(7): e323-32. PMID:27365207 3. Panel on Antiretroviral Guidelines for Adults Gui - delines Use of Antiretroviral Agents in Adults and Adoles - cents Living with HIV. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL. pdf. [acceso: 20 de octubre 2017] 4. Cohen Shaw GM, McMichael AJ, fortreating HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organiza - tion; 2016 Sep. https://www.who.int/hiv/pub/arv/arv-2016/en/ [ac- ceso: 20 Lunzen A, Cavassini M, Henry K, et al. Once-daily dolutegravir is superior to once daily darunavir/ ritonavir in treatment-na\u00efve HIV-1-positive individuals: 96 week g\u00e9nitos, siendo actualmente un f\u00e1rmaco recomendado en la gestaci\u00f3n fuera del primer trimestre [8]. Hasta nuestro conocimiento, este es el primer reporte que describe el descenso de la CV en el contexto de una infecci\u00f3n aguda por VIH con dolutegravir, donde destacamos que se par - ti\u00f3 de una viremia basal extremada elevada, por encima del punto de corte de la t\u00e9cnica. El r\u00e1pido control de la viremia en el contexto de la seroconversi\u00f3n es de fundamental impor - tancia tanto para la salud del paciente individual como para la prevenci\u00f3n de la trasmisi\u00f3n a terceros, requiri\u00e9ndose ensayos cl\u00ednicos que documenten el mejor TARGA para indicar en este escenario cl\u00ednico. AGRADECIMIENTOS A la Bioq. Claudia F Nieto, Laboratorio Central, Hospital General de Agudos Cosme Argerich. Este caso cl\u00ednico fue presentado en parte en el VII Congre - so Internacional de Infectolog\u00eda Pedi\u00e1trica y Vacunas, Buenos Aires Argentina, 19 - 20 de abril de 2018. Poster # 102 FINANCIACI\u00d3N Los autores declaran no haber recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener ning\u00fan conflicto de intereses.D\u00eda 1 D\u00eda 2 D\u00eda 5 D\u00eda 7 Semana 2 Semana 5 Semana 7 Test r\u00e1pido Negativo Negativo Negativo Negativo Positivo Elisa Positivo Positivo Positivo Positivo Positivo Relaci\u00f3n de positividad (ELISA) 40 40 238 Western Blot GP 160 GP 160/ GP 120/ GP 41/ GP 24 Carga 7,08 2,18 CD4 (cel/ul) 576 1.253 Hematocrito (%) 29,9 32,5 32 33 37,1 Hemoglobina (g/dl) 9,9 11 10,8 11,9 12,4 Globulos blancos (cel/mm3) 4.000 3.900 3.500 3.500 10.100 Neutr\u00f3filos (%) 62 53 39.5 37 55 Linfocitos (%) 30 43 9.8 55 36 Plaquetas (cel/mm3) 107.000 97.000 93.000 98.000 224.000 TARGA SI Prueba de resistencia (genotipo) SITabla 1 Evoluci\u00f3n de par\u00e1metros de laboratorio en una paciente que inicia TARGA con dolutegravir durante infecci\u00f3n aguda por VIH.Uso de dolutegravir en infecci\u00f3n aguda por VIH-1: primer caso reportado F. Garibaldi, et al. Rev Esp Quimioter 2019;32(4): 387-389389results affecting women living with HIV using dolutegravir at the time of conception. Ge - neva, Switzerland. May 18, 2018. http://www.who.int/medicines/ publications/drugalerts/Statement_on_DTG_18May_2018final.pdf [acceso: 15 de Author 2019. by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).ciencia renal oligoanurica, precisando sesiones intermitentes de hemodiafiltraci\u00f3n veno-venosa continua. Adem\u00e1s, requiri\u00f3 ventilaci\u00f3n mec\u00e1nica prolongada debido a un cuadro de neu - mon\u00eda precoz asociada a la misma, que evolucion\u00f3 a distr\u00e9s respiratorio agudo. Por otro lado, present\u00f3 numerosas compli - caciones infecciosas de tipo nosocomial, asociadas a la venti - laci\u00f3n mec\u00e1nica, secundarias al cat\u00e9ter venoso central y a la herida quir\u00fargica, entre otras, recibiendo una amplia terapia antibi\u00f3tica (tabla 1). Al cabo de 3 meses de ingreso (d\u00eda 93), el paciente pre - sent\u00f3 febr\u00edcula (37,8\u00b0 C) con ligero descenso de plaquetas (128.000/\u00b5l), con repunte de PCR (8,9 mg/dl) y procalcitonina (0,7 ng/ml). Se cursaron hemocultivos y se asoci\u00f3 de manera emp\u00edrica amikacina, al tratamiento antibi\u00f3tico ya instaurado (meropenem + tigeciclina). Al cabo de 2 d\u00edas present\u00f3 empeo - ramiento cl\u00ednico en forma de shock s\u00e9ptico, fibrilaci\u00f3n auri - cular, hipotensi\u00f3n PCR 20,6 mg/dl e \u00edndice de Quick 45%. Al d\u00eda siguiente, se recibe resultados de hemo - cultivos previos, positivos para E. meningoseptica . El m\u00e9todo empleado en la identificaci\u00f3n fue el sistema de espectrometr\u00eda de masas \"Matrix-Assisted Laser Desorption/Ionization time of Flight\" (MALDI-TOF). Se confirm\u00f3 identificaci\u00f3n de E. menin - goseptica repitiendo cultivo, pero no se realiz\u00f3 confirmaci\u00f3n mediante secuenciaci\u00f3n gen\u00f3mica del ARNr 16s. Se retir\u00f3 la amikacina y se inici\u00f3, a la espera de resultado de antibiograma, rifampicina y cotrimoxazol (tabla 2). Al cabo de 24 h, el pacien - te present\u00f3 mala evoluci\u00f3n con fallo multiorg\u00e1nico refractario, siendo finalmente \u00e9xitus. E. meningoseptica es considerado un pat\u00f3geno oportunis - ta, que presenta resistencia a la mayor\u00eda de antibi\u00f3ticos dirigi - dos frente a gramnegativos. Posee dos tipos de -lactamasas (-lactamasa de espectro extendido de tipo A y metalo -lactamasa de tipo B), que le confieren resistencia intr\u00ednseca a betalact\u00e1micos y carbapen\u00e9micos y reducen la Chryseobacterium ticum, es un bacilo gramnegativo, aer\u00f3bico, no fermentador, inm\u00f3vil y ubicuo, ampliamente distribuido en la naturaleza [1]. La mayor\u00eda de las infecciones producidas por E. meningosepti - ca, a pesar de no estar presente en la microflora humana, son de origen nosocomial, consider\u00e1ndose un pat\u00f3geno emergen - te, de ambiente hospitalario [2]. Su genoma est\u00e1 constituido por genes que le confieren capacidad de formar biofilms y sobrevivir durante tiempos prolongados [3]. Se han documen - tado colonizaciones de material sanitario como, respiradores, nebulizadores, cat\u00e9teres intravasculares, adem\u00e1s de soluciones salinas de lavado y desinfectantes como la clorhexidina [4]. Por otro lado, la presentaci\u00f3n cl\u00ednica de las infecciones de E. meningoseptica , incluye casos de bacteriemia y sepsis, neu - mon\u00eda, infecciones de piel y partes blandas (como celulitis y fascitis necrotizante), osteomielitis e infecci\u00f3n peritonitis [5, 6]. Presentamos un caso de sepsis/shock s\u00e9ptico secundario a E. meningoseptica en un paciente postquir\u00fargico con una estan - cia prolongada en la unidad de cuidados intensivos. Paciente var\u00f3n de 69 a\u00f1os de edad, con antecedentes de diabetes, obesidad e hipertensi\u00f3n arterial, que acude a Urgen - cias el 22 de mayo de 2018, por cl\u00ednica de s\u00edndrome coronario agudo y crisis hipertensiva. Fue diagnosticado de enfermedad coronaria de dos vasos y aneurisma de aorta tor\u00e1cica, practi - c\u00e1ndose doble bypass aorto-coronario y recambio de la aor - ta tor\u00e1cica. El postoperatorio estuvo marcado por etapas de inestabilidad hemodin\u00e1mica requiriendo noradrenalina en varias ocasiones, con fases de fibrilaci\u00f3n auricular e insufi -Shock s\u00e9ptico secundario a Elizabethkingia meningoseptica : descripci\u00f3n de un caso 1Servicio de Farmacia. Hospital Quir\u00f3n Barcelona. Barcelona 2Unidad de Cuidados Intensivos. Hospital Quir\u00f3n Barcelona. BarcelonaDavid Brandariz N\u00fa\u00f1ez1 Paula Rodr\u00edguez Pedreira2 Virginia Hern\u00e1ndez Corredoira1 Joaquin Francisco J Gurri Hernand2 Arturo S Boix Boix2 Correspondencia: David Brandariz N\u00fa\u00f1ez Servicio de Farmacia. Hospital Quir\u00f3n Barcelona. Barcelona Tfno.: 637762900. E-mail: vrandariz@gmail.comCarta al Director 4 March 2019Shock s\u00e9ptico secundario a Elizabethkingia meningoseptica : descripci\u00f3n de un caso D. Brandariz N\u00fa\u00f1ez, et al. Rev Esp Quimioter 2019;32(4): sistentes [10], donde la elecci\u00f3n de tratamiento inapropiado y el estado de shock en el momento de presentaci\u00f3n, son facto - res predictores independientes de mortalidad [2]. Entre los factores de riesgo relacionados con E. meningo - septica se incluyen, diabetes mellitus, malignidad, corticote - rapia, neutropenia, hemodi\u00e1lisis, estancia hospitalaria prolon - gada y la exposici\u00f3n previa a m\u00faltiples antibi\u00f3ticos dirigidos frente a bacterias gramnegativas [3]. Nuestro paciente era dia - b\u00e9tico, tuvo etapas de neutropenia, necesit\u00f3 sesiones de he - modiafiltraci\u00f3n y recibi\u00f3 una presi\u00f3n antibi\u00f3tica considerable durante un ingreso prolongado, superior a 3 meses. E. meningoseptica es un pat\u00f3geno multirresistente, con una elevada mortalidad. Ser\u00eda aconsejable potenciar medidas desti - nadas al control y prevenci\u00f3n de brotes e infecciones nosoco - miales. Debido a la falta de consenso en el tratamiento emp\u00edrico, el manejo deber\u00eda ser en funci\u00f3n de los resultados de la sensibili - dad del antibiograma. En infecciones causadas por bacilos gram - negativos que no responden a tratamientos emp\u00edricos de amplio espectro, se deber\u00eda sospechar de E. meningoseptica. FINANCIACI\u00d3N Los autores declaran no haber recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener ning\u00fan conflicto de intereses.te, muestra susceptibilidad a antibi\u00f3ticos empleados en el tra - tamiento de bacterias rifampicina, vanco - micina, quinolonas, y cotrimoxazol [7]. El perfil de resistencias var\u00eda seg\u00fan las series publicadas, siendo cotrimoxazol (91%), levofloxacino (81%), y rifampicina (87%) los antibi\u00f3ticos con mejor perfil de sensibilidad [2, 8]. No existe un consenso sobre el tratamiento emp\u00edrico de E. meningoseptica , donde la mayo - r\u00eda de autores sugieren que el uso de antibi\u00f3ticos deber\u00eda ser en funci\u00f3n de los resultados de la sensibilidad del antibiogra - ma. En el caso de nuestro paciente, de todos los antibi\u00f3ticos testados, E. meningoseptica , solo fue sensible a cotrimoxazol. E. meningoseptica tiene una tasa de mortalidad elevada D\u00eda ingreso Infecci\u00f3n Muestra Microorganismo implicado Tratamiento antibi\u00f3tico dirigido 15 Bacteriemia Hemocultivo ganciclovir 2 herida (i.v)Tabla 1 Evoluci\u00f3n del paciente durante el ingreso MR: multirresistente, BLEE: betalactamasa de espectro extendido, Sensibilidad Amikacina 64 Resistente Cefepima 64 Resistente Ceftazidima 64 Resistente Ciprofloxacino 4 Resistente Gentamicina 16 Resistente Imipenem 16 Resistente Piperacilina/tazobactam 128 Resistente Trimetroprim/sulfametoxazol 80 SensibleTabla 2 Antibiograma de la cepa de Elizabethkingia meningosepticaShock s\u00e9ptico secundario a Elizabethkingia meningoseptica : descripci\u00f3n de un caso D. Brandariz N\u00fa\u00f1ez, et al. Rev Esp Quimioter 2019;32(4): 390-392392BIBLIOGRAF\u00cdA 1. Kim KK, Kim MK, Lim JH, HY, Lee ST. Transfer CJ, KL, et al. bac - teriemia at medical Taiwan, 1999-2006. Eur J Clin - A, B, al. outbreak observed Jung N. Septic shock caused by Elizabethkingia meningoseptica : a case report and review of lite - rature. Case Reports 2013;2013:bcr2013009066. PMID: 23559661 RN. Antimicrobial susceptibility and epidemiology of a worldwide of of the therapeutic efficacy non-fluoroquinolone by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).(hemoglobina 8,6 g/dl, 400 leucocitos/\u00b5l con 180 neutr\u00f3filos absolutos y 5.000 plaquetas/\u00b5l), con PCR de 89 mg/l (valor nor - mal: 0-5 mg/l) y procalcitonina de 0,59 ng/ml (valor normal: 0-0,5 ng/ml). La radiograf\u00eda de t\u00f3rax fue normal. Se recogieron hemocultivos y con el diagn\u00f3stico de pancitopenia posquimio - terapia y neutropenia febril grave se inici\u00f3 tratamiento antimi - crobiano emp\u00edrico con ceftazidima (2 g iv/8h) y daptomicina (6 mg/kg/24h). El hemocultivo evidenci\u00f3 el crecimiento A. oris \u2014identificado mediante espectrometr\u00eda de masas (MALDI-TOF, Bruker\u00ae) \u2014 y se realiz\u00f3 un TC cervico-toraco-abdomino-p\u00e9lvico que descart\u00f3 complicaciones locales. La sensibilidad antibi\u00f3tica se realiz\u00f3 mediante los puntos de corte indicados en el Clini - cal and Laboratory Standards Institute (CLSI). El microorganis - mo fue sensible a los siguientes antibi\u00f3ticos: penicilina (CMI = 0,094 mg/L), amoxicilina-clavul\u00e1nico (CMI= 0,5 mg/L). Metronidazol (CMI > 256 mg/L) se catalog\u00f3 como resistente. Se desescal\u00f3 a amoxicilina-clavul\u00e1nico (875/125 mg iv/8h) du - rante 1 semana, con negativizaci\u00f3n de los hemocultivos a los 4 d\u00edas de inicio del tratamiento. Posteriormente, se realiz\u00f3 tera - pia secuencial de mantenimiento con amoxicilina-clavul\u00e1nico (875/125 mg vo/8h) durante 6 meses sin evidencia de recidiva. Se han descrito distintos factores de riesgo para desarrollar infecci\u00f3n por Actinomyces como deterioro del sistema inmune (infecci\u00f3n por VIH, quimioterapia y toma cr\u00f3nica de esteroi - des), cuerpos extra\u00f1os \u2014en especial dispositivos intrauterinos\u2014 y procedimientos quir\u00fargicos en especial la cirug\u00eda abdominal y manipulaci\u00f3n dental. La marcada presencia de A. oris e n la flora de la cavidad bucal, su poca virulencia y la inusual pre - sencia de estos g\u00e9rmenes en hemocultivo obliga a pensar en la disrupci\u00f3n de la barrera mucosa como factor fundamental en su papel pat\u00f3geno. En este sentido, distintos estudios [5] han puesto en relieve la presencia de bacteriemia por A. oris despu\u00e9s de manipulaciones dentales, por lo que la valoraci\u00f3n minuciosa en busca de enfermedad bucodental podr\u00eda ser pe - rentorio en el estudio de una bacteriemia en el contexto de una neutropenia febril.Sr. Editor : Actynomices spp. \u2014del griego aktinos (rayo) y mykes (hongo) en referencia a su aspecto microsc\u00f3pico\u2014 son bacilos grampositivos de forma filamentosa o ramificada, anae - robios, no \u00e1cido-alcohol resistentes. Se consideran microbiota habitual de las mucosas, en especial, de la orofaringe, tracto genital femenino y tubo digestivo [1]. Hasta hace relativamente poco, la clasificaci\u00f3n de Actyno - mices spp. se realizaba mediante las diferencias en las pruebas fenot\u00edpicas convencionales. En los \u00faltimos a\u00f1os, gracias a las t\u00e9cnicas genot\u00edpicas de identificaci\u00f3n, se han conseguido gran - des avances taxon\u00f3micos con redefinici\u00f3n e identificaci\u00f3n de nuevas especies. Henssge et al [2]. propusieron reclasificar las genoespecies 2 bacteriemia por Actynomices spp. es una forma de ac - tinomicosis poco frecuente. Hasta donde hemos podido saber, existen escasas referencias bibliogr\u00e1ficas [3] sobre el particular. Una de las especies implicadas en bacteriemia ha sido A. naes - lundi [4], sin embargo \u2014tras la reclasificaci\u00f3n de una de sus ge - noespecies en A. oris \u2014 hemos encontrado escasas referencias [5] (buscadores PubMed y Medline, palabras clave bacteremia, infection y Actynomices oris) acerca de su participaci\u00f3n como agente causal de infecci\u00f3n. Se presenta un caso de una bacteriemia por A. oris en una paciente un paciente en tratamiento quimioter\u00e1pico. Var\u00f3n de 32 a\u00f1os, diagnosticado de medulobalastoma localizado en tratamiento quimioter\u00e1pico con cisplatino, vin - cristina y ciclofosfamida. Ingres\u00f3 por fiebre de 39\u00baC y mal estado general, 20 d\u00edas despu\u00e9s de recibir el \u00faltimo ciclo de quimioterapia. En la exploraci\u00f3n f\u00edsica destacaba la presencia palidez cut\u00e1nea y anal\u00edticamente presentaba una pancitopenia Bacteriemia por Actynomices oris 1Servicio de Medicina Interna. Hospital cl\u00ednico Universitario de Valladolid, Espa\u00f1a. 2Unidad de Enfermedades Infecciosas. Servicio de Medicina Interna. Hospital cl\u00ednico Universitario de Valladolid, Espa\u00f1a. Javier Miguel Mart\u00edn Guerra1 Miguel Mart\u00edn Asenjo1 Claudia Iglesias P\u00e9rez1 Carlos Jes\u00fas Due\u00f1as Guti\u00e9rrez1,2 Correspondencia: Javier Miguel Mart\u00edn Guerra Hospital Cl\u00ednico Universitario de Valladolid. Avda. Ram\u00f3n y Cajal, 1. 47005. Valladolid (Espa\u00f1a) Tfno.: 660376561 E-mail: Actynomices oris J. et al. Rev Esp Quimioter 2019;32(4): 393-3943947. Smith AJ, DM, Warren YA, Tyrrell KL, Fernan - dez HT. Comparative in vitro sensibles a penicili - nas, se recomienda identificar la especie en cuesti\u00f3n. A parte de la resistencia intr\u00ednseca a metronidazol [6], se han descrito re - sistencias particulares en algunas especies como A. europaeus (ceftriaxona, clindamicina, macr\u00f3lidos, ciprofloxacino y/o ta tetraciclinas, macr\u00f3 - lidos, ciprofloxacino y/o linezolid) . Ambas especies son las m\u00e1s resistentes [7]. Adem\u00e1s se han observado CMIs elevadas para distintos antimicrobianos en cepas de A. funkei A. israelii (linezolid) y A. odontolyticus (clindamicina) [3, 8-10]. La duraci\u00f3n tratamiento \u2014y en especial en la bacterie - mia\u2014 no est\u00e1 bien establecido, pero se han considerado trata - mientos muy prolongados, incluso de un a\u00f1o. La bacteriemia por A. oris justifica una exhaustiva valo - raci\u00f3n bucodental. Queda patente la escasa experiencia en el manejo de bacteriemia por Actynomices spp., lo que nos obli - gar\u00eda a dise\u00f1ar estudios multic\u00e9ntricos e internacionales que aportasen evidencia al respecto. FINANCIACI\u00d3N Los autores declaran no haber recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener ning\u00fan conflicto de inte - reses. BIBLIOGRAF\u00cdA 1. Betriu Do T, Radford DR, Gilbert SC, Clark D, Beighton D. Emen - ded description of Actinomyces naeslundii tinomyces oris identified as Actinomyces CMR.00100-14 Curious Case naeslundii bacteremia Quimioter 2019;32(4): 395-397395 \u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC The patient had a clinical response, being discharged after two weeks of fluconazole at the same dose. In June, he was re-admitted with fever and hyporexia for over a month. patient\u00b4s high risk. Within a month of antifungals, he presented clinical of to are summarized in table 1. Hot spots 1 and 2 of the FKS1 and FKS2 genes were sequenced and harbored a point mutation FKS2 gene. There were two C. glabrata strains from blood culture and two morphologically different strains from the heart valve culture. Nevertheless, all them model no differences in terms virulence not glabrata major agent of ranging from <1% in Europe to over 10 % in some hospitals located in the United States of America [1]. These isolates usually harbor mutations in hot spot regions of the FKS genes, strains with FKS mutations treatment failure and even higher mortality rates [3]. To the best of our knowledge, this is the first report of endocarditis caused by a strain of C. replacement in 2011 in to a community gastrointestinal Infectious endocarditis caused by Candida glabrata 1Department of Clinical Microbiology and Infectious Diseases, Universitario Gregorio Mara\u00f1\u00f3n, Calle Doctor Esquerdo, 46, 28007, Madrid, Spain. 2Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Calle Doctor Esquerdo, 46, 28007, Madrid, Spain. 3CIBER de Enfermedades Respirat\u00f3rias (CIBERES CB06/06/0058), Av. Monforte de Lemos, 3-5. Pabell\u00f3n 11, Planta 0, 28029, Madrid, Spain. 4Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid, Plaza Ram\u00f3n y Cajal, s/n. Ciudad Universitaria, 28040, Madrid, of Clinical Microbiology and Infectious Diseases Hospital General Universitario Gregorio Mara\u00f1\u00f3n Doctor Esquerdo of in vivo development of echinocandin resistanceC. Agnelli, et al. Rev Esp Quimioter in resistant [12]. This could explain why one of the from the heart valve acquired an FKS2 mutation, whereas those from blood - where the concentration of micafungin is much higher - remained echinocandin with and may regain full susceptibility to spread of resistant clones [14]. In conclusion, we describe a of recurrent candidemia by C. complicated fluconazole C. glabrata in current guidelines [8]. He presented In fact, the gastrointestinal tract is known to be a reservoir for Candida and a potential source of antifungal resistance due to irregular drug penetration Noteworthy, is intra-abdominal, followed by endocarditis [11]. To the best of our knowledge, this is the first report of IE with an echinocandin-resistant Candida performed point out the caused by both susceptible and 0.25 2 0.25 0.5 0.015 0.03 WT Blood culture Jun 0.5 0.015 0.03 valve culture 2016 Jul 05 C. glabrata 0.125 8 0.25 0.5 2a1aS663PTable 1 FKS2 of in vivo development of echinocandin resistanceC. Agnelli, et al. Rev Esp Quimioter 2019;32(4): 395-3973979. Ashbee HR, Barnes RA, Antimicrob Chemother 2014;69:1162-76. doi:10.1093/jac/dkt508. 10. Healey KR, Nagasaki Y, Zimmerman M, Kordalewska M, Park S, Zhao Y, et al. The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a 11. Mu\u00f1oz P, Vena A, Valerio M, \u00c1lvarez-Ur\u00eda A, Guinea J, Escribano P, et al. Risk factors for late LJ, G\u00f3mez-Perosanz M, Escribano P, Zaragoza O, Bouza E, Guinea J. Biofilm Production and Antibiofilm Activity L, Pons A, Jacob S, Meyer I, Palous M, et al. Discontinuation of echinocandin and azole treatments led to de Foundation, Brazil / PDSE [88881.187981/2018-01 to C.A.], and Fondo de Investigaci\u00f3n Sanitaria (FIS PI16/01012), Instituto de Salud Carlos III [CPI15/00115 to P.E. and CPII15/00006 to J.G.]. CONFLICTS OF INTEREST The authors declare of interest. REFERENCES 1. Perlin DS, Linde J, G\u00f6lz H, Duerschmied D, et al. Comparative Genomics of Serial J-L, de la Pedrosa EGG, Cant\u00f3n R, Bouza E, et al. Mutant Prevention Concentration and Mutant L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).favorable, resolvi\u00e9ndose satisfactoriamente los episodios infec - ciosos de v\u00edas respiratorias altas. Tras recibir la muestra del contenido purulento en el Ser - vicio de Microbiolog\u00eda, se sembr\u00f3 en dos placas de agar sangre (Biom\u00e9rieux\u00ae) (una incubada en aerobiosis y otra en anae - a 36\u00baC y agar chocolate (Biom\u00e9rieux\u00ae) incubado a 37\u00baC en atm\u00f3sfera con 5% de CO2. A las 48 horas se observ\u00f3 el crecimiento en cultivo puro de colonias de peque\u00f1o tama - \u00f1o (aproximadamente 1mm de di\u00e1metro) en agar chocolate y en agar sangre incubado en anaerobiosis. La espectrometr\u00eda de masas MALDI-TOF MS (Maldi Byotyper 3.0 System, Bruker Daltonics GmbH) no identific\u00f3 correctamente el microorganis - mo, dando como resultado m\u00e1s probable Arthrobacter proto - phormiae (Score 1,432). Se realiz\u00f3 una tinci\u00f3n de Gram de las colonias con la que se concluy\u00f3 que se trataban de bacilos grampositivos no formadores de esporas. Tras varios subculti - vos, la espectrometr\u00eda de masas sigui\u00f3 determinando el g\u00e9nero Arthrobacter como m\u00e1s probable, aunque especies diferentes a la recogida previamente ( A. polychromogenes , A. oxydans ). Ante la imposibilidad de realizar una identificaci\u00f3n v\u00e1lida, se envi\u00f3 la cepa al Centro Nacional de Microbiolog\u00eda (Instituto de Salud Carlos III), que identific\u00f3 el microorganismo median - te secuenciaci\u00f3n como Actynomyces marseillensis , una nueva especie de Actinomyces . Para el estudio de la sensibilidad antibi\u00f3tica se emplea - ron Etest (Biom\u00e9rieux\u00ae) en agar sangre Brucella reincubados en anaerobiosis a 37\u00baC durante 48 horas. Las m\u00ednimas inhibitorias (CMI) obtenidas fueron: amoxicilina/\u00e1ci - do clavul\u00e1nico (2 mg/L), moxifloxacino (2 mg/L) y clindamici - na (256mg/L). Tras aplicar los puntos de corte del European Committee on Antimicrobial Susceptibility Testing (EUCAST) para microorganismos anaerobios grampositivos, se determin\u00f3 que la cepa era sensible a amoxicilina/clavul\u00e1nico y resisten - te a clindamicina. No se pudo establecer una sensibilidad para moxifloxacino debido a que no existe punto de corte publicado para este antibi\u00f3tico.Sr. Editor: La infecci\u00f3n periamigdalina constituye la com - plicaci\u00f3n m\u00e1s frecuente de la amigdalitis. Tradicionalmente el microorganismo que se asociaba con mayor frecuencia a este tipo de infecciones era Streptococcus pyogenes , aunque en la actualidad se sabe que suele tratarse de infecciones polimicro - bianas, con presencia de microorganismos aerobios y anaero - bios [1-3]. Entre ellos se encuentran las bacterias del g\u00e9nero Actinomyces , constituido por m\u00e1s de 30 especies de bacilos filamentosos grampositivos que forman parte de la flora oro - far\u00edngea, gastrointestinal y genitourinaria [2-4]. Se presenta un caso de absceso periamigdalino producido por una nueva especie de este g\u00e9nero, Actinomyces marseillensis [5]. Var\u00f3n de 42 a\u00f1os con \u00fanico antecedente personal de inter\u00e9s de adenoidectom\u00eda quir\u00fargica. Acudi\u00f3 a los servicios de urgen - cias de Otorrinolaringolog\u00eda cuatro veces en un per\u00edodo de 40 d\u00edas, aproximadamente una vez cada 10 d\u00edas, por odinofagia y fiebre de hasta 39\u00baC, diagnosticado de amigdalitis con flem\u00f3n/ absceso periamigdalino izquierdo. En dos ocasiones la punci\u00f3n fue positiva y se dren\u00f3 abundante contenido purulento del pilar anterior amigdalino izquierdo. Fue tratado con diferentes ciclos de antibi\u00f3tico, intravenoso durante el ingreso, y oral al alta a do - micilio, alternando con amoxicilina/\u00e1cido clavul\u00e1nico (875/125 mg cada 8 horas, 7 d\u00edas) clindamicina (450 mg cada 6 horas, 10 d\u00edas) y moxifloxacino (400 mg cada 24 horas, 7 d\u00edas), adem\u00e1s de prednisona como tratamiento antiinflamatorio. En el cuar - to ingreso, se recogi\u00f3 una muestra del contenido purulento del absceso periamigdalino izquierdo y se envi\u00f3 al Servicio de Micro - biolog\u00eda. A los 10 d\u00edas se realiz\u00f3 amigdalectom\u00eda y se enviaron las muestras al servicio de Anatom\u00eda Patol\u00f3gica, con diagn\u00f3stico de hiperplasia linfoide reactiva y sin sospecha de malignidad. El paciente tras la intervenci\u00f3n quir\u00fargica, present\u00f3 una evoluci\u00f3n Absceso periamigdalino producido por Actinomyces marseillensis 1Servicio de Microbiolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria Princesa, Hospital Universitario La Princesa, Madrid, Espa\u00f1a. 2Servicio de Otorrinolaringolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria Princesa, Hospital Universitario La Princesa, Madrid, Espa\u00f1aSara G\u00f3mez de Frutos1 Marta Soledad Rodr\u00edguez Anzules2 Arturo Manuel Fraile Torres1 Laura Carde\u00f1oso Domingo1 Diego Domingo Garc\u00eda1 Correspondencia: Sara G\u00f3mez de Frutos Servicio de Microbiolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria Princesa, Hospital Universitario La Princesa, Madrid, Espa\u00f1a. Tfno.: 628670617 Fax: 915202547 E-mail: producido por Actinomyces marseillensis S. G\u00f3mez de Dubourg G, Raoult D. 'Enterococcus timonensis' nov., 'Actinomyces sp. 'Actinomyces culturomici' and 'Gemella massiliensis' sp. nov., new bacterial species isolated from the human respiratory microbio A, Kapoor K, Singh A, Harcourt J. Out-patient management of patients actual. Revista Por - en de 2017 en Francia como una nueva especie filogen\u00e9ticamente pr\u00f3xima a A. odontolyticus [5]. La similitud en la secuenciaci\u00f3n de la cepa aislada y A. odontolyticus fue <68,65% por lo que se propuso como una nueva especie denominada A. marseillensis . Tras una revisi\u00f3n de la literatura, parece ser el primer caso recogido de infecci\u00f3n por este microorganismo. El manejo de los abscesos periamigdalinos se fundamen - ta en el drenaje y administraci\u00f3n de corticoides y tratamiento antibi\u00f3tico emp\u00edrico [6, 7]. Aunque no se considera necesario hacer estudios bacteriol\u00f3gicos de forma sistem\u00e1tica, s\u00ed parece interesante realizar cultivo para microorganismos aerobios y anaerobios en cuadros recurrentes como el que se presenta, puesto que puede servir de gu\u00eda para elecci\u00f3n del tratamiento antibi\u00f3tico, siendo especialmente \u00fatil en infecciones produci - das por microorganismos que no producen de forma habitual estos cuadros y que, por lo tanto, pueden no estar cubiertos con el tratamiento emp\u00edrico. Pese a que la mayor parte de las infecciones periamigdalinas tienen etiolog\u00eda polimicrobiana, el caso presentado se trata de una infecci\u00f3n monomicrobiana, en la que se aisl\u00f3 de forma exclusiva A. marseillensis . Este he - cho parece indicar que, aunque puede encontrarse formando parte de la flora orofar\u00edngea habitual tambi\u00e9n tiene potencial pat\u00f3geno. Cabe destacar la dificultad para la identificaci\u00f3n de este microorganismo mediante las t\u00e9cnicas habitualmente dis - ponibles en laboratorios de Microbiolog\u00eda Cl\u00ednica como la es - pectrometr\u00eda de masas, siendo necesaria la colaboraci\u00f3n de un laboratorio de referencia. FINANCIACI\u00d3N Los autores declaran no haber recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener ning\u00fan conflicto de inte - reses. BIBLIOGRAF\u00cdA 1. Costales-Marcos M, L\u00f3pez-\u00c1lvarez F, N\u00fa\u00f1ez-Batalla F, Moreno- Galindo C, C, Llorente-Pend\u00e1s JL. Peritonsillar In - fections: Prospective 400-409400 \u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Consensus document for sepsis code implementation and development in the Community of Madrid ABSTRACT The consensus paper for the implementation and develo - pment sepsis code, April 2017 is presented here. It was adopted by the Regional Office of Health as a wor - king document for the implementation of the sepsis code in the Community of Madrid, both in the hospital setting (acute, middle and long-stay hospitals) and in Primary Care and Out- of-Hospital Emergency Services. It is now published without changes with respect to the original version, having only added the most significant bibliographical references. The document divided early organizational recommendations. In the second to fourth sections, 25 state - ments or proposals have been included, agreed upon by nine tables that are in - tended as a practical guide to the activation of the sepsis code. Both the content of the recommendations and their for - mal writing have been made taking into account their applica - bility in all areas to which they are directed, which may have very different structural and functional characteristics and features, so that we have deliberately avoided a greater de - gree of concretion: the objective is not that the sepsis code is organized and applied identically in all of them, but that the health resources work in a coordinated manner aligned in (qSOFA), consensus documentRESUMEN Se presenta el documento de consenso para la implan - taci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid, cuya redacci\u00f3n se complet\u00f3 en abril de 2017. Este documento ha sido adoptado por la Consejer\u00eda de Sanidad madrile\u00f1a como base de trabajo para la puesta en marcha del C\u00f3digo Sepsis, tanto en el \u00e1mbito hospitalario (hospitales de agudos y de media y larga estancia) como en Atenci\u00f3n Primaria y los Servicios de Emer - gencia Extrahospitalaria. Se publica ahora sin modificaciones con respecto a la versi\u00f3n original, a\u00f1adiendo \u00fanicamente las referen - cias bibliogr\u00e1ficas m\u00e1s significativas. El documento se estructura en cuatro partes: introducci\u00f3n, detecci\u00f3n y valoraci\u00f3n iniciales, tratamiento inicial y organizaci\u00f3n asistencial. En las partes se - gunda a cuarta se proponen 25 recomendaciones, consensuadas por los autores despu\u00e9s de varias reuniones presenciales y una extensa discusi\u00f3n \"online\". Se incluyen nueve tablas que preten - den servir de gu\u00eda pr\u00e1ctica para la activaci\u00f3n y aplicaci\u00f3n del c\u00f3digo sepsis. Tanto el contenido de las recomendaciones como su redacci\u00f3n formal se han realizado teniendo en cuenta su apli - cabilidad en todos los \u00e1mbitos a los que se dirigen, que cuentan con recursos y caracter\u00edsticas estructurales y funcionales muy dispares, por lo que deliberadamente se ha huido de un mayor grado de concreci\u00f3n: el objetivo no es que el c\u00f3digo sepsis se organice y se aplique de forma id\u00e9ntica en todos ellos, sino que los recursos sanitarios trabajen de forma coordinada alineados en la misma direcci\u00f3n. Palabras clave: sepsis, c\u00f3digo sepsis, quick-SOFA (qSOFA), documento de consensoDocumento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid 1Servicio de Medicina Intensiva Hospital Universitario Infanta Leonor, Madrid 2Servicio de Urgencias Hospital Cl\u00ednico San Carlos, Madrid 3Servicio de Anestesiolog\u00eda y Reanimaci\u00f3n Hospital Universitario La Princesa, Madrid 4Servicio de Microbiolog\u00eda Hospital Cl\u00ednico San Carlos, Madrid 5Servicio de Medicina Interna Hospital Universitario Infanta Leonor, Madrid 6Servicio de Urgencias Hospital Universitario La Princesa, Madrid 7Servicio de Medicina Intensiva Hospital Universitario del Henares, Coslada, Madrid 8M\u00e9dico de Urgencias SUMMA 112, Madrid 9Servicio de Urgencias Hospital Universitario La Paz, Madrid 10Servicio de Medicina Intensiva Hospital Universitario La Princesa, Madrid 11Servicio de Enfermedades Infecciosas Hospital Ram\u00f3n y Cajal, Madrid 12SAMUR-Protecci\u00f3n Civil, Madrid 13Servicio de Radiolog\u00eda Hospital Universitario La Paz, Madrid 14Enfermer\u00eda de Hospitalizaci\u00f3n Hospital Universitario Infanta Leonor, MadridEduardo Palencia Herrej\u00f3n1 Juan Gonz\u00e1lez del Castillo2 Fernando Ramasco Rueda3 Francisco Javier Candel Gonz\u00e1lez4 Beatriz S\u00e1nchez Artola5 Andr\u00e9s von Wernitz Teleki6 Federico Gordo Vidal7 Patricia Roces Iglesias8 Guillermina Bejarano Redondo9 Diego An\u00edbal Rodr\u00edguez Serrano10 Francisco Javier Cobo Reinoso11 Ervigio Corral Torres12 Milagros Mart\u00ed de Gracia13 Ana Ruiz \u00c1lvarez14 y el Grupo Multidisciplinar C\u00f3digo Sepsis Madrid* Correspondencia: Eduardo Palencia Herrer\u00f3n Servicio de Medicina Intensiva. Hospital Universitario Infanta Leonor. E-mail: epalenciah@salud.madrid.orgDocumento de ConsensoDocumento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409401de disfunci\u00f3n org\u00e1nica y sospecha cl\u00ednica de infecci\u00f3n (ta- bla 1) [4, 13, 14]. En todo paciente con disfunci\u00f3n de \u00f3rganos se debe investigar la existencia de una infecci\u00f3n como causa de la misma, y en todo paciente con sospecha o evidencia de infecci\u00f3n se debe investigar la posible existencia de disfunci\u00f3n de \u00f3rganos. La activaci\u00f3n del c\u00f3digo sepsis supone el inicio de las medidas de diagn\u00f3stico y tratamiento de forma inmediata, pendientes de la confirmaci\u00f3n diagn\u00f3stica, tanto en el \u00e1mbito extra como intrahospitalario. 2. Debe quedar reflejada como alerta en la Historia Cl\u00ednica la activaci\u00f3n del C\u00f3digo Sepsis, que se mantendr\u00e1 al menos du - rante las primeras 72 horas o hasta que se descarte su existencia. 3. El est\u00e1ndar para el reconocimiento precoz de sepsis es el sistema quick-SOFA (qSOFA) (tabla 2), y la escala SOFA (tabla 3) para el diagn\u00f3stico definitivo de sepsis y la cuantificaci\u00f3n de la disfunci\u00f3n de \u00f3rganos [4]. La disfunci\u00f3n de \u00f3rganos puede ser debida a otras causas, y solo se considerar\u00e1 sepsis cuando la disfunci\u00f3n de \u00f3rganos se considera debida a una infecci\u00f3n. Cada hospital puede emplear adem\u00e1s otros sistemas que consi - dere convenientes para la detecci\u00f3n precoz de infecci\u00f3n, como el SRIS (S\u00edndrome de Respuesta Inflamatoria Sist\u00e9mica) (tabla 4), y para la valoraci\u00f3n de las situaciones de deterioro cl\u00ednico de cualquier causa (puntuaci\u00f3n NEWS ) (tabla 5) [15, 16]. 4. En la valoraci\u00f3n cl\u00ednica del paciente con sospecha de in - fecci\u00f3n, es recomendable la determinaci\u00f3n de biomarcadores como la procalcitonina (PCT) para apoyar la sospecha cl\u00ednica de infecci\u00f3n y guiar el inicio y la interrupci\u00f3n de la antibiote - rapia [17-19]. 5. En la valoraci\u00f3n del paciente con sospecha de sepsis es necesaria la determinaci\u00f3n de lactato (en muestra arterial o venosa sin compresor) [20, 21], y en caso de existir signos cl\u00ed - nicos de compromiso respiratorio (frecuencia respiratoria alta, disnea, signos de trabajo respiratorio, saturaci\u00f3n arterial de ox\u00edgeno baja) se debe realizar gasometr\u00eda arterial .INTRODUCCI\u00d3N El presente es un documento de trabajo, elaborado por un grupo multidisciplinar de profesionales m\u00e9dicos y de enfer - mer\u00eda que se constituyen en impulsores del proyecto \"C\u00f3digo Sepsis Madrid\", con propuestas y recomendaciones que debe - r\u00e1n ser avaladas por instituciones, organizaciones y sociedades cient\u00edficas y profesionales de nuestra Comunidad. La sepsis es la primera causa de muerte en los hospitales [1]. En nuestro pa\u00eds, como en otros, su incidencia y mortalidad si - guen aumentando [2]. Es uno de los motivos m\u00e1s frecuentes de ingreso en el hospital y en las unidades de cuidados intensivos, a menudo complica el curso de otros procesos, y es el principal motivo de las llamadas por deterioro cl\u00ednico en los pacientes hospitalizados [3]. Su letalidad es del 10%, mayor que la del ictus, el infarto agudo de miocardio o el trauma grave, y au - menta hasta el 40% cuando se produce shock s\u00e9ptico [4]. En los \u00faltimos a\u00f1os, distintas iniciativas nacionales e internacionales han demostrado que la detecci\u00f3n y el tratamiento precoces y organizados de la sepsis disminuyen su mortalidad hasta en un 50% [5, 6]. Se trata por tanto de una entidad cl\u00ednica tiempo- dependiente, que es y debe tratarse como una emergencia [7]. Es en este contexto que surge la necesidad de sistematizar la asistencia a los pacientes con sepsis. Hace 15 a\u00f1os las prin - cipales sociedades cient\u00edficas desarrollaron a nivel mundial la \"Campa\u00f1a sobrevivir a la sepsis\", con el objetivo de disminuir la mortalidad de este s\u00edndrome en al menos un 25%, mediante la elaboraci\u00f3n de gu\u00edas de pr\u00e1ctica cl\u00ednica basadas en la evidencia y su aplicaci\u00f3n a la pr\u00e1ctica diaria promoviendo en los hospita - les y servicios sanitarios los cambios organizativos y la forma - ci\u00f3n necesarios para asegurar su efectividad [8, 9]. En nuestro pa\u00eds, esto se ha plasmado recientemente en el desarrollo del proyecto \"c\u00f3digo sepsis\", avalado por las principales sociedades cient\u00edficas y con el apoyo del Gobierno de la Naci\u00f3n y de todas las Comunidades Aut\u00f3nomas [10]. En la Comunidad de Madrid distintos hospitales han empe - zado a desarrollar \"c\u00f3digo sepsis\" [11], pero en la mayor\u00eda de los hospitales y en el \u00e1mbito extrahospitalario este desarrollo o bien no se ha iniciado o bien est\u00e1 circunscrito a solo determi - nadas \u00e1reas. Por otra parte, faltan la necesaria uniformidad e intercomunicaci\u00f3n en las pr\u00e1cticas de c\u00f3digo sepsis en Madrid. Aunque la realidad en cada hospital es muy diferente, existen unos m\u00ednimos que se pueden compartir para unificar los aspec - tos clave del tratamiento de la sepsis. Las recomendaciones plasmadas en este documento son ba - sadas en la evidencia y acordes a las propuestas en las gu\u00edas de pr\u00e1ctica cl\u00ednica m\u00e1s recientes de la \"Campa\u00f1a sobrevivir a la sepsis\", que cuentan con el respaldo un\u00e1nime de las socie - dades cient\u00edficas nacionales e internacionales implicadas en el manejo de la sepsis y que han demostrado ser eficaces y costo- efectivas [9, 12] . DETECCI\u00d3N PRECOZ Y VALORACI\u00d3N INICIAL 1. El C\u00f3digo Sepsis se activar\u00e1 en los pacientes con signos Tabla 1 Definici\u00f3n de sepsis Definici\u00f3n conceptual: disfunci\u00f3n org\u00e1nica grave (amenazante para la vida), debida a una respuesta an\u00f3mala del individuo a la infecci\u00f3n Definici\u00f3n operativa: aumento en dos o m\u00e1s puntos en la escala SOFA (2 o m\u00e1s puntos si se asume una puntuaci\u00f3n previa de cero) Tabla 2 qSOFA (quick SOFA) Positivo si dos o m\u00e1s de los siguientes: 1. Presi\u00f3n arterial sist\u00f3lica < 100 mmHg 2. Frecuencia respiratoria > 21 rpm 3. Alteraci\u00f3n del estado mental (puntuaci\u00f3n de Glasgow para el coma < 15)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409402de este extremo. Aunque la gasometr\u00eda arterial es necesaria para realizar el c\u00e1lculo de la puntuaci\u00f3n SOFA (relaci\u00f3n paO2/ FiO2), en pacientes sin compromiso respiratorio aparente este par\u00e1metro se puede sustituir por la relaci\u00f3n SpO2/FiO2, que solo requiere la pulsioximetr\u00eda y no la gasometr\u00eda arterial [22]. 8. En el paciente con sospecha de sepsis se deben obtener hemocultivos (dos extracciones obtenidas de venopunciones independientes y consecutivas), independientemente de su temperatura, antes de iniciar la antibioterapia emp\u00edrica [23]. Se obtendr\u00e1n tambi\u00e9n muestras para cultivo de los focos sos - pechosos de infecci\u00f3n lo m\u00e1s precozmente posible, y a ser posible antes de iniciar el tratamiento antibi\u00f3tico, sin que esto suponga una demora en el inicio de la antibioterapia. 9. La identificaci\u00f3n del foco de infecci\u00f3n causante de la sepsis es prioritaria para seleccionar el tratamiento antibi\u00f3tico m\u00e1s apropiado, dirigir la toma de muestras y valorar la necesi - dad de llevar a cabo una intervenci\u00f3n para el control del foco [24-26]. Ello requiere habitualmente la realizaci\u00f3n ordenada de pruebas diagn\u00f3sticas radiol\u00f3gicas (radiograf\u00eda simple, ecograf\u00eda, TAC), anal\u00edticas y consulta entre especialistas; para facilitar y acelerar este proceso, la solicitud de dichas pruebas estar\u00e1 etiquetada como \"C\u00d3DIGO SEPSIS\". TRATAMIENTO INICIAL 10. En los pacientes con sepsis se debe iniciar tratamiento antibi\u00f3 - tico para cubrir todos los microorganismos potencialmente causan - tes, adaptado al foco de infecci\u00f3n, a las caracter\u00edsticas del paciente y a la microbiolog\u00eda local [27-30]. El tratamiento antibi\u00f3tico se iniciar\u00e1 siempre tras la obtenci\u00f3n de hemocultivos, y en la primera hora desde la detecci\u00f3n de la sepsis [12]. La adecuaci\u00f3n del tratamiento antibi\u00f3tico se revisar\u00e1 diariamente, en base a la informaci\u00f3n cl\u00ednica y microbiol\u00f3gica existente, las pautas de antibioterapia locales y con la participaci\u00f3n del infect\u00f3logo y de los profesionales encargados en cada hospital de la optimizaci\u00f3n del tratamiento antibi\u00f3tico [30]. 11. En el paciente con sepsis e hipotensi\u00f3n o hipoperfusi\u00f3n 6. En el paciente con sospecha de sepsis (c\u00f3digo sepsis acti - vado) la evoluci\u00f3n cl\u00ednica inicial puede ser impredecible, por lo que es necesaria inicialmente una vigilancia estrecha y la reevaluaci\u00f3n cl\u00ednica peri\u00f3dica , para valorar la evoluci\u00f3n de la disfunci\u00f3n de \u00f3rganos y la respuesta al tratamiento. Se consi - derar\u00e1 el ingreso en una Unidad de Cuidados Intensivos en caso de hipotensi\u00f3n o hiperlactacidemia persistentes, necesidad de f\u00e1rmacos vasoactivos (noradrenalina), disfunci\u00f3n de \u00f3rganos grave, persistente o progresiva, o deterioro cl\u00ednico. 7. Dentro de la valoraci\u00f3n cl\u00ednica del paciente con sepsis es necesaria la evaluaci\u00f3n sistem\u00e1tica de la funci\u00f3n de \u00f3rganos (cardiovascular, neurol\u00f3gico, respiratorio, renal, hep\u00e1tico y coagulaci\u00f3n), lo que requiere, adem\u00e1s de las constantes vitales y la valoraci\u00f3n de diuresis y nivel de conciencia, la realizaci\u00f3n de un perfil anal\u00edtico de sepsis , que incluye, como bilirrubina, lactato y pro - calcitonina (o en su defecto prote\u00edna C reactiva) (tabla 6). Se recomienda repetir estas determinaciones anal\u00edticas en las pri - meras 24 horas, dependiendo el momento \u00f3ptimo de su extrac - ci\u00f3n de la evoluci\u00f3n cl\u00ednica particular de cada caso. Siempre que el lactato inicial se encuentre elevado se debe seriar su determinaci\u00f3n hasta comprobar su normalizaci\u00f3n. Si la hiper - lactacidemia se considera un error de laboratorio o de la toma de muestras, se debe repetir la determinaci\u00f3n para asegurarse Tabla 4 SRIS (s\u00edndrome de respuesta inflamatoria sist\u00e9mica) Positivo si dos o m\u00e1s de los siguientes: 1. Temperatura corporal > 38 o < 36\u00baC 2. Frecuencia cardiaca > 90 mmHg 3. Frecuencia respiratoria > 20 rpm o paCO2 < 32 mmHg o necesidad de ventila - ci\u00f3n mec\u00e1nica 4. Recuento de leucocitos > 12.000 o < 4.000 o > 10% de formas inmaduras0 1 2 3 4 Respiratorio: paO2/FiO2b 400 < 400 < 300 < creatinina, diuresis < 1,2 1,2-1,9 2,0-3,4 ml/d\u00eda bilirrubina f\u00e1rmacos vasoactivos No hipotensi\u00f3n PAM < 70 DA < 5 o DBT DA > 5,1-15 o N/A 0,1 DA > 15; N/A > 0,1 Hematol\u00f3gico: plaquetas 150 < 150 < 100 < 50 < 20 Neurol\u00f3gico: Glasgow 15 13-14 10-12 6-9 < 6Tabla 3 Puntuaci\u00f3n disfunci\u00f3n SOFA (\"Sepsis Organ Failure Assessment\") aRespiratorio: las puntuaciones 3 y 4 se aplican solo si el enfermo recibe soporte ventilatorio; creatinina en mg/dl; bilirrubina en mg/dl; PAM = presi\u00f3n arterial media mm Hg; f\u00e1rmacos vasoactivos administrados durante m\u00e1s de una hora, dosis en g/kg/min; DA = dopamina; N/A = noradrenalina o adrenalina; DBT = dobutamina (cualquier dosis); Glasgow = puntuaci\u00f3n en la escala de Glasgow para el coma bSi no se dispone de gasometr\u00eda arterial pero s\u00ed de pulsioximetr\u00eda, una SpO2/FiO2 de 235 equivale a una paO2/FiO2 de 200, y una SpO2/FiO2 de 315 a una paO2/ FiO2 de 300 [Rice 2007, Chest].Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409403microbiol\u00f3gico precoz , por lo que se deben emplear siempre que sea posible pruebas microbiol\u00f3gicas r\u00e1pidas como tincio - nes, t\u00e9cnicas inmunocromatogr\u00e1ficas, PCR y otras [35, 36]. Es fundamental el contacto estrecho mediante la creaci\u00f3n de cir - cuitos espec\u00edficos con el laboratorio de Microbiolog\u00eda. El equipo multidisciplinar de sepsis debe contar siempre con la participa - ci\u00f3n de un microbi\u00f3logo. ORGANIZACI\u00d3N ASISTENCIAL 15. El c\u00f3digo sepsis tiene como objetivo fundamental mejorar la asistencia a la sepsis, incidiendo especialmente en aquellos aspectos organizativos necesarios para asegurar la aplicaci\u00f3n completa y a tiempo de las medidas diagn\u00f3sticas y terap\u00e9uticas que han demostrado eficacia. En este sentido, son problemas comunes por solucionar el retraso en la detecci\u00f3n, evaluaci\u00f3n y tratamiento, la falta de formaci\u00f3n de los profesionales, los problemas de comunicaci\u00f3n durante las transferencias (tras - lados), o la falta de sistematizaci\u00f3n en los criterios y procedi - mientos de trabajo [5, 37-48]. 16. Se constituir\u00e1 un Comit\u00e9 Central del C\u00f3digo Sepsis Ma - drid, formado por representantes de las sociedades cient\u00edficas implicadas. Su labor ser\u00e1 atender el buen funcionamiento del (lactato 4 mmol/L) se administrar\u00e1 una carga de cristaloi - des de al menos 30 ml/kg en las tres primeras horas [12]; la ad - ministraci\u00f3n posterior de fluidos se guiar\u00e1 por la reevaluaci\u00f3n continuada del estado hemodin\u00e1mico. La hiperlactacidemia de menor grado (lactato > 2 y < 4 mmol/L) generalmente indica hipoperfusi\u00f3n y se asocia a mal pron\u00f3stico en el paciente con sepsis; en estos casos est\u00e1 indicado generalmente el inicio de fluidoterapia, que ser\u00e1 individualizada seg\u00fan las cifras de lac - tato y su evoluci\u00f3n, as\u00ed como otros signos de hipoperfusi\u00f3n y disfunci\u00f3n de \u00f3rganos [31]. 12. Cuando la hipotensi\u00f3n es profunda y/o no se corrige con fluidoterapia se utilizar\u00e1 como vasopresor de primera elecci\u00f3n la noradrenalina [32, 33], a una diluci\u00f3n de 200 mg/mL, para mantener una presi\u00f3n arterial media de 65 mm Hg (tabla 7) [34]. La infusi\u00f3n de noradrenalina a cualquier dosis requiere la monitorizaci\u00f3n invasiva de la presi\u00f3n arterial en cuanto las circunstancias cl\u00ednicas y estructurales lo permitan. 13. Cuando est\u00e9 indicado, se llevar\u00e1 a cabo el control del foco (cirug\u00eda, drenaje, retirada de dispositivos) lo antes posible [24-26]. El control del foco no debe demorarse hasta completar la resucitaci\u00f3n, y ser\u00e1 tanto m\u00e1s urgente cuanto mayor sea el in\u00f3culo bacteriano. 14. En el paciente con sepsis es fundamental el diagn\u00f3stico 3 2 1 0 1 2 3 Frecuencia respiratoria 8 9-11 12-20 21-24 25 SaO2 % 91 92-93 Temperatura 39,1 PA sist\u00f3lica Warning Score\") aConciencia: sistema AVPU: A = alerta; V = respuesta a la voz; P = respuesta al dolor; U = no respuesta Puntuaciones entre 0 y 4 indican bajo riesgo; entre 5 y 7 riesgo medio (precisa observaci\u00f3n en \u00e1rea intermedia), y por encima de 7 riesgo alto (puede precisar Cuidados Intensivos). Tabla 6 Determinaciones de laboratorio (\"perfil de sepsis\") Hemograma Coagulaci\u00f3n Creatinina (urea, iones) Bilirrubina total y directa (bioqu\u00edmica hep\u00e1tica completa en caso de shock o sospecha de foco hepato-bilio-pancre\u00e1tico) Lactato Gasometr\u00eda arterial en caso de compromiso respiratorio Procalcitonina (en su defecto, prote\u00edna C reactiva)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409404momento el ingreso en la Unidad de Cuidados Intensivos (UCI), el preaviso de sepsis se realizar\u00e1 directamente al responsable de la UCI. 18. El servicio de urgencias hospitalario tendr\u00e1 establecido un circuito para la asistencia del paciente con c\u00f3digo sepsis desde su llegada al hospital, bien por preaviso de los SEM bien desde el triaje [39], o desde la aparici\u00f3n de la alerta de sepsis en el paciente que ya se encuentra en observaci\u00f3n. En el pa - ciente que llega tras preaviso, la obtenci\u00f3n de hemocultivos y el inicio de la antibioterapia se llevar\u00e1n a cabo a la llegada del paciente al hospital, salvo en circunstancias extremas a valorar por los SEM. 19. En todos los \u00e1mbitos donde pueda aparecer la alerta de sepsis (SEM, urgencias hospitalarias, plantas de hospitalizaci\u00f3n, UCI/REA) se debe asegurar la disponibilidad inmediata de todo lo nece - sario para el manejo inicial de la sepsis: frascos de hemocultivos, antibi\u00f3ticos de amplio espectro, fluidoterapia y noradrenalina. 20. Se consideran criterios de consulta con la Unidad de c\u00f3digo, evaluando sus debilidades y fortalezas, evaluar sus re - sultados y promover su mejora continuada tanto a nivel asis - tencial como organizativo, en funci\u00f3n de las nuevas evidencias cient\u00edficas y el an\u00e1lisis de los indicadores obtenidos en los dis - tintos hospitales. 17. Los servicios de emergencia m\u00e9dica extrahospitalaria (SEM) son responsables de la activaci\u00f3n del c\u00f3digo sepsis en su \u00e1mbito de actuaci\u00f3n, siguiendo las mismas pautas que en el hospital; es responsabilidad de los SEM la valoraci\u00f3n y el tratamiento iniciales del paciente con sospecha de sepsis, in - cluyendo la canulaci\u00f3n venosa, el inicio de la fluidoterapia y, si es necesario, del soporte vasoactivo [44, 45, 49-51]. En casos seleccionados est\u00e1 justificado el inicio de la antibioterapia an - tes de la llegada al hospital (sospecha de meningitis bacteriana grave, shock s\u00e9ptico, etc.) [52]. La activaci\u00f3n del c\u00f3digo sepsis se acompa\u00f1ar\u00e1 de preaviso de sepsis al servicio de Urgencias del hospital de destino, especificando si el paciente ha presen - tado hipotensi\u00f3n o hiperlactacidemia y requiere por tanto re - sucitaci\u00f3n. En caso de que el paciente requiera desde el primer Tabla 8 Definici\u00f3n de shock s\u00e9ptico Definici\u00f3n conceptual: Se define como la sepsis en que las alteraciones circulatorias, celulares y metab\u00f3licas son lo suficientemente profundas como para incrementar sustancialmente la mortalidad. Definici\u00f3n operativa: sepsis que precisa de tratamiento vasopresor para mantener una presi\u00f3n arterial media mayor o igual a 65 mmHg y lactato mayor de 2 mmol/L tras una adecuada resucitaci\u00f3n con fluidosml/hora mg/min mg/kg/min 50 kg 60 kg 70 kg 80 kg 90 kg 100 kg 3 10 0,2 0,17 0,14 0,13 0,11 0,10 6 20 0,4 0,33 0,29 0,25 0,22 0,20 9 30 0,6 0,50 0,43 0,38 0,33 0,30 12 40 0,8 0,67 0,57 0,40 15 50 1 0,83 0,56 0,50 18 60 1 0,86 0,75 0,67 0,60 21 70 1 0,88 0,78 0,70 24 80 1 0,89 0,80 27 90 1 0,90 30 100 1Tabla y dosificaci\u00f3n Viales de 1 mg/ml de noradrenalina base (viales de 10 ml con 10 mg y de 50 ml con 50 mg de noradrenalina base). Diluir siempre en glucosa al 5%, no en suero salino. Contiene bisulfito s\u00f3dico, que puede producir reacciones al\u00e9rgicas y broncoespasmo en sujetos predispuestos. La infusi\u00f3n de noradrenalina a cualquier dosis requiere la monitorizaci\u00f3n invasiva de la presi\u00f3n arterial tan pronto como sea posible. Diluci\u00f3n: 20 mg en 100 ml G5% o 50 mg en 250 ml G5% (concentraci\u00f3n: 200 mg/ml)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409405detecci\u00f3n precoz de las situaciones de riesgo, incluida la sep - sis, sugerimos la puesta en marcha en el hospital de sistemas de detecci\u00f3n autom\u00e1tica de deterioro cl\u00ednico , basados en la puntuaci\u00f3n NEWS o similares [48, 55, 56]. En los servicios o centros donde a\u00fan no existe posibilidad de crear una alerta electr\u00f3nica, se establecer\u00e1n los m\u00e9todos de detecci\u00f3n acordes a sus recursos o modos de trabajo, contando con la participaci\u00f3n de los profesionales de enfermer\u00eda para su implantaci\u00f3n. 23. Cada hospital debe implementar un sistema de respuesta r\u00e1pida ante la detecci\u00f3n de una situaci\u00f3n de deterioro cl\u00ednico en el paciente hospitalizado, que sea adecuada a la gravedad de la situaci\u00f3n, y acorde a sus recursos y modos de trabajo [57-59]. Los profesionales que formen parte de dicho sistema son responsables de asegurar la evaluaci\u00f3n, diagn\u00f3stico y tra - tamiento de la sepsis y de cualquier otra causa de deterioro cl\u00ednico hasta la estabilizaci\u00f3n del paciente o su ingreso en una Unidad de Cuidados Intensivos. El sistema de respuesta r\u00e1pida no reemplaza la labor de los profesionales responsables del pa - ciente, sino que la complementa. 24. Cada organizaci\u00f3n (SEM, hospitales) debe disponer de un programa de formaci\u00f3n reglada para m\u00e9dicos y enfermeras Cuidados Intensivos : shock s\u00e9ptico (tabla 8), hipotensi\u00f3n o hiperlactacidemia persistentes, disfunci\u00f3n de \u00f3rganos grave, persistente o progresiva, deterioro cl\u00ednico. Esta consulta no se debe retrasar por la espera de respuesta al tratamiento. 21. Cada hospital dispondr\u00e1 de un equipo multidisciplinar de sepsis [5, 53, 54], integrado por profesionales de distintos estamentos (m\u00e9dicos, farmac\u00e9uticos, enfermeras) y especiali - dades (urgencias, medicina interna, medicina intensiva, cirug\u00eda, anestesiolog\u00eda y reanimaci\u00f3n, pediatr\u00eda, microbiolog\u00eda, etc.), abiertos a la participaci\u00f3n espor\u00e1dica o permanente de otros profesionales. Dicho equipo es el responsable del seguimiento del c\u00f3digo sepsis en el hospital: revisar las activaciones del c\u00f3 - digo, evaluar su eficacia, y mantener un registro de las actua - ciones realizadas sobre los pacientes con activaci\u00f3n del c\u00f3digo sepsis y sus resultados (ver m\u00e1s abajo el ep\u00edgrafe \"Indicadores de calidad\"). El equipo multidisciplinar de sepsis desarrollar\u00e1 su labor de forma conjunta y sin\u00e9rgica con la Comisi\u00f3n de Infec - ciones, infect\u00f3logos y grupos de optimizaci\u00f3n del tratamiento antibi\u00f3tico (PROA) del hospital. 22. Muchas de las alertas de sepsis se generan en pacientes ya hospitalizados por infecci\u00f3n o por otros motivos. Para la S N NP 1. \u00bfTiene el paciente una infecci\u00f3n aguda sospechada o documentada? 2. \u00bfCumple dos o m\u00e1s criterios qSOFA? (anotar n\u00famero) 3. \u00bfCumple otros criterios de disfunci\u00f3n org\u00e1nica? (especificar) Si son positivas las respuestas a la pregunta 1 y 2 o 3, activar el c\u00f3digo sepsis. Registrarlo en la historia cl\u00ednica y anotar la fecha y hora de inicio de la sepsis y de activaci\u00f3n (la hora de inicio es la de la determinaci\u00f3n de qSOFA positivo o detecci\u00f3n de la disfunci\u00f3n org\u00e1nica). Toma y registro de constantes vitales (PA, FC, FR, temperatura), nivel de conciencia, medici\u00f3n de diuresis, pulsioximetr\u00eda Puntuaci\u00f3n NEWS perfil de sepsis, incluyendo determinaci\u00f3n de lactato. C\u00e1lculo de la puntuaci\u00f3n SOFA (anotar n\u00famero) y confirmaci\u00f3n del diagn\u00f3stico de sepsis Toma de cultivos de los focos sospechosos de infecci\u00f3n Inicio de la antibioterapia emp\u00edrica en la primera hora desde el inicio de la sepsis (acorde a los protocolos locales de antibioterapia). Registrar la fecha y hora de administraci\u00f3n de la primera dosis En caso de hipotensi\u00f3n o hiperlactacidemia > 4 mmol/L, administrar al menos 30 ml/kg de cristaloides en las primeras 3 horas Investigaci\u00f3n del foco completa (pruebas de imagen, anal\u00edtica, toma de muestras para microbiolog\u00eda, interconsultas si procede, etc.) Control del foco de infecci\u00f3n, si procede Iniciar noradrenalina en caso de hipotensi\u00f3n refractaria a la fluidoterapia, para mantener PAM 65 mm Hg Seriaci\u00f3n de los niveles de l\u00e1ctico, en caso de hiperlactacidemia > 2 mmol/L o hipotensi\u00f3n Consulta con Medicina Intensiva/Reanimaci\u00f3n Ingreso en UCI/Reanimaci\u00f3n Reevaluaci\u00f3n completa en seis horas Reevaluaci\u00f3n completa en 24 horas Anal\u00edtica de control en las primeras 24 horas Revisar diariamente la adecuaci\u00f3n del tratamiento antibi\u00f3ticoTabla 9 Check-list de activaci\u00f3n del c\u00f3digo sepsisDocumento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409406 Pilar L\u00f3pez Vadillo (M\u00e9dico de Urgencias SUMMA 112, Madrid) Fernando Mart\u00ednez Sagasti (Servicio de Medicina Intensiva Hospital Cl\u00ednico San Carlos, Madrid) Emilio Maseda Garrido (Servicio de Anestesiolog\u00eda y Reani - maci\u00f3n Hospital Universitario La Paz, Madrid) Milagros Mart\u00ed de Gracia (Servicio de Radiolog\u00eda Hospital Universitario La Paz, Madrid) Rosario Molina Lobo (Servicio de Medicina Intensiva Hospital Universitario del Henares, Coslada, Madrid) Ana Mar\u00eda Montero Feijoo (Servicio de Anestesiolog\u00eda y Rea - nimaci\u00f3n Hospital Universitario La Paz, Madrid) Marta Najarro de la Parra (Servicio de Urgencias Hospital Ra - m\u00f3n y Cajal, Madrid) Mar\u00eda Jos\u00e9 N\u00fa\u00f1ez Orantos (Servicio de Medicina Interna Hos - pital Cl\u00ednico San Carlos, Madrid) Eduardo Palencia Herrej\u00f3n (Servicio de Medicina Intensiva Hospital Universitario Infanta Leonor, Madrid) Antonio P\u00e9rez Alonso (Enfermer\u00eda de Urgencias SUMMA 112, Madrid) Fernando Ramasco Rueda (Servicio de Anestesiolog\u00eda y Rea - nimaci\u00f3n Hospital Universitario La Princesa, Madrid) Patricia Roces Iglesias (M\u00e9dico de Urgencias SUMMA 112, Madrid) Diego An\u00edbal Rodr\u00edguez Serrano (Servicio de Medicina Inten - siva Hospital Universitario La Princesa, Madrid) In\u00e9s Rubio P\u00e9rez (Servicio de Cirug\u00eda General Hospital Uni - versitario La Paz, Madrid) Ana Ruiz \u00c1lvarez (Enfermer\u00eda de Hospitalizaci\u00f3n Hospital Universitario Infanta Leonor, Madrid) Mart\u00edn Ruiz Grinspan (Servicio de Urgencias Hospital Univer - sitario del Henares, Coslada, Madrid) Carmen S\u00e1ez B\u00e9jar (Servicio de Medicina Interna Hospital Universitario La Princesa, Madrid) Beatriz S\u00e1nchez Artola (Servicio de Medicina Interna Hospital Universitario Infanta Leonor, Madrid) Milagros Sancho Gonz\u00e1lez (Servicio de Medicina Intensiva Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid) Regino Serrano Heranz (Servicio de Medicina Interna Hospi - tal Universitario del Henares, Coslada, Madrid) Elena Velasco L\u00f3pez (Servicio de Medicina Intensiva Hospital Cl\u00ednico San Carlos, Madrid) Angela Trueba Vicente (Servicio de Urgencias Hospital Ra - m\u00f3n y Cajal, Madrid) Andr\u00e9s von Wernitz Teleki (Servicio de Urgencias Hospital Universitario La Princesa, Madrid) BIBLIOGRAF\u00cdA 1. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, et al. Hospital deaths in patients with sepsis from 2 independent co -sobre el diagn\u00f3stico, evaluaci\u00f3n y tratamiento precoces de la sepsis; este programa incluir\u00e1 tanto sesiones cl\u00ednicas peri\u00f3dicas como ayudas cognitivas (carteler\u00eda, d\u00edpticos, etc.) [60, 61]. La organizaci\u00f3n del C\u00f3digo Sepsis Madrid elaborar\u00e1 e impartir\u00e1 actividades formativas dirigidas a todos los profesionales im - plicados en la asistencia a la sepsis. 25. Se crear\u00e1 un registro de datos electr\u00f3nico donde reco - ger la informaci\u00f3n de todos los pacientes de la Comunidad de Madrid en los que se haya activado el c\u00f3digo sepsis. Esta infor - maci\u00f3n puede utilizarse para analizar las respuestas y planificar las actividades de mejora donde y cuando sea necesario, y para mantener el feed-back sobre los \u00e9xitos y aspectos a mejorar en la aplicaci\u00f3n del c\u00f3digo. Adem\u00e1s, la documentaci\u00f3n adecua - damente estructurada permitir\u00e1 establecer una Red de Inves - tigaci\u00f3n dentro de la Comunidad de Madrid para llevar a cabo proyectos en esta \u00e1rea de conocimiento. *INTEGRANTES DEL GRUPO MULTIDISCIPLINAR C\u00d3DIGO SEPSIS MADRID (ORDEN ALFAB\u00c9TICO) Jos\u00e9 Manuel A\u00f1\u00f3n Elizalde (Servicio de Medicina Intensiva Hospital Universitario La Paz, Madrid) M\u00aa Jos\u00e9 Asensio Mart\u00edn (Servicio de Medicina Intensiva Hos - pital Universitario La Paz, Madrid) Jos\u00e9 Barber\u00e1n L\u00f3pez (Servicio de Medicina Interna HM Hos - pitales, Madrid) Guillermina Bejarano Redondo (Servicio de Urgencias Hospi - tal Universitario La Paz, Madrid) Carlos Bibiano Guill\u00e9n (Servicio de Urgencias Hospital Uni - versitario Infanta Leonor, Madrid) Francisco Javier Candel Gonz\u00e1lez (Servicio de Microbiolog\u00eda Hospital Cl\u00ednico San Carlos, Madrid) Isabel Casado Fl\u00f3rez (SAMUR-Protecci\u00f3n Civil, Madrid) Francisco Javier Cobo Reinoso (Servicio de Enfermedades In - fecciosas Hospital Ram\u00f3n y Cajal, Madrid) Ervigio Corral Torres (SAMUR-Protecci\u00f3n Civil, Madrid) Carlos Mar\u00eda Elvira Mart\u00ednez (Servicio de Medicina Preventiva Hospital Cl\u00ednico San Carlos, Madrid) Juan Gonz\u00e1lez del Castillo (Servicio de Urgencias Hospital Cl\u00ednico San Carlos, Madrid) Carlos Gonz\u00e1lez Maldonado (M\u00e9dico de Urgencias SUMMA 112, Madrid) Federico Gordo Vidal (Servicio de Medicina Intensiva Hospital Universitario del Henares, Coslada, Madrid) David Jim\u00e9nez Jim\u00e9nez (Enfermero de UCI, Hospital Universi - tario La Princesa, Madrid) Bel\u00e9n Joyanes Abancens (Servicio de Pediatr\u00eda Hospital Cl\u00edni - co San Carlos, Madrid) Esther Mar\u00eda L\u00f3pez Ramos (Servicio de Medicina Intensiva Hospital Universitario Pr\u00edncipe de Asturias, Alcal\u00e1 de Henares, Madrid)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-4094072016;315(8):775-787. doi:10.1001/jama.2016.0289 15. Churpek MM, Snyder A, Han X, Sokol S, Pettit N, Howell MD, et al. Crit Care 2017;195(7):906-911. doi:10.1164/rccm.201604-0854OC 16. Singer AJ, in Adult Suspected cri tically ill adult patients: systematic review and meta-analysis. J Intensive Care. 2019;7(1):22. doi:10.1186/s40560-019-0374-4 19. Li Q, Wang BS, Yang L, Peng C, Ma LB, Chai C. Assessment of adre the - rapy in patients with sepsis: a Bakker lactate monitoring in critically ill patients: a systematic Care Med. 2009;37(10):2827-2839. DA, Ware Comparison Ratio and the PaO2 / ARDS. Chest. 2007;132(2):410-417. doi:10.1378/chest.07-0617 23. Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with Kawano D, Komatsu T, Sakurai A, Chiba Y, et al. Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gas - associated septic shock. Crit Care. 2014;18(3):R87. doi:10.1186/cc13854 25. Mart\u00ednez ML, Ferrer R, Torrents E, Guillamat-Prats R, Gom\u00e0 G, Su\u00e1 - rez D, et al. Impact of Source Control in Patients With J. Source Identification Control. Emerg Med Clin North Am. 2017;35(1):43-58. doi:10.1016/j. emc.2016.08.005 27. Kumar Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. in human sep -horts. JAMA. 2014;312(1):90-92. 2014;14(1):3863. doi:10.1186/s12879-014-0717-7 G, Bilgrami I, Eastwood G, Johnson P, Howden BP, Bello - mo R, et al. The epidemiology of sepsis during rapid respon - se CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Ellicott AC, Vitberg Suffredini AF, O'Grady NP, Banks SM, et al. Bundled care for septic shock: an analysis of ME, Iwashyna TJ, Phillips GS, et al. Time to Treatment and Mortality during Manda - ted Emergency Care for al. Surviving Sepsis Campaign guidelines for management of se - vere and septic shock. Intensive Care Med. 2004;30(4):536- 555. doi:10.1007/s00134-004-2210-z 9. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6 10. Borges Sa M, Candel Gonz\u00e1lez F, Ferrer Roca R, Zaragoza Crespo R. C\u00f3digo sepsis: documento de consenso. 2014. https://www.se - guridaddelpaciente.es/en/information/publicaciones/2016/codigo- sepsis-documento-de-consenso/. 11. Ramasco F, Figuerola A, Mendez R, Rodr\u00edguez Serrano D, von Wernitz A, Hern\u00e1ndez-Aceituno A, et al. Initial clinical outcomes and prognostic variables in the implementation of a Code Sep - sis in a high complexity University Hospital. Rev Esp Quimioter. 2019;32(3):238-245. PMID: 30968675 12. Levy MM, Evans LE, The Surviving Sepsis Campaign Bundle: 2018 update. al. Assessment of Clinical Criteria for Sepsis: For the VX, Deuts - chman CS, et Assessing New Clinical Criteria for Septic Shock: For the sensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409408tic shock. Crit Care Med. 2006;34(6):1589-1596. doi:10.1097/01. CCM.0000217961.75225.E9 28. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al. Effectiveness of Treatments for Severe Sepsis: ATS. 2013;10(5):466-473. doi:10.1513/ AnnalsATS.201304-099OC 32. Stratton L, Berlin DA, Arbo JE. Vasopressors and Inotropes in Sep - sis. Emerg Med Clin Am. 2017;35(1):75-91. doi:10.1016/j. emc.2016.09.005 B, Anguel N, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583-1593. doi:10.1056/NEJ - Moa1312173 35. Burillo A, Bouza E. Use of rapid diagnostic techniques in ICU pa Intensive Unit AL, Gupta N, Lulaj E, Furgiuele M, Hidalgo I, Jones MP, et al. Predictors of early progression to severe Nurs. 2019;45(3):254-256. doi:10.1016/j. jen.2018.08.002 40. Mohr NM, Harland KK, Shane DM, Ahmed A, Fuller BM, Torner JC. Inter-hospital transfer is associated with increased costs in severe JR, Oniki TA, Sorensen J, Jephson AR, Allen TL, et al. Emergency Department Crowding Is Associated With Dela - yed Sepsis. Ann Emerg Med. 2019;73(4):345-355. doi:10.1016/j.annemergmed.2018.10.007 42. Brown SM, Bledsoe JR, Sorensen J, Samore MH, Allen TL, et al. ED Door-to-Antibiotic Time and Long-term Mortality in Sep - sis. doi:10.1016/j.chest.2019.02.008 Mitchell KH, Rudd Carlbom DJ, Hough CL, et al. Physician in Time Antimicrobial Treatment for Rudd BA, Carlbom DJ, Rea TD, et al. Prehospital and review. Open. 2016;6(8):e011218. Stevenson JE, Israelsson Nilsson GC, Petersson GI, Bath PA. Re in acute patients: The documen - tation of vital signs within electronic health records in patients who suffered in-hospital cardiac arrest. Health J, Petersson Bath PA. Factors influencing the quality of vital sign data in electronic health records: A - Vallone CV, Impagnatiello M, Li Pu - ma DD, et al. Sepsis in Internal Medicine wards: current knowledge, uncertainties and new approaches for management optimization. Ann Med. 2017;49(7):582-592. doi:10.1080/07853890.2017.13327 76 49. septic patients: observatio Med. doi:10.1186/s13049-017-0393-x Brace-McDonnell S, G. Impact of Prehospi - tal Care Outcomes in Sepsis: Systematic WestJEM. N, Oskam E, Stassen PM, Exter P van, van de Ven PM, Ha - ak HR, et al. Prehospital antibiotics in the ambulance randomised trial. Lancet Respir Med. 2018;6(1):40-50. doi:10.1016/S2213-2600(17)30469-1 53. de Dios B, Borges M, Smith TD, del Castillo A, Socias A, Guti\u00e9rrez L, et al. Protocolo inform\u00e1tico de manejo integral de la sepsis. Des - cripci\u00f3n de un sistema de identificaci\u00f3n precoz. Enferm Infecc Mi - crobiol Clin. S, Scudeller L, Badia L, Bartoletti M, et al. Infectious Diseases Team for the Early Management of Severe Sepsis and Septic Shock in Identifying Patients Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al. Rev Esp Quimioter 2019;32(4): 400-409409With 2019 Jan 30. pii: S0210-5691(18)30337-1. doi:10.1016/j. medin.2018.12.004 57. Dummett BA, Adams C, Scruth E, Liu V, Guo M, Escobar GJ. Incor - porating an Early Detection Practice in Two Community Hospitals: an EWS Into Practice. J Hosp Med. 2016;11:S25-S31. doi:10.1002/jhm.2661 58. Gordo F, Molina R. Evoluci\u00f3n a la detecci\u00f3n precoz de gravedad. \u00bfHacia d\u00f3nde vamos? Medicina Intensiva. 2018;42(1):47-49. doi:10.1016/j.medin.2017.06.008 59. Granich R, Sutton Z, Kim YS, Anderson M, Wood H, Scharf JE, et al. Early detection of critical illness the ICU. J Hosp Med. 2016;11:S40-S47. doi:10.1002/jhm.2660 60. Ferrer R, Artigas A, Levy MM, Blanco J, Gonz\u00e1lez-D\u00edaz G, Garnacho- Montero J, et al. Improvement in process care and outcome after a sepsis educational program in Spain. JAMA. 2008;299(19):2294-2303. doi:10.1001/jama.299.19.2294 61. for the ABISS-Edusepsis Study group, Ferrer R, Mart\u00ednez ML, Gom\u00e0 G, Su\u00e1rez D, \u00c1lvarez-Rocha L, et al. Improved empirical "}